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Noble metals comprise any of several metallic chemical 
elements that are outstandingly resistant to corrosion 
and oxidation, even at elevated temperatures. This 
group is not strictly defined, but the tentative list 
includes ruthenium, rhodium, palladium, silver, 
osmium, iridium, platinum and gold, in order of atomic 
number. The emergence of noble metal nanotechnology 
is attracting huge interest from the scientific 
community and has led to an unprecendented 
expansion of research and exploration of applications in 
electrochemistry, catalysis and biomedicine. Noble 
metal nanocomposites can be synthesised both by top-
down and bottom up approaches, as well as via 
organism-assisted routes, and subsequently modified 
appropriately for the field of use. Nanoscale analogues 
of gold, silver, platinum, and palladium in particular, 
have gained primary importance owing to their 
excellent intrinsic properties and diversity of 
applications; they offer unique functional attributes, 
which are quite unlike the bulk material. Modulation of 
noble metal nanoparticles in terms of size, shape and 
surface functionalisation has endowed them with 
unusual capabilities and manupulation at the chemical 
level, which can lead to changes in their electrical, 
chemical, optical, spectral and other intrinsic 
properties. In this comprehensive review, we highlight 
recent advances in the adaptation of noble metal 
nanomaterials and their applications in therapeutics, 
diagnostics, sensing, and environmental monitoring. 
Introduction  
In chemistry, noble metals are defined as metals that are outstanding 
resistant to corrosion and oxidation even at elevated temperatures 
and these include the metals of groups VIIb, VIII and 1b of the second 
and third transition series of the periodic table i.e. rhodium (Rh), 
ruthenium (Ru), palladium (Pd), silver (Ag), osmium (Os), iridium (Ir), 
platinum (Pt), and gold (Au).1 Noble metals have a long and rich 
history, which probably dates back to as early as the Egyptian First 
Dynasty. They belong to a class of elements that has found a wide 
range of applications encompassing aerospace, electronic industries 
and most importantly, the health sector2–5. The amalgamation of 
nanoscience and biotechnology has spawned a growing field of 
research in the form of nanobiotechnology. In this new arena, the 
technological leap of synthesising and controlling materials at 
nanoscale level has provided an immense opportunity to progress 
medical and healthcare treatment, diagnostics and therapies.6 Noble 
metals are eclectic non-toxic agents in the sense that they have a 
wide diversity of biomedical applications, which include use in highly 
sensitive diagnostic assays,7 thermal ablation as radiotherapy 
enhancers,8–11 and drug and gene delivery vehicles.12–18 Among all 
noble metals, Au and Ag nanoparticles are most extensively studied 
due to the well-established synthesis routes, their relatively higher 
content in the earth crust, and better safety profile. Nanoparticle-
based systems are now becoming an effective tool in “Theranostics” 
(i.e. simultaneous diagnosis and therapy) because of their unique 
properties of excellent penetration and traceability within the body, 
which allows for a more efficient therapy with a reduced risk of any 
toxic side effects in comparison to conventional therapies.19,16,20,21
The unique characteristics of noble metal nanostructures, in terms of 
high surface-to-volume ratio, broad optical properties, ease of 
synthesis, and tunability of surface functionalisation and 
modification, provide an important added dimensions in bio-
diagnostics, biophysical studies, biosensing and medical 
therapy.16,20,21 Noble metal nanoparticles (NMN) have played an 
equally important role in the development of novel biosensors, to 
add to or enhance the accuracy and specificity of already existing 
biomolecular diagnostics. The physicochemical attributes of noble 
metals at the nanoscale level have led to the development of a wide 
variety of biosensors such as: (i) nanobiosensors for point care 
disease detection, (ii) nanoprobes for in vivo cell imaging, tracking 
and pathogenesis of disease progression and (iii) other 
nanobiotechnology-based tools that enhance basic biological 
research.22–25
The colloidal state of noble metals has been the subject of intensive 
investigations because of their effectiveness, and various questions 
have been raised regarding their safety profile in human body. 
Colloidal gold, silver, platinum, palladium, iridium, ruthenium and 
rhodium are easily and widely available on the market for use in 
combating many diseases, free radicals and bacteria. In this review, 
we provide an extensive literature survey covering recent 
developments in this field.  
Synthetic Routes for NMN 
The preparation of nanoparticles fundamentally follows two 
distinctly different approaches, top-down and bottom-up (Scheme 
1).26 The top-down processes involve bulk materials which are 
reduced to particles with nano-dimension using various physical and 
chemical methodologies. On the other hand, in a bottom-up 
approach, nanoparticles are constructed through the assembly of the 
atoms, the molecules, or the clusters and thus this is generically 
termed self-assembly.  
Externally controlled tools are utilised in a top-down approach for 
cutting, milling and shaping the materials into the desired order and 
shape. Several physical methods, such as pyrolysis,27 lithography,28–
30 thermolysis,31,32 and radiation-induced methods33 belong in this 
category. A major limitation of the top-down approach is the 
imperfect surface structure of metallic nanoparticles, which 
substantially affects their physical and chemical properties.34
Moreover, enormous energy is required to maintain the high 
pressure and high-temperature conditions during these synthetic 
procedures and this makes these processes expensive. 
In a bottom-up methodology, the originally formed nanoparticles are 
subsequently assembled into the final material, using chemical as 
well as biological procedures. The bottom-up approach is 
advantageous as it provides a far better control over the final product 
formation with less surface deformation and more homogeneous 
chemical composition. Moreover, the processes are in general less 
expensive as well.  The bottom-up approach is commonly used for 
wet-chemical synthesis procedures, such as chemical,35–37
electrochemical,38,39 polyol reduction40 and sonochemical.41,42
However, one major challenge associated to these processes is the 
purification of the nanoparticles from toxic chemicals, organic 
solvents and reagents for further biomedical applications.
Top-down approaches  
One of the commonly used protocols is micropatterning.43 Apart 
from the most common approach of photolithography, various other 
techniques have evolved in the recent past.44 Scanning, soft, nano-
imprint, colloidal, nanosphere and E-beam lithography are among 
some of these new methods. In principle, all these techniques use 
either light, electrons, a focused beam of electrons or electrostatic 
forces to selectively remove nano-structures from a precursor to 
develop ordered arrays of nano-materials. 
In a milling process, macro-scale materials are ground in a ball mill to 
generate particles of nano dimensions.45 The kinetic energy transfer 
from balls to powder is behind the reduction in grain size. Various 
parameters like, type of mill, milling atmosphere, milling media, 
intensity, time, temperature, etc. play a crucial role in controlling the 
shape and size of the nanoparticles.46 Different devices designed for 
various purposes have been developed in order to overcome these 
constrains including shaker mills, tumbler mills, vibratory mills, 
attrition mills, planetary mills, etc. For bulk production of nano-
materials, the attrition process is highly advantageous. However, one 
major limitation of this process is the imperfect surface and 
significant crystallographic damage of the processed materials. 
Pyrolysis is another important technique commonly used.47 A 
precursor in its vapour state is forced through an orifice with high 
pressure and burning. Through further processing of the obtained 
solid ash, nanoparticles are recovered. Pyrolysis is frequently used 
for the preparation of noble metal nanoparticles.27,48 One important 
drawback of the method is the requirement for large amounts of 
energy. 
Bottom-Up approaches  
The most commonly utilised and easiest bottom-up approach is the 
chemical reduction of metal ions in solutions. In principle, an ionic 
salt is reduced using various reducing agents under appropriate 
reaction conditions and in presence of a stabilising agent.35–37 A 
plethora of reducing agents, such as Na-citrate, hydrazine, hydrogen, 
LiAlH4, NaBH4, and alcohols can be used. According to Lee-Meisel 
method,49 nitrate and sulphate salts are reduced using NaBH4, 
sodium citrate, and hydrogen. The pH of the medium plays a crucial 
role in modulating the size and shape of the particles.50 At high pH, 
owing to faster reduction, both rod and spherical nanoparticles were 
found, while at relatively lower pH (5-6), triangular and other 
polyhedral structures were obtained because of the slower reaction. 
Similarly, Au nanoparticles can be prepared from an aqueous 
solution of HAuCl4 using citrate as the reducing agent.51,52 The 
average particle size can be controlled by varying the ratio of 
reducing/stabilising agents as well as the pH of the system.53,54 On 
the other hand, platinum, another important class of noble metal 
nanoparticles is relatively under explored. Sodium polyacrylate 
stabilised cubic and tetrahedral platinum nanoparticle synthesis in 
solution phase has been reported by El-Sayed et al.55 A general 
strategy based on a chemical reduction method involving different 
metal combinations (cobalt, iron, and nickel) with platinum has been 
reported by Zhang.56 Another popular nanoparticle fabrication 
process involves microemulsions. The first microemulsion-based 
synthesis was reported for palladium, rhodium, and platinum 
nanoparticles synthesis.57 Since then, the process gained popularity 
owing to its ease of operation and control over the size and shape of 
the products.58–60 Herein, two separate microemulsions containing 
salts and reducing agents are mixed together in presence of 
amphiphile. Inter microemulsion collision leads to the mixing of the 
reactants and consequently nanoparticles are formed. This strategy 
helps in growing nanoparticles with uniform shape and size as the 
microemulsions are used as a template while the nanoparticles are 
growing during the process. This method offers benefits to prepare 
thermodynamically stable and monodispersed nanoparticles.61
Scheme 1 Schematic presentation of the top-down and bottom-up approaches for 
nanoparticle synthesis. 
In a laser ablation process, a solid surface is irradiated with a laser 
beam and the materials become heated at low laser flux and are 
finally evaporated or sublimated.62 At a higher flux, the materials are 
converted to form plasma. The lack of any requirement to remove 
excess reagents as well as the possibility of metal nanoparticle 
synthesis in both aqueous and organic solvents has allowed the laser 
ablation method to emerge as a potential alternative for chemical 
reduction methods. There have been several reports where this 
process was used to prepare a variety of noble metal nanoparticles 
including silver, gold, and platinum.63–65 Fast processing times, 
control over the size and shape of the particles and high yields are 
among the major advantages of this process. 
Microwave-based synthesis and electrochemical methods are the 
other two important approaches to be mentioned. Microwave 
irradiation is used for the “one-pot” preparation of metal 
nanoparticles from their salts and polymeric surfactant solutions.66 It 
is a relatively fast and easy method with high selectivity and control 
over size and morphology of the end products.67 The electrochemical 
method was first introduced by Reetz.68 A metal sheet was dissolved 
from the anode and the metal salt thus produced was reduced on 
the cathode of an electrochemical cell producing the desired metal 
nanoparticles.69,70 Importantly, control over the particle size can 
easily be achieved without any template. Considering the excess use 
of chemicals and solvents in the chemical synthesis of nanoparticles, 
greener approaches with minimal use of such hazardous chemicals 
have been developed. One major driving force for these greener 
approaches is nature’s efficiency in making these nano-materials. 
Mimicking nature, may not be not easy, but it has allowed chemists 
to develop several green synthetic protocols for nanoparticle 
synthesis using water as the medium and proteins or carbohydrates 
as capping agents.71,72 Starch has been used as both a reducing as 
well as a stabilising agent for the synthesis of stable silver 
nanoparticles.73,74 Similarly, gold nanoparticles have been prepared 
utilising different biomolecules as capping agents and lactic acid as 
the reducing agent.74 Chitosan, a natural biopolymer, has also been 
used as a reducing and stabilising agent.75 In another “greener” 
approach, hydrogels of synthesised peptides and other small 
molecules were successfully used to create nanoparticles where the 
hydrogel nano-structures act as the template and help in creating the 
shape and size of the nanoparticles.76,77 Das et al. prepared a 
tryptophan-appended peptide amphiphile able to form hydrogel 
where gold nanoparticles with defined shape and size could be 
prepared using the indole residue as the reducing agent, without the 
need for any external agent.78,79
Organism-based synthesis of NMN 
The quest for the development of economically as well as 
environmentally benign methods led to exploration of the potential 
of micro-organisms in this respect.80 Biological systems are excellent 
examples of hierarchical organisations of atoms or molecules and 
this attracted researchers to use micro-organisms as potential cell 
factories for nano-material preparation. Both prokaryotic (bacteria) 
and eukaryotic (algae, fungi, plants) species are used for this 
purpose. 
Bacteria are often exposed to metal rich environments and have the 
ability to develop resistance to these extreme conditions. Thus, 
prokaryotes like bacteria are an automatic choice for the production 
of nanomaterials.  Pseudomonas stutzeri AG259, a metal 
accumulating bacterium, was utilised by Klaus et al. to create 
intracellular nanocrystals of metallic silver and monoclinic silver 
sulphide.81 Extracellular synthesis of nanoparticles was first reported 
by Shahverdi and co-workers.82 Nanocrystals of silver were prepared 
by incubating the biomass of Bacillus licheniformis in presence of 
silver nitrate, where NADH acted as the reducing agent in presence 
of nitrate reductase.83 Gold nanoparticles are also prepared by 
accumulation and reduction of gold salts by bacteria. Bacillus 
licheniformis, Shewanella algae, Stenotrophomonas maltophilia, 
Lactobacillus strains, present in the whey of butter milk are some of 
the examples of bacteria which have been used to produce gold 
nanomaterials.84–87 In addition to these, bacteria like Schewanella
and Acinetobactor calcoaceticus PUCM 1011 were utilised for the 
preparation of platinum nanoparticles.88,89 Though promising in 
terms of its green nature and control over the shape and size of the 
particles, bacterial-mediated synthesis suffers from disadvantages 
such as difficulty in handling and low yield. In recent years, eukaryotic 
organisms have emerged as a better alternative for the synthesis of 
noble metal nanoparticles, owing to easier protocols as well as cost-
effectiveness. Fungi were first tested by Sastry et al. for the 
preparation of metal and metal oxide nanoparticles.90 Gold 
nanoparticles were prepared using Verticillium sp. when AuCl4 was 
reduced within the fungal cells. Fusarium oxysporum was used to 
prepare gold and silver nanoparticles with uniform dimensions.91 An 
environmentally friendly and cost-effective method for the synthesis 
of silver nanoparticles using cell-free filtrate of Aspergillus flavus was 
reported by Panwar and coworkers.80 Another important biological 
media are the algae. Algae, like Chlorella vulgaris and Pithophora 
oedogonia, have been used successfully to construct silver 
nanoparticles.92,93 Gold nanoparticles have been prepared involving 
various seaweeds like Sargassum wightii by Singaravelu et al.94 Plant 
extracts are also attractive media for the synthesis of nanoparticles 
and the process has been referred to as Phytosynthesis.  Live alfalfa 
plant can take gold ions from solid media and the secretome from 
live alfalfa plant can reduce gold ions to Au0, which can be taken up 
by the plant and consequently used to produce gold nanoparticles.95
Neem (Azadirachta indica) leaf extract was successfully used by 
Shankar et al. to prepare silver, gold, and bimetallic Au/Ag core–shell 
nanoparticles.96 Similar plant extracts (bark, leaf, fruit, and gum) 
have been used by several researchers to produce a variety of noble 
metal nanoparticles.97–100
As discussed, several physical, chemical as well as biological methods 
have been developed for the synthesis of nanoparticles. All these 
processes are widely used based on the utility and applicability of the 
nano-products. However, the existing protocols all suffer from 
certain drawbacks. Thus, the development of alternative processes 
to fabricate nanoparticles with controlled and tuneable properties is 
still an open challenge.  
Surface Modification and Functionalisation of 
NMN 
NMN have attracted significant attention in various applications 
ranging from electronics to sensing, biolabeling, photonics, 
nanomedicine and catalysis, due to their electrical, chemical, optical, 
spectral and other intrinsic properties.101,102,103 To increase the 
biocompatibility, sensing, and specific targeting of NPs, it is 
necessary to stabilise NPs against agglomeration and to functionalise 
them.104–106 Attaching appropriate organic groups to the metal 
surfaces is the most common way to achieve this (Fig. 1). Through 
metal−thiolate (M−S) linkages,107 organosulphur groups coordinate 
to various metals such as Ag, Cu, Fe, Au.108 Metal−carbon (M‐C=) 
covalent bonds using aryl diazonium as the precursors109 have been 
used to stabilise metal NPs. Metal−carbene (M=C) or metal−nitrene 
(M=N) π bonds formed with diazo derivatives, have been utilised to 
functionalise various metal NPs such as Au, Pt, Ti, Ru, and Pd.110,111
Metal−acetylide/−vinylidene bonds are formed via acetylene 
derivatives onto metal surfaces.112 Surface modification or 
functionalisation of metal NPs can be accomplished with amines or 
ammonium ions, negatively charged carboxylate groups, and 
phosphines.113
Fig. 1 Schematic illustration of representative anchor moieties, stabilizing spacers, 
tethering groups, and conjugation groups for functionalising noble nanoparticles. NHC = 
N-heterocyclic carbenes, NHS = N-Hydroxysuccinimide, EDC = 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride.
Analytical techniques for NMN characterisation 
The unique properties of noble metal NPs such as thermal, electrical, 
chemical, and optical rely on the size, morphology and surface 
charge. Various techniques have been developed to characterise the 
metal NPs.114 Size distribution, average particle diameter, surface 
charge, and shape govern the physical stability of metal NPs.115
Scanning electron microscopy (SEM),116 dark-field and field-emission 
scanning electron microscopy (FE-SEM),117,118 transmission electron 
microscopy (TEM),119 high-resolution TEM (HRTEM),120–122 and 
atomic force microscopy (AFM)123,124 are commonly utilised to 
estimate the size, shape, and surface morphology. Dynamic light 
scattering (DLS) observations enable the determination of particle 
sizes and their size distributions in situ.125,126 Small-angle X-ray 
scattering (SAXS), extended X-ray absorption fine structure (EXAFS), 
X-ray absorption near-edge structure analysis (XANES), and electron 
spin resonance (ESR) provide information about the local structure 
and electronic properties of metal NPs with different surface 
chemistry and morphology.127,128 X-ray photoelectron spectroscopy 
(XPS),129 Fourier transform infrared (FTIR) spectroscopy and solid-
state nuclear magnetic resonance spectroscopy (SSNMR) can be 
used to obtain information about surface chemistry of metal NPs.130
Matrix-assisted laser-desorption ionisation time-of-flight (MALDI-
TOF) mass spectrometry (MS), inductively coupled plasma mass 
spectrometry (ICP‐MS), UV−vis spectroscopy and exclusion 
chromatography with UV−vis detection (SEC‐UV−vis) have also all 
been utilised to characterise various properties of nanomaterials 
(Fig. 2).114,131,132 Energy-Dispersive X-ray spectroscopy (EDX) analysis 
can be used to confirm the chemical composition of the metal NPs.119
Fig. 2 Evolution of optical absorption spectra of gold clusters with various sizes, 
measured at different temperatures, as indicated. Aun clusters with n = 38, 130 and 144 
show discrete energy states in the spectra and have icosahedral (I) or Marks decahedral 
(M-Dh) structures, whereas the clusters with n = 187, ∼226, 329 and ∼520 have 
plasmonic resonances originating from their metallic band structure and a face-centered 
cubic (fcc) structure. Reprinted with permission from Reference133
Biomedical applications of NMN  
Complexes of noble metals have been used as therapeutic agents 
since ancient times. With the advent of nanobiotechnology, there 
has been a surge towards the development of different kinds of 
nanostructures with a diverse range of biomedical applications (Fig. 
3). In this regard, NMN have gained primary importance; there are 
several reasons for this including: (i) ease of size and shape 
modulation; (ii) unique optical and photothermal properties; and (iii) 
surface functionalisation. Since these nanomaterials can interact 
with biomolecules both at the surface and inside the cell, they 
represent an excellent repertoire of biocompatible nanoscale drugs. 
These NMN can be synthesised both chemically and biogenically with 
high efficiency,134,135 and these engineered nanoscale versions of 
noble metals have inspired researchers to develop innumerable 
therapeutic agents for the treatment of a wide range of 
diseases,136,137 where nanotechnology-based approaches have been 
shown that play a significant role in treatment and early diagnosis of 
these diseases. NMN are the most common nanobiotechnological 
materials used for developing biosensors for clinical diagnostics, due 
to their ease in fabrication, physiochemical malleability, and high 
surface areas,138 allied with their unique spectral and optical 
properties. NMN have had a promising impact on the development 
of new biosensors and on enhancing the specificity and sensitivity of 
already existing biosensing techniques for biomolecular diagnostics 
(Table 4). Noble metal nanostructures can be engineered to 
specifically recognise biomolecules and provide a rapid and accurate 
estimation of the concentration of an analyte.  This can be achieved 
by exploiting changes in the optical properties of noble metal colloids 
as a result of affinity interactions modulating their size and electronic 
configuration (Fig. 8).139 The unique optical properties of different 
surface modified noble metal nano formulations have been used for 
targeting biological components such as DNA, RNA, cells, proteins, 
small organic molecules, and other biological components. This
section will point out some of the unique therapeutic and diagnostic 
abilities of NMN. 
Therapeutic efficacy of NMN
The uptake of inorganic or NMN has been studied extensively in 
recent years. The mechanism of cellular internalisation of noble 
metal nanoparticles such as gold, silver and platinum are not 
necessarily similar and are, at the same time, ambiguous. Size, shape, 
surface charge, and surface chemistry play extremely important roles 
in cellular uptake both in vitro and in vivo. Spherical gold 
nanoparticles (GNPs) exhibit greater cellular uptake than their 
corresponding rod structures.140 It has been reported that 40-50 nm 
particles have the most effective cellular internalisation.141,142 In a 
separate study, it was shown that 50 nm GNPs can enter into cells at 
a relatively faster rate and at a higher concentration than other 
sizes.140 This observation was further validated by both in vitro and 
in vivo studies.143 AsPC-1, PANC-1, and MiaPaca-2 (pancreatic cell 
lines) upon incubation with GNPs of varying hydrodynamic radii, 
exhibited the greatest uptake for 20 nm particles, as shown by TEM 
analysis. Another important factor which modulates cellular 
internalisation of noble metal nanoparticles is surface charge.144,145
The exterior of the cell is mostly anionic; hence positively charged 
noble metal nanoparticles can easily traverse through the cell 
membrane via electrostatic interaction.144 However, negatively 
charged noble metal nanoparticles have also been observed in the 
cell interior as a result of them passively targeting lipophilic 
domains.146 One report suggests that zwitterionic noble metal 
nanoparticles can be a potent and highly efficient drug delivery 
system.147,148
Fig. 3 Biomedical applications of nanoparticles through conjugation with various active 
moieties including nucleic acids, peptides, receptors, antibodies, and small molecules. 
Angiogenesis has been shown to be critically involved in a number of 
diseases such as cancer, rheumatoid arthritis, and macular 
degeneration.149,150 Under normal conditions, angiogenesis is tightly 
regulated by various anti-angiogenic factors such as 
thrombospondins (TSP-1), platelet factor 4, vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF), and 
transforming growth factor beta (TGF‐β).151 Under pathological 
condition, this balance is disrupted that leads to angiogenesis.151 In 
such cases, there is generation of highly abnormal blood vessels, 
which become hyperpermeable to plasma proteins. 
A number of anti-angiogenic agents have been clinically tested but 
they seem to target only the VEGF152 mediated signalling.153 Also, 
these agents possess serious toxicities which result in hypertension, 
thrombosis, and fatal hemorrhage.149,150 Here, noble metal 
nanoparticles can be used as an effective anti-angiogenic agent, 
since they have the ability to target multiple pathways involved in 
angiogenesis.154 Uncapped GNPs exhibit anti-angiogenic properties 
by inhibiting the activity of heparin-binding proteins such as VEGF152
and basic fibroblast growth factor (bFGF) in vitro and VEGF induced 
angiogenesis in vivo.155 It was observed that heparin-binding proteins 
are absorbed on the surface of the GNPs and lose their functional 
attributes.156 The size of GNPs also dictates their anti-angiogenic 
activity; in one study it was shown that VEGF152 preincubated with 
GNPs of varying size (5-20 nm) had a dramatic effect on VEGF 
signalling events.157 The suppression of heparin-binding growth 
factors by nanoparticles has further explained their effectiveness 
against multiple myeloma via inhibiting VEGF- and bFGF- dependent 
proliferation as tested in cell lines OPM-1, RPMI-8266, and U-266. 
This study revealed that cells are arrested in the G1 phase of the cell 
cycle with an up-regulation of p21 and p27.158 The anti-angiogenic 
properties of GNPs could also modulate the status of B-chronic 
lymphocytic leukemia (B-CLL) cells.155 Exposure of GNPs to B-CLL cells 
resulted in an increase in apoptosis in a dose-dependent manner.159
Angiogenesis also plays a crucial role in the promotion and 
maintenance of inflammatory diseases such as rheumatoid arthritis 
(RA). It has been observed that 13 nm GNPs exhibit anti-rheumatoid 
activity in collagen-induced arthritis in rats.160 GNPs bind to VEGF in 
the synovial fluid of patients suffering from RA and affect their 
cellular proliferation and migration. Further, histological studies 
showed that there is reduction in tumour necrosis factor alpha (TNF-
α) and interleukin beta (IL‐β) after intra‐articular administration of 
GNPs. Silver nanoparticles (AgNPs) have also been shown to act as an 
anti-angiogenic agent. AgNPs with size of 40 nm were used to study 
their anti-angiogenic properties in bovine retinal epithelial cells 
(BREC). AgNPs successfully inhibited cell proliferation and migration 
in VEGF induced angiogenesis in BRECs and prevented the formation 
of new blood vessels.159 Furthermore, tumour bearing mice 
demonstrated a reduction of ascite production and suppression of 
tumour progression upon treatment with AgNPs.161,162
Cancer is one of the largest life-threatening diseases worldwide and 
has led to millions of deaths, most of them in developing countries. 
A combination of surgery, chemotherapy and radiation therapy 
constitutes the major treatment procedures for almost all cancer 
therapy. Since these conventional therapeutic regimens are whole 
body approach, there is significant systemic damage to healthy 
tissues and subsequently health-related issues.154 In order to 
minimise the damage to non-cancerous tissue, noble metal 
nanoparticles have been utilised as a potential cancer therapeutic 
agent for non-invasive tumour treatment.163 In this regard, 
application of a magnetic field selectively heats the nanomaterials, 
which allows for selective and effective destruction of tumour 
cells.163 Currently, photodynamic therapy (PDT), regional 
hyperthermia, and radiotherapy are actively being exploited for 
localised cancer treatment.101,164,165 PDT treatment is mainly 
achieved by focusing the light source on the affected area of the 
body. The spectrum of light used here is in the range of 630-900 nm, 
that is the near infrared region (NIR), which is readily absorbed by 
the tissue.164 This range of wavelength minimises the light extinction 
by intrinsic chromophores in the normal or healthy tissue.166 In 
regional hyperthermic tumour therapy, the cancerous cells are 
damaged upon exposure to elevated temperatures.167 There is loss 
of membrane integrity, DNA damage, and induction of apoptosis as 
well as necrosis within a few hours.168 In radiation therapy, cancer 
patients are treated with ionising radiations, which is effective but at 
the same time it is invasive with numerous side effects on healthy 
tissues. Noble metal nanoparticles hold great promise as PDT, 
hyperthermia, and radiotherapy agents. Surface plasmon resonance 
(SPR) of noble metal nanoparticles has been effectively exploited for 
PDT anticancer treatment.169 In one study, it has been shown that 
GNPs can act as PDT agents and selectively destroy cancerous cells 
at very low laser frequency.170 Citrate capped GNPs (15 nm) have also 
been deployed as photothermal therapy (PTT) agents against A431 
cells. This study showed that upon exposure to low levels of laser 
light, GNPs induce the destruction of the malignant cells through 
reactive oxygen species (ROS) mediated apoptosis (Fig. 4a).171
Further, the shape of the GNPs plays an extremely important role in 
PDT therapy, GNPs with different geometry were tested against 
HUVEC cells and it was noted that gold nanorods were 100 times 
more potent than the other shapes tested.172 Similarly, mice injected 
with GNPs had a significant reduction of deep tissue tumours after a 
brief exposure to NIR.173 GNPs have been used for treatment of skin 
cancer; GNPs were administered into the tail vein of mice and local 
laser induced hyperthermia was employed for reduction and 
complete inhibition of skin tumours.174 Radio frequency ablation 
(RFA) in conjunction with GNPs has proved to be an effective 
treatment strategy for liver cancer cell (HepG2) lines; here citrate 
coated GNPs demonstrated a time-dependent cytotoxic effect upon 
exposure to the RF field.175 Noble metal nanoparticles offer an 
attractive advantage in radiotherapy owing to their excellent optical 
properties, surface plasmon resonance, and surface modalities. For 
example, upon X-ray irradiation, GNPs have been shown to induce 
cellular apoptosis by the generation of ROS.176 This therapeutic 
treatment strategy has effectively increased the percentage of 
cancer cells killed without harming the nearby surrounding healthy 
tissue.177,178 Mice injected with GNPs upon X-ray exposure exhibit a 
fourfold reduction in tumour size and also an extended lifetime of 
the animal.179
Fig. 4 (a) Schematic representation of ROS generated tumour cell death using NIR 
induced metal nanoparticles (b) TEM images of Au nanocages for which the surface was 
covered by a pNIPAAm-co-pAAm copolymer with an LSCT at 39oC. The inset shows a 
magnified TEM image of the corner of such a nanocage. (c) Schematic illustration of the 
controlled-release system (cross-sectional view): upon exposure to a near-infrared laser, 
the light is absorbed by the nanocage and converted into heat, leading to the collapse of 
smart polymeric brushes and release off loaded drugs. 
Transport of drugs or therapeutic agents into the cells by GNPs have 
been the subject of intensive studies in biomedical treatment. 
Surface functionalised gold colloids have been extensively studied 
for interaction with the cell membrane for efficient and improved 
drug delivery.145,180,181 In one report, it was observed that surface 
ligand rearrangement on GNPs can regulate cell membrane 
permeability.146 Gold nanoparticles functionalised with an ordered 
arrangement of amphiphilic molecules were able to penetrate the 
cell membrane more efficiently than particles with a disordered 
arrangement of the same molecules that were entrapped in vesicular 
bodies. The therapeutic activity of GNPs on cells can be regulated 
through passive and active targeting mechanisms. Passive targeting 
is based on the concept of an enhanced permeability and retention 
(EPR) effect; here gold colloids can extravasate into the tumour 
stroma because of the defective vasculature and increased lymphatic 
drainage leading to its accumulation at the target site (Fig. 5).154,182
Active targeting relies on surface tuneability of GNPs specifically 
designed for the target molecules to provide high specificity and 
selectivity.183–185 These attributes of gold nanostructures have been 
developed for applications in photothermal therapy,186–188 genetic 
regulation,189–191 and drug treatment.192,193 GNPs are considered a 
potential and powerful therapeutic probe for specific and selective 
killing of cancer cells.194 GNPs scaffolds have been synthesised for 
use as transfection agents in gene therapy for curing cancer and 
genetic disorders. GNPs coated with oligonucleotides are being 
applied as intracellular gene alteration agents for controlling protein 
expression in cells.195 Ribonucleic acid (RNA) modulated colloidal 
gold nanoparticles have been successfully tested for knockdown of 
luciferase activity,196 because the conjugated nanomaterials possess 
an extended half-life as compared to double-stranded(ds)-RNA, 
demonstrating a high gene knockdown capability in cell models. 
Positively charged amino acid (first generation lysine dendrons) 
coated GNPs have proved to be effective and non-toxic transfection 
vectors for DNA delivery, providing up to 28 times greater 
effectiveness than the conventional negatively charged polylysine 
version.197
EPR debate 
It is worth mentioning, however, the debate within the 
nanotechnology community on EPR effect. The general belief is that 
PEGylated nanoparticles have elongated blood circulation time and 
could result in enhanced EPR effect. This concept seems problematic 
when considering the astonishingly small number of translational 
products as compared to the large number of research articles 
produced based on this assumption.9 It is yet to be determined that 
whether the intercellular or intracellular extravasation is the 
predominant mechanism for macromolecules accumulation within 
tumors, as intercellular gaps are very rare.10 Therefore, further 
investigation on the extravasation mechanism of nanoparticles to 
tumours is required to provide useful insight and guidelines for 
designing nanoparticle formulations. 
Targeted delivery of drugs has been carried out efficiently using gold 
colloids by loading drugs onto GNPs through non-covalent or 
covalent interactions. Drug entrapment with GNPs is achieved 
through the use of hydrophobic or hydrophilic pockets198 presented 
by the monolayer. Polymer encapsulated GNPs provide an 
amphiphilic surrounding for the entrapment of hydrophobic silicon 
phthalocyanine 4 (Pc 4), a photodynamic therapy (PDT) agent.199 This 
conjugation releases the drug efficiently and quickly and deep into 
tumour tissues within hours of incubation. Covalently conjugated 
GNPs drugs are released through glutathione (GSH) displacement200
or through linker cleavage.201 A GSH-mediated release strategy using 
6-mercaptopurine-9-b-D-ribofuranoside functionalised GNPs, has 
been used to enhance anti-proliferative activity against K-562 cell 
lines compared to the free drug.202 The GSH-mediated pathway has 
also been investigated to track the movement of GNPs carrying 
either fluorescein or doxorubicin molecules into a tumour model.203
Fig. 5 (a) Schematic illustration of tumour microenvironment. (b) Mother vessels with 
thinned or compressed endothelial cells, degraded basement membranes, and pericyte 
detachment are highly permeable to both small molecules and proteins. Mother vessels 
can further differentiate into glomeruloid microvascular proliferations, vascular 
malformations, and capillaries. (c) Schematic representation of transcellular and 
intercellular transport of nanoparticles from across vessel wall.
Although, no GNPs have been approved clinically, a few of them have 
been going through clinical trials. These nanodrugs harness the light-
absorbing ability of GNPs and are being currently explored for 
treating solid tumours and acne. One such gold colloid nanodrug 
approved for clinical trials is AuroLase, developed by Nanospectra, 
this comprises silica-gold nanoshells coated with polyethylene glycol 
(PEG) designed for the treatment of solid tumours by thermal 
ablation using a NIR source.204 Here, silica provides a dielectric core, 
gold nanoshells confer thermal ablation ability, while the PEG 
induces an overall stability to the nanocomposite.11 In another 
example, Sebashells developed by Sebacia Inc., which are similar to 
AuroLase, have been applied to treat acne by disrupting overactive 
sebaceous glands in the skin.205 These Sebashells are topically 
administered to the site of acne, delivered deep into the sebaceous 
glands by low frequency ultrasound and ultimately stimulated via a 
NIR laser, utilising the heating capacity of the gold nanoshells for 
effective acne treatment (Fig. 4 b and c). These studies have been 
done in vivo showing the potential efficacy of Sebashells in 
preventing inflammatory acne lesions.204
Silver nanoparticles (AgNPs) possess anticancer and antitumour 
properties by inhibiting angiogenesis around tumour tissues. This has 
led to an extensive research regarding the potential application of 
AgNPs in cancer treatment both in vitro and in vivo. These studies 
have been conducted on different cancerous cell line models such as 
MCF-7, B10F17, A549, SiHa, and HeLa cell lines. Monomeric polymer 
encapsulated AgNPs have shown antileukemic properties against 
AML human cell lines.206 This study provides a dose and size 
dependent response of AgNPs against these cell lines in vitro. AgNPs 
proved to be a potent antileukemic agent by providing high 
specificity against AML cell lines as opposed to normal hematopoietic 
cells. The mechanism behind this activity is that AgNPs increase the 
production of ROS and release of silver ions (Ag) from nanomaterials, 
this results in the induction of apoptosis and DNA damage. The 
release of Ag ions from AgNPs has also been proposed to induce 
tumour cell sensitisation,207 these Ag ions are captured by free 
electrons, generating an oxidising agent which reduces the 
production of ATP in tumour cells and subsequently enhances 
intracellular ROS concentration. It has also been reported that 
release of Ag ions from AgNPs is greater as compared to bulk or 
powder silver.208 Silver ions do not produce hydroxyl radicals (OH) 
in the presence of H2O2, which is a mild reducing agent. In contrast, 
AgNPs produce OH in the presence of H2O2 only at acidic pHs. This 
pH dependent OH production by AgNPs confers their anticancer 
and antitumour activity. Biogenically synthesised AgNPS have also 
shown anticancer properties,209 like AgNPs synthesised from 
mushroom which were tested against MDA-MB-231 human breast 
cancer cell lines. AgNPs disrupt the cell membrane integrity and 
increase production of lactate dehydrogenase (LDH), a biomarker for 
cell death. AgNPs synthesised using Bacillus funiculus and leaf extract 
from Podophyllum hexandrum, causes caspase mediated apoptotic 
cell death.210,211 The antitumour activity of AgNPs was studied in 
multiple drug resistant (MDR) malignant melanoma cell tumours in 
vivo.212 Here, transactivator of transcription (TAT) was anchored 
onto AgNPs surface; this conjugation increases the antitumour 
activity by several fold. 
Cisplatin, a platinum complex, has been used for several decades for 
treating a number of abnormalities. In contrast, the application of 
platinum nanoparticles (PtNPs) as therapeutic agents is still in its 
infancy.213 PtNPs possess the penetration capacity of entering cells214
and the uptake and bioactivity of PtNPs have been investigated 
thoroughly which includes their cytotoxicity, genotoxicity, and 
effects on protein expression in human cells.214 PtNPs penetrate into 
the cells through diffusion and are localised inside the cytoplasm. 
Upon exposure to PtNPs several events take place inside the cells 
such as, DNA damage at the S-phase of the cell cycle ultimately 
leading to apoptosis, up regulation of p53 and p21, and down 
regulation of proliferating cell nuclear antigens. These intracellular 
effects of PtNPs make it a potent anticancer therapeutic candidate 
for future use. In vitro PtNP treatment elicits DNA damage and 
antioxidant response.142 The anti-cancer activity of platinum 
nanomaterials215 has been shown in a recent study where 
synchronous application of PtNPs in conjunction with hadron 
therapy resulted in enhanced DNA strand disruption. Irradiation of 
platinum by carbon ion leads to the generation of OH radicals which 
in turn amplifies the extent of damage to DNA.216 An investigation 
with human colon carcinoma cells (HT29) exhibited a size-, dose-, and 
time-dependent response upon incubation with PtNPs.142 The 
mechanistic reason behind the DNA damage was due to the release 
of Pt2+ ions from PtNPs causing a significant DNA damage and cellular 
apoptosis.214,217 Hence, it was predicted that the nanoparticle itself 
does not interact directly with DNA, instead the soluble Pt2+ ions 
form a complex with DNA similar to cisplatin.214 Culturing cells with 
PtNPs leads to the subsequent activation of p53 and p21, which 
causes genotoxic stress.217 Thus, PtNPs can be potentially used in 
radiosensitisation as well.215 Apart from being effective in cancer 
therapy,  PtNPs have been applied for the treatment of Parkinson’s 
disease by functioning as a mitochondrial complex I, by lowering ROS 
generation, and by scavenging free radicals such as superoxide and 
H2O2.218 PtNPs synthesised using leaf extract have also been used to 
treat Parkinson’s disease.219 The neuroprotective activity of the 
phytochemical conjugated PtNPs was studied in experimentally 
induced Parkinsonism in the zebra fish model. The results verified 
that upon pre-treatment with PtNPs, experimentally induced 
Parkinsonism could be reversed. PtNPs have been revealed to 
provide protection against oxidation-induced inflammation, this 
action of PtNPs decreases the osteoblastogenesis which causes bone 
loss.220 PtNPs play an important role in reducing cellular oxidative 
stress by acting as a quencher for ROS such as H2O2 and superoxide, 
thus resembling two biological enzymes, catalase and superoxide 
dismutases (SOD). Apoferritin surface functionalised PtNPs (AF-
PtNPs) have been applied for studying the scavenging capability of 
H2O2 and superoxide on mammalian cell line Caco-2. It was observed 
that AF-PtNPs successfully compensated H2O2 and superoxide. 
Owing to the receptor mediated internalisation of ferritin-
functionalised nanoparticles into the cells, the membrane integrity 
was preserved and other adverse interactions with cellular proteins 
were avoided. After incorporation into Caco-2 cells, PtNPs decrease 
the oxidative stress within the cell and increase cell viability.221 ROS 
scavenging and apoptotic properties of PtNPs have also shown 
promising potential in treating ultraviolet (UV) induced inflammatory 
responses in the skin.222 An in vitro study in cell lines revealed a 
marked increase in ROS generation in UV-treated HaCaT 
keratinocytes cell lines, while a decrease in ROS production was 
observed in PtNPs treated cell lines. It was shown that mice treated 
with PtNPs gel prior to UV irradiation demonstrated a significant 
inhibition of UVB-induced inflammation and UVA-induced photo 
allergy compared to untreated controls. 
Well documented studies on metal nanodrugs such as gold, silver 
and platinum have been thoroughly carried out for an extended 
period of time and some of them have even found their way into 
clinical trials (Table 1&2).223 Technologies based on alternative noble 
metal nanocomposites are being intensively studied for probable 
applications in the medical sector. Palladium is one such noble metal 
and its nanostructure has drawn tremendous interest in the last 
decade for a variety of applications.224–229 Despite the remarkable 
property of palladium as a metal and its diversified exploitation in 
several biomedical applications,230,231 palladium nanocomposites 
have made a late entry into the nanobiotechnology field. Here, we 
discuss the therapeutic property of palladium nanomedicines routed 
in their catalytic, photothermal and biological activity. Firstly, 
polymer functionalised palladium resin has been used as a prodrug. 
This palladium nanocomposite resin complex has been shown to 
activate a number of biologically inert drugs such as 5-fluoro-1-
propargyluracil232 and N4-propargyloxycarbonyl gemcitabine.233
These two drugs are otherwise biologically inactive, but combined 
treatment with palladium nanocomposite resin restores the anti-
proliferative and cytotoxic activity of these drugs in colorectal and 
pancreatic cancer cells. Toxicity of these resin palladium conjugates 
has been performed in the yolk sac of zebra fish and the results 
indicate no apparent toxicity while the chemical activity of the 
prodrug remains intact.232 Photothermal efficiency of palladium 
nanostructures such as palladium nanosheets, has opened the door 
for their incorporation in cancer therapeutics. Hexagonal palladium 
nanosheets displayed efficient photothermal conversion efficiency 
due to their strong adsorption in the NIR region.234 This 
photothermal efficiency depends on size and surface coating, which 
in turn affects the cellular uptake of these nanosheets.235,236 An 
interesting finding is that palladium nanosheets tend to show better 
photostability than even gold and silver nanostructures. When 
palladium nanosheets are coated with GSH, they demonstrate better 
renal clearance.237 In vivo studies have shown that in the absence of 
any irradiation, these GSH-palladium nanosheets exhibited longer 
retention time in the circulating blood, accumulate near the tumour 
site, and showed no toxicity, whereas upon irradiation with NIR laser, 
tumour ablation occurs.237 The attractive properties of these 
nanostructured materials have further extended their application in 
more complex assemblies for combined photothermal-
chemo/photothermal-photodynamic therapy treatment. Anti-
cancer drug loaded silica nanoparticles entrapped within palladium 
nanosheets have proved to be an effective treatment strategy for 
combined photothermal and chemo-therapy; heat resulting from the 
NIR light conversion leads to pH dependent release of anti-cancer 
drugs and the cellular uptake of palladium nanosheets was 
significantly enhanced by the mesoporous coating of the silica 
nanoparticles.238 Other lesser known nanomaterials of Rh, Ir, and Os 
have still not been put to wide use in biomedical research, although 
there have been a few examples. The UV plasmonic properties of Rh 
nanocomposites have been extensively studied to show their 
potential uses in UV plasmonic and photocatalytic applications.239 Ir 
and Os nanoparticles remain less explored and need a thorough 
investigation regarding their future efficacy in clinical and human 
health research. 
Table 1 Noble metal nanoparticles in clinical trials 
Type of noble 
metal 
nanoparticles 
Condition or disease Properties of noble metal 
nanoparticles 
NCT number Phase Recruitment Status 
GNPs Coronary Artery Disease 
Atherosclerosis 
GNPs with silica-iron oxide shells 
with photothermic burning or 
melting effect onto the lesion 
NCT01436123 Phase I Terminated (under 
political pressure) 
GNPs Type 1 Diabetes GNPs with attached peptide 
fragment related to insulin  
NCT02837094 Phase I Recruiting 
GNPs Gliosarcoma 
Recurrent Glioblastoma 
Small GNPs with nucleic acid 
arranged on the surface (NU-
0129) 
NCT03020017 Phase I Active, not recruiting 





GNPs with silica-iron oxide shells 
with photothermic burning or 
melting effect onto the lesion 
NCT01270139 N/A Completed 
GNPs/AgNPs Caries Class Ii AgNPs & GNPs suspended in 70 % 
isopropyl alcohol used for cavity 
pre-treatment 
NCT03669224 N/A Not yet recruiting 
GNPs Pulmonary Hypertension GNPs coated with organic ligands 
as sensor array for detecting 
volatile organic compounds in 
exhaled breath in patients 
NCT02782026 N/A Unknown 
GNPs Stomach Diseases Functionalised GNPs & carbon 
nanotubes nanosensors array 
identifying gastric diseases 
NCT01420588 N/A Unknown 
GNPs Parkinson's Disease Functionalised GNPs & carbon 
nanotubes nanosensors array 
identifying Parkinson’s diseases 
NCT01246336 N/A Completed 
AgNPs Foot Infection Fungal 
Infection, Bacterial 
AgNPs containing cream NCT03752424 Phase I Recruiting 
AgNPs Oral microbial colony 
formation 
AgNPs containing gel NCT02761525 N/A Completed 
AgNPs Dental Caries Nanosilver fluoride (5%) solution NCT01950546 Phase I Completed 
AgNPs Tooth Demineralization AgNPs incorporated into the 
primer orthodontic Transbond XT 
NCT02400957 Phase III Unknown 
AgNPs Chronic Rhinosinusitis Colloidal AgNPs NCT03243201 Phase I Withdrawn (IND not 
approved) 
AgNPs Down Syndrome AgNPs containing fluor varnish  NCT01975545 Phase II Unknown 
AgNPs Partial Dentin Caries 
Removal 
Nanosilver fluoride solution NCT03193606 N/A Active, not recruiting 
AgNPs Central Venous Catheter 
Related Infections 
Central venous catheter 
impregnated with AgNPs 
(AgTive®) 
NCT00337714 Phase IV Completed 
AgNPs Antimicrobial efficacy 
In healthy subjects 
Nanosilver gel NCT00659204 Phase III Unknown 
AgNPs Rhinosinusitis Topical silver colloid NCT02403479 Phase I/II Unknown 
AgNPs Postoperative Pain AgNPs gel NCT03692286 Phase IV Not yet recruiting 
AgNPs Dental Caries Nanosilver fluoride solution NCT03186261 Phase III Not yet recruiting 
AgNPs Plantar Warts Colloid silver and fig extract 
mixture 
NCT02338336 Phase I/II Completed 
AgNPs Surgical Site Infection Colloid silver containing bath 
wipes 
NCT03401749 Phase IV Recruiting 
Exploring the anti-viral potential of NMN: Concern regarding 
growing microbial resistance to all types of antimicrobial agents used 
against different infectious diseases has led to a fusion between 
nanotechnology and microbiology. Broad-spectrum activities of 
noble metal nanostructures and their application to resolve 
microbial resistance issues have initiated a positive development in 
this field. The antibacterial, antifungal, antiviral, and antiprotozoal 
property of noble metal nanoparticles have attracted huge interest 
from the scientific community throughout the world (Fig. 6). This 
section will elucidate some of these diversified and multifunctional 
facets of noble metal nanoparticles with regards to their 
antimicrobial potentials (Table 3). Apart from their roles as 
antitumour agents, GNPs have been employed to deliver antibiotics 
and antibacterial agents as well. A variety of antibiotic conjugated 
gold colloids have shown promising activity against various bacterial 
strains.240 The exact mechanism behind this antibacterial activity of 
GNPs has evaded researchers, but one of the primary reasons could 
be stable antibiotic-GNP conjugate formation. In one report it has 
been suggested that the direct use of antibiotic in the synthesis of 
GNPs offers a much-improved antibacterial activity.241 GNPs are also 
investigated for their antiviral activity against human 
immunodeficiency virus (HIV), the cause of acquired 
immunodeficiency syndrome (AIDS). Functionalisation of GNPs with 
HIV-1 integral protein transduction domain (PTD) was tested in vitro 
in a human fibroblast cell line. It was observed that surface modified 
GNPs (~5 nm) can traverse across the plasma membrane, whereas 
larger particles (~30 nm) are unable to do so. This study provides 
clear evidence that smaller sized GNPs can be used as a drug delivery 
vehicle for AIDS.242 Free SDC-1721, a derivative of TAK-779 and a 
known CCr5 antagonist, which is the primary entry co-receptor for 
transmitted strains of HIV-1, has no inhibitory effect on HIV infection. 
However, when conjugated with GNPs, the resulting SDC-1721-GNPs 
conjugates showed enhanced inhibitory activity against HIV 
infection.243 Another anti-HIV activity was studied with bare and PEG 
coated GNPs, in which it was demonstrated that bare GNPs exhibit 
significant anti-HIV properties as compared to PEG-GNPs; this may 
be due to the fact that nanoparticles coated with charge stabilisers 
(PEG) are larger in size and hence cannot enter into the cells and 
inhibit viral growth.244 Receptor binding inhibitory activity of GNPs 
against HIV was studied using sugar coated nanoparticles. This study 
showed that sugar coated GNPs block the function of dendritic cell-
specific ICAM-3 grabbing non-integrin (DC-SIGN), which constitutes a 
major receptor for HIV-1.245 GNPs have also been applied for 
treatment of Tuberculosis (TB) by utilising multi-block copolymer 
conjugated GNPs as a successful delivery vehicle for TB drugs such as 
Rifampicin.246 Application of GNPs as a drug delivery machinery has 
led to their incorporation in immunisation therapy due to their small 
size and ability to enter cells. For example, GNP-conjugated chitosan 
exhibits an enhanced serum antibody response which is several folds 
more powerful than the naked DNA vaccine.247 GNPs are potential 
carriers for the development of synthetic peptide vaccine against 
foot-and-mouth disease virus (FMDV). A synthetic peptide 
resembling FMDV proteins was conjugated with GNPs, and after 
immunisation it was observed that there was production of specific 
antibodies against the peptide.248 The role of GNPs in cancer 
immunotherapy has also been studied extensively.249 There are 
several reviews regarding the advancements of conjugated GNPs in 
vaccine delivery.250 One group of researchers illustrated the adjuvant 
properties of GNPs in facilitating the delivery of both the ovalbumin 
(OVA) peptide antigen and CpG adjuvant, resulting in an enhanced 
therapeutic effect in a B16-OVA tumour model.251 Silver 
nanoparticles (AgNPs) represent one of the most common 
nanocomposites used in consumer goods and in medical products, 
including wound healing bandages and a variety of antiseptic 
sprays.252 AgNPs have been shown to provide protection against 
various infectious diseases, since they act as antifungal, 
antiarthropod, antiviral and antiprotozoal agents.253 Additionally, 
the powerful antimicrobial as well as highly toxic activity of silver 
nanocomposites have been extensively studied and reported.252,254–
257 AgNPs have been shown to possess higher cytotoxicity compared 
to the well documented GNPs.258–260 Three probable explanations 
are given in order to describe the antibacterial activity of AgNPs: (i) 
direct interaction of AgNPs with the bacterial cell membrane results 
in membrane disruption and complex formation with substances 
located intracellularly;261 (ii) AgNPs interact with the thiol groups (-
SH) and produce ROS;262 and (iii) subsequently, there is release of Ag+
ions which inhibit respiratory enzymes and also increase ROS 
generation (Fig. 7).263
Fig. 6 Schematic representation of the proposed mechanism of antibacterial activity of 
the iodinated chitosan-Ag NP composite. Modified from Ref 262. 
Table 2 Therapeutic applications of noble metal nanoparticles.
Type of noble metal 
nanoparticles 
Application Properties of noble metal 
nanoparticles 
References 
GNPs Inhibition of VEGF165 and bFGF Anti-angiogenic 155–157
GNPs Prevention of multiple myeloma Anti-angiogenic 160
GNPs  Inhibition of B-chronic lymphocytic 
leukemia 
Anti-angiogenic 264
GNPs  Prevention of collagen-induced arthritis Anti-angiogenic 265
GNPs  As PDT agents for cancer treatment LSPR 199,204,266
GNPs  As PTT agents for cancer treatment LSPR 171,186–188
Gold nanorods As PDT therapy for cancer treatment LSPR 172–174
GNPs  For skin cancer treatment LSPR/hyperthermia 174,204,205
GNPs Treatment for liver cancer LSPR/Radio frequency ablation 175
AgNPs Inhibition of VEGF Anti-angiogenic 161,162
AgNPs Cancer treatment Anti-angiogenic 206,207
AgNPs Breast cancer treatment Anti-angiogenic 209–211
AgNPs Prevention against MDR malignant 
melanoma cell tumours 
Anti-angiogenic 212
PtNPs Cancer treatment LSPR/radiation therapy 215
PtNPs Cancer treatment Anti-angiogenic 214,217
PdNPs Cancer treatment Anti-angiogenic 232,233
PdNPs As PTT agents for cancer treatment LSPR/Hyperthermia 234–236
PdNPs Tumour treatment LSPR/Photothermal ablation 237
Table 3 Antimicrobial properties of noble metal nanoparticles. 
Type of noble metal 
nanoparticles 
Application Antimicrobial properties References 
GNPs  Inhibition of vancomycin-resistant 
enterococci 
Antibacterial 240
Cefaclor capped GNPs Inhibition of E. coli and S. aureus Antibacterial 241
GNPs functionalised with 
PTD 
Prevention of HIV-1 Antiviral  242
GNPs-SDC 1721 conjugate Inhibition of HIV-1 Antiviral 243
PEG-GNPs Prevention of HIV Antiviral 244
Sugar coated GNPs Inhibition of receptor binding in HIV-1 Antiviral 245
Copolymer conjugated GNPs As drug delivery vehicle for Rifampicin for 
treatment of Tuberculosis  
Antibacterial 246
AgNPs Inhibition of S. aureus, Streptococcus 
pyrogenes, S. enteric  and Enterococcus 
faecalis 
Antibacterial 267
PEG-AgNPs Inhibitory action against S. aureus, 
Salmonella typhimurium 
Antibacterial 268
AgNPs Prevention of Tuberculosis Antibacterial 269
AgNPs Inhibitory action against Candida albicans, 
C. Tropicalis, Trichophyton 
mentaprophytes, C. glabrata  and C. krusei 
Antifungal 253,270
AgNPs  Prevention of severe keratitis Antifungal 271
AgNPs Inhibition of plaque formation in MPV Antiviral 272
AgNPs Prevention of HIV Antiviral 273–277
AgNPs Inhibition of virus binding in HIV-1 Antiviral 275
AgNPs Prevention of H1N1 Antiviral 278
AgNPs Inhibitory action against HSV-1, HSV-2 and 
HPIV-3 
Antiviral 279,280





Inhibition of TCRV Antiviral  282
AgNPs Inhibitory action against Cryptosporidium 
parvum in water purification 
Antiprotozoal 283,284
AgNPs Prevention of leishmania Antiprotozoal 284,285
AgNPs Inhibitory action against Plasmodium 
falciparum  
Antiprotozoal 286,287
AgNPs Wound healing Antibacterial and Antifungal 288–290
PtNPs Prevention of Parkinson’s disease Antioxidant 218,219
PtNPs  Prevention of bone loss Antioxidant 220
PtNPs and AF-PtNPs ROS scavenger Antioxidant 221
PtNPs Prevention of UV-induced inflammatory 
responses in skin 
Antioxidant 222
PtNPs Inhibitory activity against P. aeruginosa Antibacterial 291
Ru nanoparticles Inhibition of Gram-positive and Gram-
negative bacteria 
Antibacterial  292
Mycosynthesised AgNPs using different strains of fungi have shown 
significant efficacy against Staphylococcus aureus, Streptococcus 
pyrogenes, Salmonella enteric and Enterococcus faecalis.267 AgNPs 
associated with traditional antimicrobial drugs have been deployed 
to provide the possibility of more rational therapies. AgNPs 
synthesised using Aspergillus flavus and upon conjugation with 
several antibiotics such as ciprofloxacin, gentamicin, vancomycin and 
trimethoprim have been studied.293 When AgNPs were used in 
combination with gentamicin, ampicillin, vancomycin, and oflaxacin, 
there was an improvement in antimicrobial activities. This enhancing 
effect of AgNPs emphasises the potency of Ag in increasing the 
membrane permeability.294 One of the reports suggests that AgNPs 
enter the cell by disrupting the cell membrane and interfering with 
the cytoplasmic content.295 The size-dependent antibacterial activity 
of AgNPs has been investigated and it has been indicated that smaller 
AgNPs exhibit enhanced antibacterial activity as a result of relative 
increase in contact surface area.296 PEG-AgNPs of different sizes were 
tested for their antibacterial activities against Gram-positive (S. 
aureus) and Gram-negative (Salmonella typhimurium) bacteria, the 
results demonstrated that size modulation of PEG-AgNPs can 
significantly enhance the antimicrobial properties of AgNPs against 
both these pathogens.268 There are several reports which throw light 
on the antibacterial activity of AgNPs against MDR.269 It has been 
demonstrated that AgNPs and GNPs are equally effective against E. 
coli and Mycobacterium tuberculosis (MTB), but a higher 
antimicrobial activity has been reported by AgNPs. This result 
suggests that AgNPs can be used for TB therapies. In consistency with 
the above observation, it has been established that AgNPs coated 
with bovine serum albumin (BSA) offer better biocompatibility 
against TB without losing their effectiveness, as opposed to polyvinyl 
pyrrolidone (PVP)-AgNPs. 
The antifungal property of colloidal silver is comparatively less 
studied in comparison to its antibacterial activity. Still, there are 
numerous reports which confirm that AgNPs can be a potent 
antifungal agent. AgNPs have shown significant activities against 
different fungal species such as Candida albicans, C. tropicalis, 
Trichophyton mentagrophytes, C. glabrata and C. krusei.269
Biosynthesised AgNPs seem to have antifungal properties against 
Phoma glomerata, P. herbarum, Fusarium semitectum, and 
Trichoderma species; they also showed synergistic effect when in 
conjugation with a standard antifungal agent such as fluconazole.270
Antifungal action of AgNPs in combination with heterocyclic 
compounds, namely thiazolidine, phthalazine, pyrazolo, and 
hydrazide, were investigated against Aspergillus flavus and C. 
albicans. The results indicate an enhanced antifungal activity in 
combination with above mentioned compounds as compared to 
heterocycles alone.297 In a separate study, AgNPs and natamycin 
were tested against various strains of fungi among patients suffering 
from severe keratitis and the authors observed a higher antifungal 
activity of AgNPs in comparison to natamycin.271 A possible 
explanation for the antifungal properties of AgNPs might be due to 
its role in disrupting cell membrane integrity and by inhibiting the 
normal budding process in yeasts.298 AgNPs are also emerging as one 
of the possible potent options for managing viral diseases due to 
their potential antiviral properties.299 AgNPs are capable of acting on 
broad range of viruses and offer a lower probability of developing 
resistance against viruses as compared to conventional antivirals.  
AgNPs synthesised by biological processes tends to exhibit higher 
antiviral properties as compared to chemically synthesised 
particles.279,300 Kidney epithelial cells extracted from an African green 
monkey and co-incubated with AgNPs displayed significantly 
reduced plaque formation with Monkeypox virus (MPV).272 The 
preventive antiviral nature of AgNPs has been extended to HIV, 
where they are seen to prevent the host cells from binding with the 
virus in vitro.273,274 AgNPs effectively decrease HIV-1’s infectivity by 
acting directly on the virus by binding to the glycoprotein gp120.275
This structural alteration in turn, decreases the CD4-dependent 
virion affinity, thereby preventing HIV-1 infection.275 Recent studies 
have yielded promising results regarding the antiviral property of 
AgNPs against influenza A H1N1 virus.278 The antiviral potency of 
AgNPs has been further demostrated against Herpes simplex virus 
types 1 and 2 (HSV-1 and HSV-2) and human parainfluenza virus 
types-3 (HPIV-3) in a dose-dependent manner.279 A similar study was 
carried out against adenovirus type 3 (AD3) where it was illustrated 
that AgNPs processed cytotoxic effect against AD3 by not only 
damaging the virus particles, but also disrupting the DNA structure. 
In addition, AgNPs can damage the capsid protein which inhibits the 
virus attachment to the host.281 Capping agents play a significant role 
in reducing infectivity and enhancing biological compatibility. AgNPs 
coated with stabilising agents such as PVP, PEG, and citrate have also 
been proved to be powerful antiviral agents, in a size-dependent 
manner. It has been shown that a polysaccharide coating on AgNPs 
protects the cell from the toxic effect of the nanoparticles, but also 
reduces the NP’s activity against tacaribe virus (TCRV).282 In contrast, 
the same capping agent results in better antiviral activity efficiency 
against MPV.272 Other examples of coated AgNPs as effective 
antiviral agents have been offered in several studies such as HIV-
1,275–277 HSV,280 and respiratory syncytial virus (RSV).301 PVP capped 
AgNPs have been used to prevent transmission of HIV-1 infection 
using an in vitro human cervical tissue-based organ culture275 and 
also as a coating for polyurethane condoms in order to inactivate 
infectious microorganisms.280
Fig. 7 Schematic diagram of anti-infective properties of NMN.
The studies showed effective reduction in HIV infection, but the 
mode of action is yet to be ascertained. One possible mechanism 
suggested is that AgNPs interact directly with surface glycoproteins 
and thereby interfere with the binding and fusion events during viral 
penetration into susceptible cells. Additionally, AgNPs are also able 
to inhibit post-entry stages of the HIV-1 life cycle by blocking various 
functional HIV-1 proteins or reducing the rate of proviral 
transcription by binding to the RNA or DNA moieties. The 
antiprotozoal activity of AgNPs has also been studied recently. The 
efficacy of AgNPs as an antiprotozoal agent against Cryptosporidium 
parvum was assessed and the disinfectant properties of AgNPs for 
water purification was demonstrated.283,284 Green-synthesised 
AgNPs using F. oxysporum have shown promising result against 
Leishmania amazonesis promastigotes both in vitro and in vivo.284
AgNPs inhibit the biological activity of Leishmania tropica and this 
effect was enhanced under UV irradiation. The enhancement in anti-
leishmanial activity under UV light was attributed to the ability of 
AgNPs to release Ag+ ions, leading to the interaction of the AgNPs 
with the parasitic surface lipophosphoglycan and glycoproteins, 
which are responsible for spreading infection.285 AgNPs have 
profound influence against plasmodia, biosynthesised AgNPs using 
Acanthaceae and leaf extract of Catharanthus roseus have 
demonstrated promising indication against Plasmodium falciparum 
in a size-dependent study.286,287 Wound healing promoted by AgNPs 
provides possible direction of research. Topical application of AgNPs 
in a mice model exhibited wound healing and reduced scar formation 
properties in a dose-dependent manner.288 When it was used for 
burns, AgNPs of <20 nm in diameter at very low concentrations were 
able to work simultaneously as an antimicrobial as well as an anti-
suppressant against local systematic inflammation in vivo. Studies of 
AgNPs acting as skin wound-healing agents in vivo have been. It was 
observed that low concentrations of AgNPs (~10 nm) promoted 
wound closure and wound contraction by enhancing the 
proliferation and differentiation of keratinocytes and fibroblasts.289
Another study concerning the skin penetration efficacy of colloidal 
silver and silver nanoclusters has shown that they are able to 
penetrate into human stratum corneum as well as the outermost 
surface of the epidermis.290 Polymer conjugated AgNPs in the size 
range of <50 nm can promote penetration through intact as well as 
damaged human skin; these future applications of AgNPs could have 
relatively long-lasting therapeutic benefits. 
Studies on the antibacterial property of PtNPs performed with the 
pathogen, P. aeruginosa, observed that PtNPs showed size-
dependent bacterio-toxic and bacterio-compatible properties.291
Ruthenium (Ru), rhodium (Rh), iridium (Ir) and osmium (Os) are the 
other so-called noble metals; they have gained considerable 
importance in the drug industry owing to their anticancer, 
antirheumatic, antimalarial, and antibacterial activities. Their 
assimilation into nanobiotechnology research is not as mature as 
other well-known nanomaterials such as gold, silver, platinum, and 
palladium. Ru is a 4d transition metal belonging to the platinum 
group.302,303 Despite the limited use of Ru nanoparticles in biomedical 
and clinical research, they have impacted on several other important 
application areas including catalytic dehydrogenation,304 methanol 
fuel cells,305 synthesis of diesel fuels,306 degradation of azo dye,307
and removal of organic pollutants from water,308 to name but a few. 
Recently, one group showed the antibacterial activity of Ru 
nanoparticles.292 In this study, they synthesised Ru nanoparticles 
using leaf extract; green-synthesised Ru nanoparticles, in the size 
range of ~40 nm, were tested against gram-negative and gram-
positive bacteria in order to determine their antibacterial efficacy. 
The results obtained demonstrated that Ru nanostructures tend to 
be most effective against gram-positive bacteria. Ru nanoparticles 
attach themselves onto the bacterial membrane by electrostatic and 
coordinated covalent interactions, leading to generation of ROS 
within the bacterial cell and subsequent ultimate cell death.239
Hence, we could see Ru nanoparticles being applied for development 
of drugs against gram positive bacterial diseases. 
Fig. 8 The arrangement of actin is followed as cells spread on a monolayer of collagen IV. 
Time points at 4 h (left) and 8 h (right) are shown. White stars indicate a cell body and 
arrows indicate actin alignment. Scale bar is 20 µm. Reprinted with permission from139
Diagnostic and imaging potential of NMN 
Diagnosis and sensing applicability of NMN: The phenomenon of 
Localised Surface Plasmon Resonance (LSPR) in noble metal 
nanoparticles has been most widely used for the development of 
new biosensors. LSPR arises from the electromagnetic waves that 
travel along the surface of conductive metals and semiconductors.309
Upon excitation with an external light source, noble metal 
nanoparticles produce an intense absorption and scattering as a 
result of the collective oscillation of the conductive electrons present 
at their surface and conductive bands. Noble metals, especially gold 
and silver, have been employed in many biosensors.
Table 4 Diagnostic application of noble metal nanoparticles.
Type of noble metal 
nanoparticles 
Application  References  
GNPs Detection of DNA 310–315
GNPs Detection of SNPs, UV-induced mutagenic or carcinogenic DNA 
dimmers and detection of unamplified hepatitis C virus RNA 
316–319
Citrate capped GNPs Sensing of thiourea and melamine 320,321
Fibrinogen functionalised GNPs Detection of genes associated with sickle-cell anaemia 313
Gold nanobeacons Mutation associated with cystic fibrosis 322,323
GNPs Detection of HIV-1 p24 antigen 324,325
GNPs Detection of HBV genes 326
GNPs  Detection of Mycobacterium tuberculosis DNA sequence 327–329
GNPs Biomarkers for Alzheimer’s disease 330
Graphene oxide-GNPs Detection of MB 331
GNPs Quantification of NAADP 332
AgNPs Detection of bombesin, a neurotransmitter tumour marker 333
AgNPs Sensing protein-protein and protein-small molecule interaction 334,335
AgNPs Glucose detection 336,337
AgNPs Detection of DNA 338
Peptide functionalised GNPs Anthrax biomarker detection 339
GNPs/AgNPs Detection of DNA sequence for HIV 340–343
GNPs-MBA conjugate Hepatitis B virus antigen 344
Gold nanobeacons Detection of erbB-2 and ki-67 breast cancer biomarkers 345
Graphene oxide-PtNPs Detection of cancer cells 346,347
GNPs Detection of E. coli 348
GNPs modified with 4-amino-1-(-
3-mercapto-propyl)-pyridine 
hexafluorophosphate 
Sensing human IgG concentration 349
Graphene oxide-GNPs Detection of alpha-fetoprotein 350
PdNPs Detection of alpha-fetoprotein 351
PdNPs Detection of prostate specific antigen 352
AgNPs-titanium phosphate Immunodetection of IL-6 353
Graphene oxide-AgNPs Immunodetection of E. coli 354
6-ferrocenyl hexanethiol 
functionalised GNPs 
Immunosensing of prostate specific antigen 355
LSPR leads to exceptionally high absorption and scattering properties 
within the UV-visible wavelength which confers the particles with 
higher sensitivity in comparison to conventional organic dyes, 
making them a perfect foil for colorimetric sensor applications.356,357
The sensing efficiency of GNPs depends upon their intrinsic localised 
surface plasmon resonance, with wavelengths around 510-530 nm 
for gold nano formulations of around 4-40 nm, which can be used for 
biosensing.358 This effect is generally absent in the individual atoms 
and the bulk form.359,360 The binding of molecules onto the particle 
surface changes the LSPR, which is reflected by the scattered light in 
dark field microscopy.361 In addition, SPR is drastically changed when 
the average distance between the Au particles changes during the 
formation of gold colloid aggregates.362 This attribute of GNPs has 
been utilised, for example, for the detection of DNA,310,311 by taking 
advantage of the binding affinity of single and ds-DNA onto their 
surface. Complementary charged GNPs interact electrostatically with 
the free bases of single stranded (ss)-DNA, which in turn provides 
colloidal stability to the nanoparticles in the presence of high salt 
concentrations. In contrast, dsDNA molecules adsorb less to the 
GNPs surface and hence are unable to provide colloidal stability 
under increasing ionic strength, leading to aggregation of GNPs, 
which results in LSPR and colour change simultaneously. GNPs 
conjugated with oligonucleotides that are complementary to the 
target sequence appear as a red solution in the absence of the target 
sequence, whereas in the presence of the target, hybridisation 
occurs and the solution changes to violet/blue due to LSPR.312 This 
approach has been successfully deployed for the detection of single 
nucleotide polymorphism (SNPs), UV induced mutagenic or 
carcinogenic DNA dimmers, and in the detection of unamplified 
hepatitis C virus RNA isolated from clinical specimens.316–319 Citrate 
capped GNPs and AgNPs have been investigated for sensing thiourea 
and melamine using a colorimetric assay system.320,321 In this 
method, the presence of thiourea and melamine significantly 
reduces the overall surface charge of GNPs leading to their 
aggregation and this in turn is detected colorimetrically indicating 
the concentration of thiourea and melamine present. Detection of 
DNA, aptamers, and oligonucleotides has received considerable 
attention in recent years because it has important implications in 
medical diagnostic, food safety monitoring, and the drug industry. 
Many studies have been conducted using surface functionalised 
GNPs for the detection of DNA, aptamers, and oligonucleotides.313–
315 GNPs functionalised with thiol (–SH) modified ssDNA probes have 
been used to detect a single mismatch through a cross-linking 
approach in the presence of a complementary ssDNA.363,311 A non-
cross-linking approach was used for the specific detection of genes 
associated with sickle-cell anaemia using fibrinogen functionalised 
GNPs and a thrombin binding aptamer.313 Fluorescence-based noble 
metal nanoparticle biosensors have been developed by utilising the 
quenching property of these nanomaterials. This is not to be 
confused with plasmonic nanoparticles, where the surface electrons 
can couple with electromagnetic waves with wavelength much larger 
than the size of the particles. Two approaches have been used so far: 
(i) molecular nano-beacons, where noble metal nanoparticles are 
surface conjugated with fluorescent-labelled ssDNA which forms a 
hair-pin loop like structure; and (ii) noble metal nano-probes, which 
consist of noble metal nanoparticles functionalised with ssDNA that 
hybridise with another fluorescent-labelled ssDNA probe. Molecular 
nano-beacons have been used to detect single-base mismatches in 
DNA with a higher sensitivity as compared to conventional molecular 
beacons.322 In another example, nano-beacons based on 13 nm 
GNPs have been successfully used to detect mutation associated 
with cystic fibrosis.323 In all these cases, the loop forming structure of 
the nano-beacon brings the fluorescent dye moiety in close proximity 
to the noble metal nanoparticle’s surface resulting in quenching of 
the fluorescence intensity of the fluorophore. In the presence of a 
complementary DNA/RNA target, the hairpin structure is disrupted 
by hybridisation and restores the fluorescence of the labelled 
strands. A gold nanorods containing gelatin hydrogel is developed for 
rapid recognition of circulating tumour cells (Fig. 9). An innovative 
“chemical nose” technique has been developed using conjugates of 
GNPs and fluorophore which provides high sensitivity sensing of 
biomolecular targets (Fig. 10).364–366 This method was used for rapid 
and accurate differentiation between normal, cancerous, and 
metastatic cells.367 Appropriately functionalised gold nanoparticles 
can be used for a simple colorimetric test for small concentrations of 
aqueous heavy metal ions, which includes toxic heavy metals such as 
lead, cadmium and mercury. GNPs are aggregated in the solution in 
presence of divalent metal ions by ion-templated chelation 
process.368 The development of a fast and reliable method for 
glucose sensing is a prerequisite for the treatment and control of 
diabetes.369,370 Most electrochemical methods use enzymes such as 
glucose oxidase or glucose dehydrogenase to catalyses the specific 
oxidation of glucose. GNPs entrapped in a silica network can enhance 
the non-enzymatic oxidation of glucose providing one possible 
alternative to the use of enzyme electrodes under appropriate 
circumstances.371 A sandwich interface containing chitosan/Au 
nanoparticles/glucose oxidase multilayer on platinum electrodes has 
been claimed to provide high sensitivity and a low detection limit for 
glucose, presumably due to the high electrochemically active surface 
area and diffusion characteristics of GNPs at the sandwich 
interface.372
Fig. 9 (a) Near-infrared (NIR)-responsive cell-imprinted gelatin for capture and 
photothermal selective release of single circulating tumour cells (CTCs) from peripheral 
blood. The cell-imprinted substrate is fabricated by imprinting target cancer cells on a Au 
nanorod-embedded gelatin hydrogel. CTCs are then separated by anti-epithelial cell 
adhesion molecule (anti-EpCAM)-modified cell-imprinted gelatin. This is followed by 
selective site release of an individual cell by exposure to a cell-sized NIR laser spot. (b) 
Schematic showing the selective photodegradation of the thermoresponsive gel doped 
with Au nanorods. Fluorescence microscope image of the fluorescein isothiocyanate 
(FITC) gelatin with a mask on top (bottom left). Fluorescence microscope image of the 
FITC gelatin without the mask and after removal of the gel degraded via selected NIR 
irradiation (bottom right). Reprinted with permission from 373
Fig. 10 Scheme illustration of GNP-based chemical nose for sensing of biomolecules 
based on competitive binding and fluorescence quenching. Modified from ref364
Antibody conjugated GNPs have been used for biological staining in 
electron microscopy and for radioactive labelling in vivo. The 
application of gold colloids in bio-diagnostics over conventional 
organic dyes and quantum dots offers a number of advantages which 
include reduced toxicity and contrast enhancing agents for imaging. 
Gold nano formulations can provide signal enhancement to standard 
enzyme-linked immunosorbent assays (ELISAs), such as 
immunochromatographic test strips where both primary and 
secondary antibodies are attached to GNPs.374 Surface modification 
of GNPs with Cy5-antibody as a fluorescence probe could replace the 
conventional ELISA assay, since this technique does not require a 
secondary antibody and offers high sensitivity.375 Gold nanoshells are 
capable of detecting nanogram quantities of various analytes present 
in whole-blood in chemiluminescent analysis of antibodies. This 
technique is far superior to ELISA in terms of technical proficiency.376
The intense light scattering by large GNPs makes them a potent 
probe for cancer detection. Immuno-targeting of antibody-GNPs to 
label cancer cells is achieved by conjugating them with antigens 
overexpressed in cancer cells. For example, cervical epithelial cancer 
cells (SiHa cells), which overexpress the transmembrane 
glycoprotein, epithelial growth factor receptor (EGFR), were 
successfully detected by immune-targeted gold colloids.377 GNPs 
nanoprobes have also potentially simplified diagnosis of cancer by 
detecting SNPs and mutation.378,379 A new approach has been added 
in the already existing repertoire of GNPs in the diagnosis of cancer, 
wherein a combined solid-phase microextraction with gas 
chromatography/mass spectrometry has been employed for the 
identification of volatile organic compounds acting as biomarkers for 
lung cancer.380
Gold colloid bio-barcode amplification assays (BCA) can detect HIV-1 
p24 antigen at very low concentration levels (0.1 pg/mL). The 
conventional detection limit with ELISA is reported as 1-15 pg/mL,324
while using GNPs there was a 100 to 150-fold enhancement in the 
detection limit.325 Another, technique for reliable and sensitive 
method for HIV-1 virus is based on gold colloid labelled silver staining 
in conjunction with polymerase chain reaction (PCR). The results 
demonstrated the highly sensitive and accurate potential for HIV-1 
diagnosis using GNPs.381 Functionalisation of gold colloids with 
Hepatitis B virus (HBV) DNA gene probes could be used to detect HBV 
DNA directly. This fluorescence-based method was highly sensitive 
and cost effective and could in future replace the highly complex 
multi-gene detection chips.326 Diagnostic applications of gold nano-
formulation probes have found their way into tuberculosis detection 
also. A target oligonucleotides sequence, suitable for mycobacteria 
identification was used here. At high ionic strength, aggregation of 
the nanoprobe takes place in the absence of any complementary 
DNA sequence specific to target oligonucleotides and turns the 
solution purple. On specific probe hybridisation to a complementary 
sequence (i.e. DNA from Mycobacterium tuberculosis), no 
aggregation of GNP nanoprobe occurs and the solution remains 
red.327 GNPs have been applied for the diagnosis of Alzheimer’s 
disease biomarkers based on the SPR property of gold colloids. Here, 
gold nanoparticles are used to monitor the interaction between the 
antigen, amyloid‐β derived diffusible ligands (ADDLs) and specific 
anti-ADDL antibodies.330
GNPs have been used as nanoprobes for detection and 
differentiation of Mycobacterium tuberculosis (MB) from other 
members of M. tuberculosis complex (MBC). In one report, 
oligonucleotide modified GNPs were developed as a selective 
nanoprobe for DNA-based detection and differentiation of MB and 
MBC. The technique was highly selective for distinguishing between 
MB and MBC.328 In yet another approach, Mycobacterium bovis and 
MBC were successfully differentiated by GNP nanoprobes.329 A new 
DNA-based biosensor for the highly sensitive detection of the specific 
IS6110 DNA sequence of MB has been achieved by using reduced 
graphene oxide-GNPs as a sensing platform and GNPs-polyaniline as 
a label for signal amplification.331 The nanoprobing activity of GNPs 
for sensing MB shows potential for use in clinical diagnostics. Noble 
metal nanoparticles have been used for enhancement of Raman 
signals in Surface-Enhanced Raman Scattering (SERS) for different 
types of analytes, and this has led to a wide variety of biosensors for 
the detection of nucleic acids, antibodies, proteins, and other 
biological molecules.382,383 Raman scattering arises from the inelastic 
scattering of photons that hit the analyte molecule in such a way that 
energy is either gained or lost so that the scattered photons are 
shifted in frequency. This interaction generates a narrow spectrum 
of bands unique for each analyte, and this signal is greatly enhanced 
in presence of noble metal nanoparticles by an order of 105 to 106
than the respective non-SERS Raman signals.384 This enhancement is 
mainly attributed to the LSPR properties of the noble metal 
nanostructures.385 A label-free SERS biosensor has been developed 
based on a glass surface coated with a layer of GNPs to detect and 
quantify nicotinic acid adenine dinucleotide phosphate (NAADP), 
which plays a crucial role in intracellular Ca2+ release.332 This label-
free SERS system allowed for a rapid detection of NAADP, making it 
a valuable tool for the study of normal and cancerous cells. In a 
similar approach, a surface covered with AgNPs were used instead of 
GNPs to detect bombesin, a neurotransmitter tumour marker and its 
analogues by SERS.333 This research group has also developed a 
protocol to monitor protein-protein and protein-small molecules 
interaction using AgNPs staining of the samples for producing active 
substrates for SERS.334,335 Another group of researchers used SERS to 
detect glucose levels by employing a self-assembled monolayer of 
decanethiol over an aggregated AgNPs film to increase glucose 
adsorption, which is otherwise minimal for bare-SERS 
substrates.336,337 SERS has also been used for detecting ssDNA by 
applying a slide derivatised with uncharged peptide nucleic acids 
which recognise and hybridise with specific, negatively charged 
ssDNA. This system mediated the adsorption of positively charged 
AgNPs upon hybridisation.338 The use of functionalised noble metal 
nanoparticles has been investigated for a more versatile and specific 
SERS-based sensing of biomolecules. In this method, SERS signals 
were generated by using a probe (DNA, antibody) functionalised 
noble metal nanoparticles and a Raman-labelled probe. This sensor 
system has been applied to detect a specific Anthrax biomarker by 
means of peptide functionalised GNPs,339 and detect specific DNA 
sequences such as HIV DNA using Raman-active dye labelled DNA on 
GNPs or AgNPs.340–343 Similarly, detection of hepatitis B virus antigen 
was reported using GNPs-antibody conjugates with 4-
mercaptobenzoic acid (MBA) acting as a Raman-active probe.344 Also, 
the detection of viral pathogens using monoclonal antibody 
conjugated GNPs and a Raman reporter has also been studied.386 In 
a separate study, a molecular nano-beacon approach using a Raman 
dye-labelled DNA functionalised on AgNPs was applied to detect and 
quantify a gag gene sequence of the HIV-1.387 Here, the presence of 
a complementary target decreased the SERS signal as a consequence 
of the disruption of the hairpin structure that would otherwise place 
the Raman dye in proximity to the NP’s metallic surface. This method 
has been further expanded successfully to detect the erbB-2 and ki-
67 breast cancer biomarkers using gold nanobeacons.345
A nanocomposite of PtNPs and graphene oxide has been successfully 
used as signal transducer to develop a colour-based assay for the 
detection of cancer cells by deploying folic acid functionalised 
nanocomposite of PtNPs and graphene oxide. Folic acid acts as a 
recognition factor since folate receptors are over expressed on the 
cell membranes of different types of cancer cells.346 The result 
obtained above is due to the peroxidase-like activity of the 
nanocomposite, which catalyses the oxidation of 3,3’,5,5’-
tetramethylbenzidine (TMB) by H2O2. Another example of the 
peroxidase activity of PtNPs has been applied in enzyme-linked 
immunosorbent assays (ELISAs), a nanohybrid of magnetic 
nanoparticles and PtNPs was immobilised on the surface of graphene 
oxide. This sandwich of nanocomposite was effectively used for the 
colorimetric detection of cancer cells via reaction of the peroxidase 
substrate, TMB.347
Electrochemical immunoassays (EIs) have been widely reported due 
to their high sensitivity, simplicity, and low cost. NMN-based 
electrochemical immunodetection offers added advantages such as 
high conductivity and large surface-to-volume ratio. These nanoscale 
materials are promising future candidates as signal tags for the 
development of electrochemical platforms for immunosensing. The 
tuneability of noble metal nanoparticles in terms of size, shape, and 
surface conjugation has yielded positive results in amplification and 
enhancement of electrochemical immunosensing signals. 
Development of an accurate and sensitive electrochemical 
immunosensor requires signal amplification and background noise 
reduction owing to the relatively weak electrochemical action of the 
immunocomplex.388,389 Enzyme labels are generally used for this 
purpose, but due to the instability issues related to most enzymes, 
there is interest in nano-templates as alternatives for signal 
enhancement.390–392 Preparation of non-enzymatic electrochemical 
immunoassays (NEEIs) based on nanoscale system can be used for 
two purposes. First, they can be applied to transform the 
electrochemical transducer matrix, which will result in low 
background noise and fast electron transfer, and secondly as tags for 
the amplification of the signals. NMN seem to be well suited to the 
development of NEEIs because of their highly stable nature, 
conductivity, biocompatibility, and catalytic efficiency.393,394 The 
large surface area of noble metal nanoparticles together with their 
ease of surface functionalisation with biomolecules (e.g. antibodies), 
electroactive tags and polymers, makes them a promising and 
interesting candidate for these systems. GNPs and PtNPs of various 
sizes, shapes, and structures are inherently capable of catalysing 
oxidation, hydrogenation, and dehydrogenation of innumerable 
analytes,395 and these properties of noble metal nanosystems can be 
successfully employed for the development of sensitive, reliable and 
cost-effective NEEIs. The introduction of GNPs in NEEIs as electrode 
materials for the immobilisation of biomolecules has produced 
significant results.396 GNPs are capable of binding a wide range of 
substances to build up an efficient electrochemical transducer 
surface, containing amino acid, protein, porous silica, metal 
nanoparticles, and carbon nanomaterials.397–403 In this regard, an 
effective impedimetric immunoassay was developed based on GNP-
modified graphene paper electrode for the rapid and sensitive 
detection of E. coli 0157:H7.348 A biocompatible nanocomposite 
comprising of GNPs and 4-amino-1-(-3-mercapto-propyl)-pyridine 
hexafluorophosphate was developed for sensing human IgG 
concentration with high sensitivity.349 Another such nanocomposite 
containing GNP-graphene oxide and polydopamine-thionine was 
effectively used for developing a label-free electrochemical 
immunoassay system for determination of alpha-fetoprotein.350 The 
charge transfer and high conductivity properties of GNPs greatly 
enhanced the sensitivity of this detection method. Palladium 
nanoparticles (PdNPs) are another important noble metal 
nanoparticle, which has been utilised as electrode material due to its 
high catalytic efficiency. Palladium nanoplates, ultrathin metal films, 
have also been successfully used for amperometric immunoassay for 
the accurate detection of alpha-fetoprotein.351 The sensitive 
detection of these cancer biomarkers was due to excellent 
electrochemical properties of the nanoplates, which enhanced the 
electrochemical signal. PdNPs with a reduced graphene oxide-based 
electrochemical immunodetection system have been fabricated for 
the development of prostate-specific antigen. Low concentrations of 
these antigens could be detected using this decorated electrode due 
to the synergistic electrochemical activities of PdNPs and the 
reduced graphene oxide.352
Signal amplification is key to the development of efficient and highly 
specific electrochemical immunosensors with low limits of detection 
(LOD) and high sensitivity. Noble metal nanoparticles have been used 
for signal amplification in NEEIs utilising 3 different strategies; (i) as 
electroactive labels, (ii) as carriers, and (iii) as electrocatalytic labels. 
Direct application of NMN as electroactive tags has shown promising 
results in signal enhancement. This method comprises two stages. 
Firstly, strong oxidants are used to dissolve the NMN into their 
metallic form, and secondly stripping voltammetry is employed for 
the sensitive detection of the dissolved ions. Utilising this method, a 
group of researchers synthesised a nanohybrid of AgNPs and 
titanium phosphate and applied it as a label for electrochemical 
immunodetection of human interleukin-6.353 In the presence of the 
target antigen, the nanohybrid of AgNPs and titanium phosphate was 
anchored to the magnetically modified sensing array through 
sandwich-typed immunoreactions and upon addition of a strong 
oxidant, the Ag+ ions are released from the complex. This system 
achieved an excellent LOD for IL-6. In a separate study, AgNPs and 
graphene oxide nanocomposite was used for electrochemical 
immunodetection of E. coli using solid-state voltammetry.354 GNPs 
have been used as carriers in NEEIs for loading of multiple 
electroactive labels for the preparation of functionalised signal tags 
in order to enhance the immunoreaction system. The most 
commonly used electroactive labels are thionine, ferrocene and 
metal ions. The functionalisation of GNPs with 6-ferrocenyl 
hexanethiol for the development of a sensitive electrochemical 
immunosensor provided an efficient signal enhancing label for the 
determination of prostate specific antigen.355
In this era of enhanced environmental concern, catalytic reactions 
play an important role in the field of environmental and material 
sciences.404 Growth of pollution from industry and agricultural has 
posed a life-threatening challenge to human society, in the form of 
hazardous pollutants such as heavy metals ions, pesticides, dyes, 
toxic chemicals, pathogens, and contaminants.405,406 Various optical 
sensors have been developed for detecting heavy metal ions which 
include organic dyes,407,408 fluorescent polymers,409 and noble metal 
nanoparticles (Fig. 11).396,410–412 Among these sensors, noble metal 
nanoparticles have attracted considerable attention owing to their 
size, shape, chemical and optical properties, high surface-to-volume 
ratio, good stability, and excellent biocompatibility.396,413,414 In this 
section, we described some of the important sensing functionalities 
of NMN (Table 5).
Table 5 Noble metal nanoparticles as detection probes 
Type of noble metal nanoparticles Application Property References 
GSH modified GNPs Pb2+ detection LSPR 415–417
MTA modified GNPs Hg2+ detection LSPR 418,419
Protein coated gold nanoclusters Hg2+ and CH3Hg detection Fluorescence 420
BSA-GNPs nanoclusters Ag+ detection Fluorescence 307
Pepsin-gold nanoclusters Hg2+ and Pb2+ sensing Fluorescence 421
BSA-gold nanoclusters Sensing of H2O2 and pesticides (dithizone, fenitrothion and 
paraoxonethyl) 
Fluorescence 422
AgNPs Ni2+, Co2+, Cd2+, Pb2+ and As3+ detection LSPR 423
AgNPs  Hg2+ detection LSPR 424,425
Ag nanoclusters Hg2+ sensing Fluorescence 426
Polymethacrylic acid functionalised Ag 
nanoclusters 
Cu2+ detection Fluorescence  427
PtNPs Hg2+ detection LSPR 428
GSH modified GNPs with a core size of 5-8 nm have been used for 
detecting Pb2+ ions in solution by a colorimetric method. GSH-GNPs 
could immediately aggregate in the presence of Pb2+ ions which 
results in a red shift in their SPR peak.415,416 This method is size-
dependent, with a better sensitivity when the core size of the GNPs 
is bigger. Such colorimetric assays are popular because they can be 
easily observed with the naked eye or using a UV-vis spectrometer 
thus providing simple, cost-effective, sensitive, and selective 
detection of harmful environmental pollutants such as heavy metal 
ions. In another study, 11-mercaptoundecyl-trimethylammonium 
(MTA) conjugated GNPs have been investigated for Hg2+ ion 
sensing.418 The colour of the GNP solution changes from red to blue 
in the presence of Hg2+ ions, which is again evidenced in the UV-
visible spectra with a red shift of the absorption peak. The high 
affinity between Hg2+ ions and GNPs have also been utilised for 
removal of mercury from water using a GNP-Al2O3 nanocomposite.419
The shape of noble metal nanoparticles proves to be a potent 
regulator in sensing capabilities of heavy metal ions. For example, 
decahedral GNPs can detect Pb2+ ions at 1000-fold lower LOD than 
their spherical counterparts.416 Similarly, AgNPs with different 
shapes such as nanospheres, nanoplates and nanorods have been 
applied for constructing colorimetric sensors for Co2+ ions. Spherical 
AgNPs showed the highest sensitivity for Ni2+, Co2+, Cd2+, Pb2+, and 
As3+ ions,423 whereas Ag nanorods possessed greater selectivity for 
Co2+ ions over other metal ions in the solution. It has been shown 
that AgNPs provide a lower LOD for Hg2+ ions than GNPs because the 
molar extinction co-efficient of AgNPs is about 100-fold greater.424
This property has been utilised to make cost-effective assays for Hg2+
ion detection using mercury-specific oligonucleotides.425 In the 
presence of Hg2+ ions, the unfolded nucleotides were linked with 
Hg2+ ions, which resulted in aggregation of AgNPs in solution as 
reflected calorimetrically. PtNPs can also be used for sensing 
mercury. PtNPs used for this purpose catalyse the reaction between 
TMB and H2O2, which leads to a blue coloured product. However, in 
the presence of trace amounts of Hg2+ ions, this catalytic activity of 
PtNPs is inhibited.428 GNPs functionalised with different organic 
ligands such as thiolates, amino acids, peptides, and DNA, have been 
described as sensitive colorimetric detectors for heavy metal 
ions.425,429 For example, citrate coated GNPs aggregate in presence 
of Hg2+ ions and lysine, because of the strong bond formation 
between Hg2+-Au (Fig. 12).430 In another example, peptide 
functionalised GNPs can be deployed for sensing Co2+, Hg2+, Pb2+, 
Pd2+, and Pt2+ ions, respectively.417
Moving on to the next property of NMN, that is fluorescence which 
confers attractive attributes for sensing heavy metal contaminants 
due to higher emission.431,432 A desirable sensor system with strong 
fluorescence can be developed by fine tuning the size, shape, 
composition, and surface functionalisation of noble metal 
nanoclusters. Metal nanoclusters with smaller size (i.e. fewer 
number of metal atoms) often produce higher fluorescence due to 
their smaller size and larger surface area and these fluorescent 
probes can be used for sensing heavy metal ions as environmental 
pollutants.433 Protein coated gold nanoclusters as a highly 
fluorescent probe have been successfully used for the detection of 
Hg2+ ions and CH3Hg+ species with low LOD.420 Traces of Ag+ ions are 
similarly tested using BSA conjugated gold nanoclusters, where the 
presence of Ag+ ions leads to the formation of Ag-Au alloy 
nanoclusters which in turn produce an increased fluorescent 
intensity.434 Ag nanoclusters also exhibit similar fluorescent probing 
activity for detecting Hg2+ ions due to strong interaction between Ag+
and Hg2+ ions.426 Metallophilic interaction between metal cores with 
a closed-shell electronic configuration can be applied for detecting 
heavy metals ions. As in the case with Ag and Au nanoclusters, a trace 
amount of Hg2+ ions could be effectively detected using this property, 
which leads to fluorescence quenching of the nanoclusters.435
Polymethacrylic acid-functionalised Ag nanoclusters were used to 
detect Cu2+ ions, which quenche the fluorescence of Ag nanoclusters 
in solution.427 In a separate study, pepsin-conjugated Au 
nanoclusters were applied for sensing Pb2+ ions via fluorescence 
enhancement and can also be used for Hg2+ ion detection by a 
fluorescence quenching phenomenon.421 The sensing capabilities of 
noble metal nanoparticles is not limited to heavy metal ions; they can 
also be utilised for H2O2 and pesticide sensing as well. For example, 
BSA stabilised gold nanoclusters can detect H2O2 and common 
pesticides such as dithizone, fenitrothion, and paraoxonethyl, using 
fluorescence detection.422 Low levels of pesticides such as 
endosulfan have been sensed by GNPs as well.436
Table 6 Biomedical imaging applications of noble metal nanoparticles via LSPR 
properties. 
Type of noble metal 
nanoparticles 
Applications References  
Gold nanoshells Imaging of prostate cancer 
cells 
437
Gold nanobeacons Imaging of sentinel lymph 
nodes 
438
Gold nanoshells Contrast agents in dark-
field microscopy for HER 2, 
a cancer biomarker 
188
Gold nanoshells Imaging of live HER 2 





In vivo imaging of cancer 
cells 
440,441
PEG-GNPs Imaging of tumour cells 442,443
Gold nanoshells Imaging of tumours in 
mice model 
444
Gold nanoshells Imaging of vasculature of a 
rat brain 
445
Importance of NMN for imaging purposes: The ability of NMN to 
absorb and scatter light in the NIR region makes them one of the 
most potent candidates as contrast agents in biomedical imaging 
(Table 6).441,446,447 The highly permeable nature of human skin and 
tissues to NIR radiation has led to the development of minimally 
invasive deep tissue diagnostic imaging methods with noble metal 
nanoparticles acting as contrast enhancer vectors. The application of 
noble metal nanostructures in in vivo imaging techniques allows 
certain advantages over conventional NIR organic dyes, such as 
avoiding rapid photobleaching, better detection sensitivity, 
improved stability in biological systems, and better multiplexing 
capability.447 NMN with light scattering properties enhance the 
contrast of imaging systems, such as dark-field or dual-photon 
luminescence microscopy, and also facilitate combined imaging 
techniques to produce a synergistic effect over single imaging 
method.448,449 Since the LSPR of noble metal nanomaterials is located 
within the NIR region, they have been applied in different imaging 
modalities like Photo-Acoustic Imaging (PAI), Photo-Acoustic 
Tomography (PAT) and dark-field and two photon microscopies. In 
one study, gold nanorods conjugated with an antibody and 
simultaneously tuned to the NIR region with PAI have been 
effectively used to image early-stage prostate cancer cells. Here, the 
gold nanorods resulted in enhanced contrast images between 
healthy/non-targeted tissue and cancerous/targeted tissue.437 Gold 
nanorods as contrast agents for in vivo imaging using a laser based 
PAI system have also been reported.444 In a complementary 
approach, gold nanobeacons (2-4 nm) conjugated with PAI were 
applied for the detection of sentinel lymph nodes in ex vivo tissue 
specimens.438 In dark-field microscopy, the NIR scattering properties 
of gold nanoshells has been exploited as contrast for targeting 
human epidermal growth factor receptor 2 (HER2), a biomarker for 
cancer.188 These gold nanoshells were also used to image live HER2-
overexpressing cancer cells using two-photon microscopy.439 Gold 
nanoshells, nanorods, nanocages, and nanoclusters have shown 
considerable promise as contrast agents for in vivo cancer imaging 
due to their significant absorbance and scattering in the NIR 
region.440,441 These nanoformulations of gold are also used as 
contrast agents for Surface-Enhanced Raman Scattering (SERS), 
Photo-Acoustic Imaging (PAI), Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI), and Optical Coherence 
Tomography (OCT).442,450–455 The use of ~30 nm PEG coated GNPs for
in vivo CT was shown to increase image contrast by reducing both the 
radiation dosage needed and other toxic outcomes associated with 
using conventional contrast agents.442 The intense light scattering by 
gold nanoshells has been used to enhance image contrast in OCT to 
improve diagnostic imaging of tumours in a mice model as a result of 
nanoshell accumulation near the tumour site.444 Similarly, in PAI and 
PAT, the image of circulating gold nanoshells in the vasculature of a 
rat brain has been shown to enhance image contrast, allowing for a 
more detailed description of vasculature structures at greater 
depths.445 These applications of gold nanostructures are attractive 
because they provide higher photostability, quantum yield, 
detection sensitivity, stability in biological systems, and 
hydrophilicity than conventional organic dyes. Additionally, the 
intense scattering property of these gold colloids has played an 
important role in enhancement of image contrast in dark-field 
microscopy and dual-photon luminescence microscopy.456 The 
application of SERS in conjugation with NMN has also been described 
for the detection and intracellular molecular imaging of living cells 
and tissues. In this case, 60 nm GNPs coated with PEG and a tumour 
targeting antibody were able to detect tumours both in vitro and in 
vivo through SERS imaging.443 Here, GNPs were used to detect 
tumour biomarkers such as epidermal growth factor receptors on 
cancer cells and in xenograft tumour models more efficiently than 
NIR-emitting quantum dots. Specific cancer biomarkers like 
phospholipase Cg1 (PCg1) were also imaged in live HEK293 cell lines 
by NMN using SERS microscopy.457 SERS using GNPs attached to a 
Raman absorption reporter species has been demonstrated to 
highlight cellular and molecular structures which provide structural 
information on the cellular milieu inside live cells.458,459
Fig. 11 (a) Surface-Enhanced Raman spectroscopy (SERS)-based detection of 
magnetically separated bacteria. (b) Preparation and use of a gold/reduced graphene 
oxide (rGO) nanocomposite-based biosensor and its application for the electrochemical 
detection of organophosphorus pesticides (OP). (c) Combined magneto-fluorescence 
approach for detection of bacteria using fluorophore labelled magnetic nanoparticles. 
Reprinted with permission from ref 460
Fig. 12 Schematic representing the Hg2+ sensing mechanism of the colorimetric assay, (b) 
Photographs of AuNP solutions showing that the colour change occurring only in the 
presence of lysine (0.4 mM) and Hg2+ (10 µM) and (c) extinction spectra of the AuNP 
solutions. Reproduced with permission from ref 430
Toxicity Challenge of NMN 
The incorporation of noble metal nanostructures in this diverse 
range of applications has led to increasing concern about their 
possible toxic impact on human beings and the environment (Fig. 
13). In general, human beings are exposed to these nanomaterials 
via inhalation, ingestion, and dermal contact.461 Reports suggest that 
NMN tend to exert their toxicity when they either circulate in the 
bloodstream to organs, tissues and cells, or get absorbed in the 
spleen or bone marrow (Table 7). These absorbed nanomaterials 
evoke oxidative stress, immune response, cellular apoptosis, and 
DNA damage upon their entry into the mitochondria and the 
nuclei.462 Depending on the size of the nanoparticles, their typical 
fate after intravenously injection is summarised in Fig. 14.463
Clearance of NMN is a big challenge because these materials are not 
biodegradable and tend to accumulate in organs such as liver and 
spleen.464 The extended persistence of noble metal material can 
result in unforeseen toxic and adverse effect. The clearance of NPs 
depends on size, shape, and charges (Fig. 14). The two major 
clearance pathways of NPs are renal and hepatic pathways. The renal 
pathway is the rapid removal mechanism for clearing vascular 
compartments and is the desired clearance pathway for NPs.465 The 
general size threshold for renal clearance versus hepatic clearance is 
estimated to be 6 to 8 nm based on the permeability of the 
glomerular filtration barrier.465 Therefore one strategy to fabricate 
safe noble NPs is to make them extremely small.466,467 However, if 
the size of NPs becomes too small, they will be cleared from the 
circulation system prematurely, limiting their ability to carry out the 
designed action in vivo.468 To overcome this dilemma, researchers 
have created so-called ultrasmall-in-nano architecture, where 
ultrasmall noble NPs are assembled into clusters by biodegradable 
agents.469,470 These nano-architectures are engineered to degrade 
over a certain period of time into NPs that are small enough to be 
excreted via the renal pathway. By using poly(L-lysine) as the 
assembly agent, Voliani and coworkers fabricated gold ultrasmall-in-
nano architectures, which exhibit high photothermal efficiency and 
are promising for hyperthermia cancer treatment.470
Fig. 13 Schematic representation of toxic effect on animal model system by metallic 
nanoparticle exposure. 
Fig. 14 The fate of nanoparticles and their accumulation and clearance sites. (a) 
Schematic illustration of kidney filtration or renal clearance of NPs, SEM images and 
histology of glomerular cell surface (endothelial lining). (b) Schematic illustration lung 
capillary beds filtration of NPs in the lungs. (c) Schematic illustration of nanoparticle 
clearance mechanism in liver via endocytosis by Kupffer cells (histology) and fenestration 
by endothelial cells (SEM); (d) Schematic illustration of the enhanced permeation and 
retention (EPR). SEM images of normal and cancerous tissues. MPS, mononuclear 
phagocytic system; RES, reticuloendothelial system. Reprinted with permission from ref 
464
A size-dependent toxicity study was performed for GNPs on different 
cell lines such as fibroblast, epithelial cells, macrophages and 
melanoma cells. The study demonstrated that GNPs in the size range 
of 1.4-5 nm exhibit toxicity to all the above-mentioned cells, whereas 
15 nm GNPs exposure to cells has no profound negative side effects 
even after 3 days of treatment.471,472 In a separate study, it was 
demonstrated that bare GNPs can induced cell-specific killing in a 
concentration dependent fashion and the accumulation of GNPs is 
localised in specific cellular domains (Fig. 15).194 Co-incubation of 
immune cells with citrate capped GNPs (10 nm) showed a little 
adverse effect on the immunocellular phenotypes and cell death, 
even after 48 hours of treatment, whereas the cytokine profile (IL-1, 
IL-6, IL-10 and IL-12) significantly changes which implicates the 
activation of the immune response upon GNPs treatment.473
Fig. 15 Intracellular localisation of GNPs in A549 cells. Upper panel: The left column is 
the scattering of GNPs in the presence and absence of GNPs after excitation in the 
ultraviolet-visible range (300-450 nm). The right column shows the coexistence of 
nucleus (DAPI) and GNP scattering, in the presence and absence of GNPs. Lower panel: 
Magnified version of the red arrow marked cell. Reprinted with permission from ref 194
It has been reported that 15 nm GNPs coated with triphenyl-
phosphine are fairly unreactive in comparison to 1.4 nm GNPs, which 
cause mitochondrial disruption and generation of free radicals.474
Similarly, stress related genes were up-regulated upon treatment 
with 1.4 nm GNPs, but not with 15 nm GNPs, as revealed by gene 
array analysis.474 In another study, the epigenetic modulation was 
observed in lung fibroblasts upon exposure to 20 nm GNPs. Here, 
GNP treatment caused up-regulation of microRNA-115, down 
regulation of PROS-1 gene and condensation of chromatin in the 
nucleus.475 Gold colloids of 20 nm in size can also trigger oxidative 
stress autophagy in human lung fibroblasts,476 which results in 
elevated lipid peroxidation levels, up-regulation of many autophagy 
related genes (ATG-7), increase in inflammatory enzyme 
cyclooxigenase-2 (COX-2), and polynucleotidekinase 3’-phosphate 
(PNK) gene production.476 In another example, keratinocytes 
(HaCaT), when exposed to 1.5 nm GNPs of different charge (positive, 
negative and neutral), exhibited a noticeable disruption of cellular 
structure in a dose-dependent manner.477 The surface charge of 
GNPs determines the extent of biological response, with charged 
GNPs promoting apoptosis whereas neutral GNPs lead to necrosis.478
Similarly, when positively charged GNPs (2 nm) of varying surface 
hydrophobicity were tested in HeLa cells, the experimental outcome 
revealed that the higher the hydrophobicity, the greater the 
observed acute toxicity and production of ROS.479 It was found that 
larger surface charge density (effective electric field) of negatively 
charged GNPs results in higher degree of fluctuation in the 
cytotoxicity (Fig. 16).480 Recent investigation has revealed that 10 nm 
GNPs are widely dispersed throughout the body, whereas larger 
particles were observed only in the liver, blood, and spleen.481 In a 
similar study, Wistar-Kyoto rats treated with 10, 20 and 50 nm GNPs 
for 3-7 days, showed hepatotoxicity and renal toxicity. Smaller sized 
GNPs had a more deleterious effect than larger particles with 
concomitant generation of ROS, which led to necrosis, renal tubular 
modulations, higher Kupffer cell hyperplasia, and central veins 
intimae disruption.482 In a separate observation, it was illustrated 
that GNPs stabilised with non-toxic stabilisers, in this case PEG, also 
showed size-dependent harmful effects. PEG-GNPs of smaller 
hydrodynamic diameter (5, 10 and 30 nm) accumulated in the liver 
and spleen, whereas much larger nanoparticles (60 nm) did not 
agglomerate in either of these organs.483 Size and surface charge 
distribution of GNPs also seem to have a profound negative influence 
on aquatic life. In a study conducted in vivo in a zebra fish model, it 
was observed that upon exposure to GNPs functionalised with 
cationic ligands (~1.3 nm), fish embryos exhibited harmful side 
effects, which included morphological changes such as abnormally 
small and less pigmented eyes.484 Depending upon the route of 
administration, the toxicity profile of NMN varies. For instance, the 
toxicological features of 13.5 nm GNPs are determined on the route 
of administration.485 In this study, mice were injected with GNPs 
through (i) oral administration, (ii) intraperitoneal administration 
(IP), and (iii) tail vein injection. Tail vein injection showed minimal 
toxic effects to white blood cells and platelet counts, on the other 
hand GNPs administered orally or intraperitoneally exhibited higher 
level of toxicity with reduction in red blood cell count.485 The 
inclusion of AgNPs as an effective and tested antimicrobial agent and 
in other therapeutic applications has posed an intriguing question 
regarding their safety profile. The usage of AgNPs for industrial 
benefits has directly or indirectly presented an enormous threat to 
human health and environment alike.486,487 The size, shape, and 
surface composition of AgNPs are the major contributing factors 
which affect their intracellular uptake and cytotoxicity.472 The 
noxious side effects of AgNPs have been studied thoroughly and in a 
detailed manner using numerous models like zebra fish,258 mice, 
rats,488 fresh water flea,489 stem-cells derived fibroblast, and L929 
cell line.490 The deleterious effect of AgNPs leads to harmful ROS 
generation and lipid peroxidation, which in turn causes DNA damage, 
necrosis, and apoptosis.491–493
In another independent study, it was concluded that AgNPs exert 
their cytotoxic effect in a size-, shape-, and dose-dependent manner 
on red blood cells and hepatic stellate cells.494
Fig. 16 Cellular survival rate as function of effective electric field for negatively charged 
GNPs.480
A Trojan-horse effect has been suggested in relation to the dose and 
time-dependent harmful side effects of AgNPs in the RAW246.7 cell 
line. In this case, after exposure to the nanoparticles, intracellular 
glutathione (GSH) level decreased, leading to a cascade of reactions 
which included increased secretion of nitric oxide and increased 
expression of TNF- and matrix metalloproteinase,495 with a 
complete arrest of the cells at G1 phase of the cell cycle. A cytotoxic 
study of AgNPs in rat liver cells (BRL 3A) observed that after 24 hours 
of incubation with AgNPs,496 there was a significant decrease in the 
functional attributes of mitochondria and leakage of lactate 
dehydrogenase (LDH). AgNP toxicity is mediated through oxidative 
stress, which increases ROS and decreases GSH production.496
Further investigations clarified the mechanism of cytotoxicity of 
AgNPs using human Chang liver cells,497 where it was elucidated that 
the AgNPs create a loss of mitochondrial membrane potential (MMP) 
by regulating the expression of the mitochondrial-dependent 
apoptotic pathway (Bax and Bcl-2).497 This decrease in MMP results 
in the release of cytochrome C, which in turn activates caspase-3 and 
caspase-9. In a more recent and detailed study, it was illustrated that 
AgNPs contribute to cellular damage.498 In this experiment, the 
bioenergetics of rat liver mitochondria was determined upon 
exposure to AgNPs and it was shown that AgNPs create an increase 
in the permeability of the inner mitochondrial membrane leading to 
mitochondrial depolarisation. This functional loss of mitochondrial 
activity results in an uncoupling effect on the oxidative 
phosphorylation system.498 AgNPs, when incubated with liver cells 
such as human Chang liver and Chinese hamster lung fibroblasts for 
24 hours in a dose-dependent study, exhibited overloading of 
mitochondrial Ca2+ ions and greater endoplasmic reticulum (ER) 
stress.499 AgNPs can lead to increased phosphorylation of PERK and 
IRE1 along with an up-regulation of GRP78/Bip, which are ER stress 
markers, and altogether this induced ER stress upon AgNPs exposure 
ultimately leading to cellular apoptosis.499 AgNPs also exhibit 
cytotoxic effect in coronary endothelial cells (CECs) and aortic rings 
isolated from rats.500 In this study, it was observed that AgNPs induce 
NO-dependent proliferation in a dose and size-dependent manner in 
CECs.500 Intravenous administration of AgNPs in Balb/c mice revealed 
that particles were mostly taken up by the reticuloendothelial system 
(spleen and liver).501 However, other reports suggest enhanced liver 
enzyme activity, higher uptake by local macrophages, increased 
inflammatory response, and liver damage.501 The effect of inhalation 
of AgNPs was performed using Sprague-Dawley rats with 18 nm 
AgNPs.502 The rats were exposed to the silver colloids in a whole-
body inhalation chamber and the end results indicated that AgNPs 
reduce lung function and produce inflammatory lesions in the lungs. 
Oral administration of AgNPs (60 nm) in both male and female rats 
were extensively studied for a one-month period.488 This 
demonstrated that although AgNP treatment did not result in a 
significant change in body mass index, blood chemistry analysis 
revealed elevated liver damage as indicated by changes in alkaline 
phosphatase (ALP) and cholesterol in both groups.488
Size-dependent studies on the toxic effects of AgNPs (22, 42, 71,323 
nm) by oral administration in mice showed increased toxicity with 
higher immune cell infiltration (B cell and higher CD8+ T cell) and 
increased level of TGF‐β and cytokine production (IL‐10 and IL‐12) in 
22 nm AgNPs treated mice, whereas larger particles did not produce 
any alarming side effects.487 In another study, 20, 80 and 110 nm 
AgNPs were administered through tail veins and it was concluded 
that larger nanoparticles mostly accumulate in spleen followed by 
liver and lung, while 20 nm AgNPs mainly get deposited in the liver 
and then the kidney and spleen.503 Concentration dependent dermal 
toxicity of AgNPs conducted on male guinea pigs showed that at low 
dose, AgNP-treated animals exhibited a reduction in the thickness of 
the epidermis and dermis with an increase of inflammatory 
Langerhans cells.504 However, when given at higher dose, skin 
toxicity was apparently observed as a result of disrupted collagen 
fibres as well as higher macrophage infiltration with acidophilic 
cytoplasm.504
There are relatively fewer reports regarding the toxicity of PtNPs. 
One report studied the cytotoxic effects of 3 different noble metal 
nanoparticles (GNPs, AgNPs and PtNPs) using a zebra fish model. It 
was confirmed that PtNPs induce an increase in the hatching time, a 
drop-in heart rate, and a reduced touch response in this model.505
Another study conducted on mice reports that PtNPs cause acute 
hepatic injury as evidenced by an increased level of serum 
biomarkers of liver injury and inflammatory cytokines.506,507
Cytotoxic effect of PtNPs on skin suggest that nanoparticles of larger 
size and coated with an uncharged non-toxic stabiliser such as PVP 
have no significant toxic effect, while on the contrary, much smaller 
sized PtNPs showed deleterious side effects on primary keratinocytes 
leading to decreased cell metabolism.508 The presence of these 
nanomaterials in our day-to-day life is becoming inevitable and 
therefore a more detailed and thorough investigation needs to be 
conducted concerning the long-term usage of these engineered 
nanoparticles for the betterment of human life and society.
Table 7 Toxicity of noble metal nanoparticles. 
Type of noble metal 
nanoparticles 
Toxicity References  
GNPs (1.4-5 nm) Changes in cytokine profile (IL-1, IL-6, IL-10, IL-12) 471–473
GNPs (1.4 nm) Mitochondrial disruption and generation of free radicals 474
GNPs (1.4 nm) Up-regulation of stress related genes 474
GNPs (20 nm) Epigenetic modulation, up-regulation of microRNA-115, down regulation of PROS-1 gene 
and condensation of chromatin in the nucleus  
475
GNPs (20 nm) Triggers oxidative stress autophagy in lung fibroblasts, increase in lipid peroxidation levels, 
up-regulation of many autophagy related gene, increase in COX-2 and PNK gene production 
476
GNPs (1.5 nm) Disruption of cellular structure 477
GNPs (1.5 nm, charged and 
neutral) 
Charged GNPs leads to apoptosis while uncharged GNPs leads to necrosis 478
GNPs (2 nm) Production of ROS, renal tubular modulations 479,482
GNPs (>10 nm) Deposited in liver, blood and spleen and showed hepatotoxicity and renal toxicity 481,482
PEG-GNPs (5-30 nm) Accumulates in the liver and spleen 483
AgNPs ROS generation, lipid peroxidation, DNA damage, necrosis, apoptosis, decrease in 
intracellular GSH levels, increased nitric oxide secretion, increased TNF‐α and increased 
expression of matrix metalloproteinase 
491–495
AgNPs Loss of functional attributes of mitochondria and leakage of LDH 496
AgNPs Loss of MMP, regulation of expression of mitochondrial dependent apoptotic pathways 497,498
AgNPs Overloading of mitochondrial Ca2+ and up-regulation of ER stress biomarkers 499
AgNPs Accumulates in liver and spleen, enhanced liver enzyme activity, higher uptake of local 
macrophages, increased inflammatory response and liver damage 
501
AgNPs Reduction in liver function and production of inflammatory lesions in the lungs 502
AgNPs Liver damage 488
AgNPs (22 nm) Higher immune cell infiltration and increased levels of TGF‐β and cytokine production 487
AgNPs Collagen fibres disruption and increase of inflammatory Langerhans cells 504
PtNPs Increases hatching time period, drop in heart rate in zebra fish model 505
PtNPs Acute hepatic injury in liver, increased level of serum biomarkers of liver injury and 
inflammatory cytokines 
506,507
PtNPs Decrease of cellular metabolism 508
Control Perspectives for the Use of NMN in Biomedical Field 
Nanobiotechnology faces a major challenge due to the uncontrolled and unethical use of NMN in a wide array of applications, 
which can lead to serious and deleterious toxicity to humans and environment. The unparalleled advantages presented by 
NMN would be of no use unless the burden related to their toxicity is addressed and resolved wisely. In order to nullify or 
minimise the side effects of NMN, various strategies are being employed by researchers worldwide, such as capping the 
nanomaterials with suitable compounds which aid in reducing the toxicity, preventing aggregation of noble metal 
nanoparticles, and last but not least, engineering the size, geometry, and biocompatibility of the nanoparticles for their 
successful applications in biotechnology. 
Capping agents of nanomaterials contribute significantly in the activity profile of NMN. It has been reported that several 
attributes of capping agents increase the toxicity levels of NMN, hence in order to synthesise biocompatible nanoparticles, 
it is of primary importance that the capping agents are chosen wisely. In this regard, the use of non-toxic polyvinyl 
pyrrolidone (PVP) or polyvinyl alcohol (PVA) as a colloid stabiliser has been suggested by various research groups. PVP and 
gum Arabic (GA) coated AgNPs have shown promising result in reducing the toxic side effects of AgNPs.509 The wide 
acceptance of AgNPs as an antimicrobial agent has led to an enormous amount of AgNPs being released in the sewage water 
bodies, which results in the loss of flora and fauna. This harmful effect of AgNPs can be addressed by using sulphate anions 
in the sewage water thereby preventing or reducing the highly toxic effect of AgNPs.510 The functional attributes of NMN are 
directly positively proportional to their surface area. In the case of agglomeration or aggregation of NMN, reduction in 
surface area occurs and this is ultimately reflected in activity loss. Hence, the problem of particle aggregation should be one 
of the main focus for nanotechnologists. In one study, it has been shown that bovine serum albumin (BSA) provides a better 
colloidal stability to GNPs as a capping agent than does citrate anions. This is because the electrostatic repulsion offered by 
citrate anion can be compromised by Na+ ions from the saline solution, which leads to aggregation of GNPs, while BSA 
adsorbed on to the surface of the GNPs helps to prevent agglomeration even under harsh conditions.511 In another study, 
the aggregation behaviour of platinum colloids was studied in solution using tetradecyltrimethylammonium bromide 
(C14TAB), cetyltrimethylammonium bromide (C16TAB) and nonylphenolethoxylate (NP9). TEM analysis revealed that the 
aggregation of PtNPs reduced considerably when CTAB and NP9 were used as surfactants.512 In addition to polyethylene 
glycol (PEG), PVP, natural polymers such as dextran, chitosan, pullulan, and surfactants like sodium oleate and dodecylamine 
have also shown promising results in preventing aggregation of NMN.513 Another important aspect of nanotechnology lies in 
controlling the size of the nanoparticles and maintaining reproducibility, since the chemical properties of bulk noble metals 
are different in comparison to their nanoscale version. Citrate ions represent one of the most widely accepted reductants 
for the synthesis of metallic nanomaterials. Size-controlled synthesis of AgNPs was successfully achieved using citrate ions 
owing to the slow crystal growth as a result of interaction between silver and citrate ions.514 In a separate experiment, size-
controlled preparation of AgNPs was performed using silver and glucose under autoclaved condition. By regulating the 
concentration of glucose, the researchers were able to produce AgNPs of small, medium, and large sizes in a controlled and 
reproducible manner. Also, the caramel formed during the autoclaving of glucose functions as the stabilising agent for AgNPs, 
which in turn reduces their toxicity and increases the biocompatibility of the AgNPs.515 In a similar manner, size-controlled 
synthesis of GNPs was also conducted by UV irradiation at room temperature in the presence of air (5-20 nm). In this study, 
medium sized and larger GNPs (25-110 nm) were also successfully obtained by using ascorbic acid as a reductant.516
Therefore, by utilising the above-mentioned strategies for noble metal nanoparticles, the toxicity indices of these particles 
can be checked, which will help to expand their usefulness for biotechnological applications. 
Future prospects 
In this review, we have endeavoured to illustrate the ever growing and increasingly broad applications of noble metal 
nanomaterials in the therapeutics, diagnostics, and biosensing fields. Nanostructures have yielded significant positive results 
towards the betterment of human health, which is being reflected in their wide range of applications in the health sector. 
Metallic nanoparticles have found significant utility over a diverse spectrum of biomedical activities such as imaging, sensing, 
and therapeutics. They have provided an invaluable advance in the detection, diagnosis, and therapy of different human 
cancers and this has led to the development of a completely new discipline, nano-oncology. Colloids of gold, silver, platinum, 
and palladium have been widely used and accepted in clinical trials for treatment of cancer. Nanostructures have attracted 
considerable interest as theranostic agents, but their pharmacokinetics, biodistribution, side effects, and safety profile within 
the human body, need more thorough investigation for future applications.360,517–519 The antibacterial, antifungal, antiviral, 
and antimicrobial properties of plasmonic nanomaterials are already well established and this could be a future strategic 
approach for the design and development of nanodrugs in the pharmaceutical industries. Toxicological studies based on 
numerous nanocomposites have provided sufficient data regarding their non-toxicity, but possible toxic side effects upon 
incorporation into the human body cannot be ruled out completely. The biocompatibility issue related to nanomaterials can 
be addressed by considering: (i) the dose of nanoparticles used and (ii) the surface modulation. These two aspects in 
conjunction provide a reliable and sufficient approach to the use of nanomaterials in clinical applications. It is of utmost 
importance to test nanoparticles and biological interactions in order to modify the nanostructures for optimal 
biocompatibility and thereby prevent damage to healthy tissues. There are other lesser known NMN such as Rh, Ru, Ir, and 
Os nanocomposites, whose diagnostic, sensing, and therapeutic abilities need to be understood in more detail and there is 
still much work to be done in the area to realise the full benefits of nanobiotechnology in the field of healthcare and 
environmental preservation. 
Acknowledgements 
APFT gratefully acknowledges funding from the Swedish Research Council VR 2015-04434 DIABETSENS. HP and MA 
acknowledge funding from MIIC, PDF grant and seed grant from Linköping University, Sweden. HP acknowledge EU H2020 
Marie Sklodowska- Curie Individual Fellowship (Grant no. 706694) from European Commission.
References 
1 G. Schlamp, Noble Metals and Their Alloys, Mater. Sci. Technol., , DOI:10.1002/9783527603978.mst0087. 
2 K. U. Kainer, Metal Matrix Composites: Custom-made Materials for Automotive and Aerospce Engineering, Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim, FRG, 2006. 
3 J. Begerow, J. Neuendorf, M. Turfeld, W. Raab and L. Dunemann, Long-term urinary platinum, palladium, and gold 
excretion of patients after insertion of noble-metal dental alloys, Biomarkers, 1999, 4, 27–36. 
4 S. Caroli, A. Alimonti, F. Petrucci, B. Bocca, M. Krachler, F. Forastiere, M. T. Sacerdote and S. Mallone, Assessment 
of exposure to platinum-group metals in urban children, Spectrochim. Acta - Part B At. Spectrosc., 2001, 56, 1241–
1248. 
5 I. J. W. Snow, A. Graham, J. Smith, H. Geoffrey and J. W. Purdy, United States Patent [ 19 ]. 
6 N. Sanvicens and M. P. Marco, Multifunctional nanoparticles - properties and prospects for their use in human 
medicine, Trends Biotechnol., 2008, 26, 425–433. 
7 P. Eaton, I. Gomes, P. Quaresma, A. Miranda, E. Pereira, R. Franco, P. Baptista and G. Doria, Gold nanoparticles for 
the development of clinical diagnosis methods, Anal. Bioanal. Chem., 2007, 391, 943–950. 
8 X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Gold nanoparticles: Interesting optical properties and recent 
applications in cancer diagnostics and therapy, Nanomedicine, 2007, 2, 681–693. 
9 J. F. Hainfeld, F. A. Dilmanian, D. N. Slatkin and H. M. Smilowitz, Radiotherapy enhancement with gold 
nanoparticles, J. Pharm. Pharmacol., 2008, 60, 977–985. 
10 J. F. Hainfeld, D. N. Slatkin and H. M. Smilowitz, The use of gold nanoparticles to enhance radiotherapy in mice, 
Phys. Med. Biol., , DOI:10.1088/0031-9155/49/18/N03. 
11 L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price, J. D. Hazle, N. J. Halas and J. L. West, 
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance, Proc. Natl. 
Acad. Sci., 2003, 100, 13549–13554. 
12 G. Han, P. Ghosh and V. M. Rotello, Multi-functional gold nanoparticles for drug delivery., Adv. Exp. Med. Biol., 
2007, 620, 48–56. 
13 M. Thomas and A. M. Klibanov, Conjugation to gold nanoparticles enhances polyethylenimine’s transfer of plasmid 
DNA into mammalian cells, Proc. Natl. Acad. Sci., 2003, 100, 9138–9143. 
14 Q. Zhang, A. G. Schwartz, L. V. Wang, J. Chen, C. M. Cobley, C. Kim, Y. Xia, K. H. Song, J. Xie, M. Rycenga, Y. Cheng 
and M. S. Yavuz, Gold nanocages covered by smart polymers for controlled release with near-infrared light, Nat. 
Mater., 2009, 8, 935–939. 
15 D. A. Giljohann, J. E. Millstone, K. L. Young, M. R. Jones, C. A. Mirkin and D. S. Seferos, Plasmonically Controlled 
Nucleic Acid Dehybridization with Gold Nanoprisms, ChemPhysChem, 2009, 10, 1461–1465. 
16 S. Bhattacharyya, R. A. Kudgus, R. Bhattacharya and P. Mukherjee, Inorganic nanoparticles in cancer therapy, 
Pharm. Res., 2011, 28, 237–259. 
17 P. Ghosh, G. Han, M. De, C. K. Kim and V. M. Rotello, Gold nanoparticles in delivery applications, Adv. Drug Deliv. 
Rev., 2008, 60, 1307–1315. 
18 N. Nishiyama, Nanomedicine: Nanocarriers shape up for long life, Nat. Nanotechnol., 2007, 2, 203–204. 
19 J. Xie, S. Lee and X. Chen, Nanoparticle-based theranostic agents, Adv. Drug Deliv. Rev., 2010, 62, 1064–1079. 
20 T. K. Sau, A. L. Rogach, F. Jäckel, T. A. Klar and J. Feldmann, Properties and applications of colloidal nonspherical 
noble metal nanoparticles, Adv. Mater., 2010, 22, 1805–1825. 
21 W. Parak, 2008 Gold : Chemistry , Materials and Catalysis Issue Please take a look at the full table of contents to 
access the, Chem. Soc. Rev., 2008, 37, 1909–30. 
22 W. Zhao, J. M. Karp, M. Ferrari and R. Serda, Bioengineering nanotechnology: towards the clinic, Nanotechnology, 
2011, 22, 490201–490201. 
23 J. Conde, J. Rosa, J. C. Lima and P. V. Baptista, Nanophotonics for Molecular Diagnostics and Therapy Applications, 
Int. J. Photoenergy, 2012, 2012, 1–11. 
24 K. K. Jain, Applications of nanobiotechnology in clinical diagnostics, Clin. Chem., 2007, 53, 2002–2009. 
25 K. K. Jain, Nanomedicine: Application of nanobiotechnology in medical practice, Med. Princ. Pract., 2008, 17, 89–
101. 
26 K. V. Mahesh, S. K. Singh and M. Gulati, A comparative study of top-down and bottom-up approaches for the 
preparation of nanosuspensions of glipizide, Powder Technol., 2014, 256, 436–449. 
27 C. Li, J. H. Hsieh, M. Hung, B. Q. Huang, Y. L. Song, J. Denayer, P. Aubry, G. Bister, G. Spronck, P. Colson, B. 
Vertruyen, V. Lardot, F. Cambier, C. Henrist, R. Cloots, P. R. S. Patil, P. R. S. Patil, E. A. Ennaoui, D. Chatzikyriakou, 
A. Maho, R. Cloots, C. Henrist, G. Leftheriotis, M. Liveri, M. Galanopoulou, I. D. Manariotis, P. Yianoulis and Lado 
Filipovic, Ultrasonic spray pyrolysis for nanoparticles synthesis, J. Mater. Sci., 2004, 9, 3647–3657. 
28 K. L. Lusker, J. R. Li and J. C. Garno, Nanostructures of functionalized gold nanoparticles prepared by particle 
lithography with organosilanes, Langmuir, 2011, 27, 13269–13275. 
29 X. Yu, J. T. Pham, C. Subramani, B. Creran, Y. C. Yeh, K. Du, D. Patra, O. R. Miranda, A. J. Crosby and V. M. Rotello, 
Direct patterning of engineered ionic gold nanoparticles via nanoimprint lithography, Adv. Mater., 2012, 24, 6330–
6334. 
30 M. C. Lim, S. H. Kim, K. Park, Y. R. Kim, J. H. Kim, G. Ok and S. W. Choi, Facile synthesis of self-aligned gold 
nanoparticles by crack templated reduction lithography, RSC Adv., 2017, 7, 13228–13231. 
31 G. L. Davies, J. O’Brien and Y. K. Gun’ko, Rare Earth Doped Silica Nanoparticles via Thermolysis of a Single Source 
Metallasilsesquioxane Precursor, Sci. Rep., 2017, 7, 1–8. 
32 A. Tuchscherer, D. Schaarschmidt, S. Schulze, M. Hietschold and H. Lang, Gold nanoparticles generated by 
thermolysis of ‘all-in-one’ gold(i) carboxylate complexes, Dalt. Trans., 2012, 41, 2738–2746. 
33 N. Kamil Othman, M. A. Abdul Hamid, E. Saion, A. Abedini and A. R. Daud, A review on radiation-induced 
nucleation and growth of colloidal metallic nanoparticles, Nanoscale Res. Lett., 2013, 8, 1–10. 
34 J. Amblard, J. Belloni, H. Remita, J. Khatouri, C. de Cointet, M. Mostafavi, R. de Keyzer and M. Treguer, Dose Rate 
Effects on Radiolytic Synthesis of Gold−Silver Bimetallic Clusters in Solu on, J. Phys. Chem. B, 2002, 102, 4310–
4321. 
35 M. Schulz-Dobrick, K. V. Sarathy and M. Jansen, Surfactant-free synthesis and functionalization of gold 
nanoparticles, J. Am. Chem. Soc., 2005, 127, 12816–12817. 
36 J. Liu, K. He, W. Wu, T. Bin Song and M. G. Kanatzidis, In Situ Synthesis of Highly Dispersed and Ultrafine Metal 
Nanoparticles from Chalcogels, J. Am. Chem. Soc., 2017, 139, 2900–2903. 
37 N. H. Chou, X. Ke, P. Schiffer and R. E. Schaak, Room-temperature chemical synthesis of shape-controlled indium 
nanoparticles, J. Am. Chem. Soc., 2008, 130, 8140–8141. 
38 L. Rodríguez-Sánchez, M. C. Blanco and M. A. López-Quintela, Electrochemical Synthesis of Silver Nanoparticles, J. 
Phys. Chem. B, 2002, 104, 9683–9688. 
39 A. Uehara, S. G. Booth, S. Y. Chang, S. L. M. Schroeder, T. Imai, T. Hashimoto, J. F. W. Mosselmans and R. A. W. 
Dryfe, Electrochemical Insight into the Brust-Schiffrin Synthesis of Au Nanoparticles, J. Am. Chem. Soc., 2015, 137, 
15135–15144. 
40 B. Wiley, Y. Yin, Y. Xiong, J. Chen, Y. Xia and S. Aloni, Understanding the Role of Oxidative Etching in the Polyol 
Synthesis of Pd Nanoparticles with Uniform Shape and Size, J. Am. Chem. Soc., 2005, 127, 7332–7333. 
41 K. Okitsu, M. Ashokkumar and F. Grieser, Sonochemical synthesis of gold nanoparticles: Effects of ultrasound 
frequency, J. Phys. Chem. B, 2005, 109, 20673–20675. 
42 A. M. Golsheikh, N. M. Huang, H. N. Lim and R. Zakaria, One-pot sonochemical synthesis of reduced graphene 
oxide uniformly decorated with ultrafine silver nanoparticles for non-enzymatic detection of H2O2 and optical 
detection of mercury ions, RSC Adv., 2014, 4, 36401–36411. 
43 J. Chen, P. Mela, M. Möller and M. C. Lensen, Microcontact deprinting: A technique to pattern gold nanoparticles, 
ACS Nano, 2009, 3, 1451–1456. 
44 G. Walters and I. P. Parkin, The incorporation of noble metal nanoparticles into host matrix thin films: Synthesis, 
characterisation and applications, J. Mater. Chem., 2009, 19, 574–590. 
45 D. Debnath, S. H. Kim and K. E. Geckeler, The first solid-phase route to fabricate and size-tune gold nanoparticles 
at room temperature, J. Mater. Chem., 2009, 19, 8810–8816. 
46 S. De, R. Luque, M. Ojeda, C. Xu and A. M. Balu, Mechanochemical synthesis of advanced nanomaterials for 
catalytic applications, Chem. Commun., 2015, 51, 6698–6713. 
47 C. Zhu, D. Du, A. Eychmüller and Y. Lin, Engineering Ordered and Nonordered Porous Noble Metal Nanostructures: 
Synthesis, Assembly, and Their Applications in Electrochemistry, Chem. Rev., 2015, 115, 8896–8943. 
48 P. Y. Ho, S. C. Yiu, D. Y. Wu, C. L. Ho and W. Y. Wong, One-step synthesis of platinum nanoparticles by pyrolysis of 
a polyplatinyne polymer, J. Organomet. Chem., 2017, 849–850, 4–9. 
49 P. C. Lee and D. Meisel, Adsorption and surface-enhanced Raman of dyes on silver and gold sols, J. Phys. Chem., 
1982, 86, 3391–3395. 
50 X. Dong, X. Ji, H. Wu, L. Zhao, J. Li and W. Yang, Shape Control of Silver Nanoparticles by Stepwise Citrate 
Reduction: Supporting Information, J. Phys. Chem. C, 2009, 113, S1–S3. 
51 N. T. K. Thanh, N. Maclean and S. Mahiddine, Mechanisms of Nucleation and Growth of Nanoparticles in Solution, 
Chem. Rev., 2014, 114, 7610–7630. 
52 J. Turkevich, P. C. Stevenson and J. Hillier, A study of the nucleation and growth processes in the synthesis of 
colloidal gold, Discuss. Faraday Soc., 1951, 11, 55. 
53 G. FRENS, Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions, Nat. 
Phys. Sci., 1973, 241, 20–22. 
54 X. Ji, X. Song, J. Li, Y. Bai, W. Yang and X. Peng, Size control of gold nanocrystals in citrate reduction: The third role 
of citrate, J. Am. Chem. Soc., 2007, 129, 13939–13948. 
55 T. S. Ahmadi, Z. L. Wang, T. C. Green, A. Henglein and M. A. El-Sayed, Shape-Controlled Synthesis of Colloidal 
Platinum Nanoparticles, Science (80-. )., 1996, 272, 1924–1925. 
56 J. Zhang and J. Fang, A General Strategy for Preparation of Pt 3d-Transition Metal (Co, Fe, Ni) Nanocubes, J. Am. 
Chem. Soc., 2009, 131, 18543–18547. 
57 C. Tojo, D. Buceta and M. A. López-Quintela, Synthesis of Pt/M (M = Au, Rh) Nanoparticles in Microemulsions: 
Controlling the Metal Distribution in Pt/M Catalysts, Ind. Eng. Chem. Res., 2019, 58, 2503–2513. 
58 D. S. Bae, E. J. Kim, J. H. Bang, S. W. Kim, K. S. Han, J. K. Lee, B. I. Kim and J. H. Adair, Synthesis and characterization 
of silver nanoparticles by a reverse micelle process, Met. Mater. Int., 2005, 11, 291–294. 
59 J. N. Solanki and Z. V. P. Murthy, Controlled size silver nanoparticles synthesis with water-in-oil microemulsion 
method: A topical review, Ind. Eng. Chem. Res., 2011, 50, 12311–12323. 
60 J. Rajput, A. R. Kumar and S. Zinjarde, A simple microemulsion based method for the synthesis of gold 
nanoparticles, Mater. Lett., 2009, 63, 2672–2675. 
61 K. Holmberg, Organic reactionsin microemulsions Krister, Curr. Opin. Colloid Interface Sci., 2003, 8, 145–155. 
62 V. Amendola and M. Meneghetti, What controls the composition and the structure of nanomaterials generated by 
laser ablation in liquid solution?, Phys. Chem. Chem. Phys., 2013, 15, 3027–3046. 
63 C. Rehbock, V. Merk, L. Gamrad, R. Streubel and S. Barcikowski, Size control of laser-fabricated surfactant-free 
gold nanoparticles with highly diluted electrolytes and their subsequent bioconjugation, Phys. Chem. Chem. Phys., 
2013, 15, 3057–3067. 
64 T. Tsuji, T. Yahata, M. Yasutomo, K. Igawa, M. Tsuji, Y. Ishikawa and N. Koshizaki, Preparation and investigation of 
the formation mechanism of submicron-sized spherical particles of gold using laser ablation and laser irradiation in 
liquids, Phys. Chem. Chem. Phys., 2013, 15, 3099–3107. 
65 E. Jiménez, K. Abderrafi, R. Abargues, J. L. Valdés and J. P. Martínez-Pastor, Laser-ablation-induced synthesis of 
SiO2-capped noble metal nanoparticles in a single step, Langmuir, 2010, 26, 7458–7463. 
66 S. Horikoshi, T. Sumi and N. Serpone, A hybrid microreactor/microwave high-pressure flow system of a novel 
concept design and its application to the synthesis of silver nanoparticles, Chem. Eng. Process. Process Intensif., 
2013, 73, 59–66. 
67 J. A. Gerbec, D. Magana, A. Washington and G. F. Strouse, Microwave-enhanced reaction rates for nanoparticle 
synthesis, J. Am. Chem. Soc., 2005, 127, 15791–15800. 
68 M. T. Reetz and W. Helbig, Size-Selective Synthesis of Nanostructured Transition Metal Clusters, J. Am. Chem. Soc., 
1994, 116, 7401–7402. 
69 G. R. Nasretdinova, R. R. Fazleeva, R. K. Mukhitova, I. R. Nizameev, M. K. Kadirov, A. Y. Ziganshina and V. V. 
Yanilkin, Electrochemical synthesis of silver nanoparticles in solution, Electrochem. commun., 2015, 50, 69–72. 
70 C. Li, T. Sato and Y. Yamauchi, Electrochemical Synthesis of One-Dimensional Mesoporous Pt Nanorods Using the 
Assembly of Surfactant Micelles in Confined Space, Angew. Chemie Int. Ed., 2013, 52, 8050–8053. 
71 J. A. Dahl, B. L. S. Maddux and J. E. Hutchison, Toward greener nanosynthesis, Chem. Rev., 2007, 107, 2228–2269. 
72 P. Raveendran, J. Fu and S. L. Wallen, Completely ‘Green’ Synthesis and Stabilization of Metal Nanoparticles, J. Am. 
Chem. Soc., 2003, 125, 13940–13941. 
73 N. Vigneshwaran, R. P. Nachane, R. H. Balasubramanya and P. V. Varadarajan, A novel one-pot ‘green’ synthesis of 
stable silver nanoparticles using soluble starch, Carbohydr. Res., 2006, 341, 2012–2018. 
74 P. Raveendran, J. Fu and S. L. Wallen, A simple and ‘green’ method for the synthesis of Au, Ag, and Au-Ag alloy 
nanoparticles, Green Chem., 2006, 8, 34–38. 
75 H. Huang and X. Yang, Synthesis of chitosan-stabilized gold nanoparticles in the absence/presence of 
tripolyphosphate, Biomacromolecules, 2004, 5, 2340–2346. 
76 X. Yan, P. Zhu and J. Li, Self-assembly and application of diphenylalanine-based nanostructures, Chem. Soc. Rev., 
2010, 39, 1877–1890. 
77 A. Dasgupta, J. H. Mondal and D. Das, Peptide hydrogels, RSC Adv., 2013, 3, 9117–9149. 
78 S. Roy, A. Dasgupta, S. Debnath, P. K. Das, D. Das and R. N. Mitra, Water Gelation of an Amino Acid-Based 
Amphiphile, Chem. - A Eur. J., 2006, 12, 5068–5074. 
79 R. N. Mitra and P. K. Das, In situ preparation of gold nanoparticles of varying shape in molecular hydrogel of 
peptide amphiphiles, J. Phys. Chem. C, 2008, 112, 8159–8166. 
80 N. Jain, A. Bhargava, S. Majumdar, J. C. Tarafdar and J. Panwar, Extracellular biosynthesis and characterization of 
silver nanoparticles using Aspergillus flavus NJP08: A mechanism perspective, Nanoscale, 2011, 3, 635–641. 
81 T. Klaus, R. Joerger, E. Olsson and C.-G. Granqvist, Silver-based crystalline nanoparticles, microbially fabricated, 
Proc. Natl. Acad. Sci., 2002, 96, 13611–13614. 
82 A. R. Shahverdi, A. Fakhimi, H. R. Shahverdi and S. Minaian, Synthesis and effect of silver nanoparticles on the 
antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli, Nanomedicine 
Nanotechnology, Biol. Med., 2007, 3, 168–171. 
83 D. Venkataraman, K. Kalimuthu, S. Gurunathan, R. Suresh Babu and M. Bilal, Biosynthesis of silver nanocrystals by 
Bacillus licheniformis, Colloids Surfaces B Biointerfaces, 2008, 65, 150–153. 
84 K. Kalishwaralal, V. Deepak, S. Ram Kumar Pandian and S. Gurunathan, Biological synthesis of gold nanocubes 
from Bacillus licheniformis, Bioresour. Technol., 2009, 100, 5356–5358. 
85 J. Venkatesan, P. Manivasagan, S. K. Kim, A. V. Kirthi, S. Marimuthu and A. A. Rahuman, Marine algae-mediated 
synthesis of gold nanoparticles using a novel Ecklonia cava, Bioprocess Biosyst. Eng., 2014, 37, 1591–1597. 
86 Y. Nangia, N. Wangoo, S. Sharma, J. S. Wu, V. Dravid, G. S. Shekhawat and C. Raman Suri, Facile biosynthesis of 
phosphate capped gold nanoparticles by a bacterial isolate Stenotrophomonas maltophilia, Appl. Phys. Lett., 2009, 
94, 1–4. 
87 B. Nair and T. Pradeep, Coalescence of Nanoclusters and Formation of Submicron Crystallites Assisted by 
Lactobacillus Strains, Cryst. Growth Des., 2002, 2, 293–298. 
88 S. V. Gaidhani, R. K. Yeshvekar, U. U. Shedbalkar, J. H. Bellare and B. A. Chopade, Bio-reduction of 
hexachloroplatinic acid to platinum nanoparticles employing Acinetobacter calcoaceticus, Process Biochem., 2014, 
49, 2313–2319. 
89 Y. Konishi, K. Ohno, N. Saitoh, T. Nomura, S. Nagamine, H. Hishida, Y. Takahashi and T. Uruga, Bioreductive 
deposition of platinum nanoparticles on the bacterium Shewanella algae, J. Biotechnol., 2007, 128, 648–653. 
90 P. Mukherjee, A. Ahmad, D. Mandal, S. Senapati, S. R. Sainkar, M. I. Khan, R. Ramani, R. Parischa, P. V. Ajayakumar, 
M. Alam, M. Sastry and R. Kumar, Bioreduction of AuCl4− Ions by the Fungus, Ver cillium sp. and Surface Trapping 
of the Gold Nanoparticles Formed D.M. and S.S. thank the Council of Scientific and Industrial Research (CSIR), 
Government of India, for financial assistance., Angew. Chemie Int. Ed., 2001, 40, 3585. 
91 P. Mukherjee, S. Senapati, D. Mandal, A. Ahmad, M. I. I. Khan, R. Kumar and M. Sastry, Extracellular Synthesis of 
Gold Nanoparticles by the Fungus Fusarium oxysporum, ChemBioChem, 2002, 3, 461. 
92 J. Xie, J. Y. Lee, D. I. C. Wang and Y. P. Ting, Silver Nanoplates: From Biological to Biomimetic Synthesis, ACS Nano, 
2007, 1, 429–439. 
93 S. N. Sinha, D. Paul, N. Halder, D. Sengupta and S. K. Patra, Green synthesis of silver nanoparticles using fresh 
water green alga Pithophora oedogonia (Mont.) Wittrock and evaluation of their antibacterial activity, Appl. 
Nanosci., 2015, 5, 703–709. 
94 G. Singaravelu, J. S. Arockiamary, V. G. Kumar and K. Govindaraju, A novel extracellular synthesis of monodisperse 
gold nanoparticles using marine alga, Sargassum wightii Greville, Colloids Surfaces B Biointerfaces, 2007, 57, 97–
101. 
95 J. Peralta-Videa, P. Santiago, H. E. Troiani, J. G. Parsons, J. L. Gardea-Torresdey, M. J. Yacaman and E. Gomez, 
Formation and Growth of Au Nanoparticles inside Live Alfalfa Plants, Nano Lett., 2002, 2, 397–401. 
96 S. S. Shankar, A. Rai, A. Ahmad and M. Sastry, Rapid synthesis of Au, Ag, and bimetallic Au core–Ag shell 
nanoparticles using Neem (Azadirachta indica) leaf broth, J. Colloid Interface Sci., 2004, 275, 496–502. 
97 J. Yu, D. Xu, H. N. Guan, C. Wang, L. K. Huang and D. F. Chi, Facile one-step green synthesis of gold nanoparticles 
using Citrus maxima aqueous extracts and its catalytic activity, Mater. Lett., 2016, 166, 110–112. 
98 G. Balasubramani, R. Ramkumar, N. Krishnaveni, R. Sowmiya, P. Deepak, D. Arul and P. Perumal, GC–MS analysis 
of bioactive components and synthesis of gold nanoparticle using Chloroxylon swietenia DC leaf extract and its 
larvicidal activity, J. Photochem. Photobiol. B Biol., 2015, 148, 1–8. 
99 M. Nasrollahzadeh, S. Mohammad Sajadi, A. Rostami-Vartooni, M. Alizadeh and M. Bagherzadeh, Green synthesis 
of the Pd nanoparticles supported on reduced graphene oxide using barberry fruit extract and its application as a 
recyclable and heterogeneous catalyst for the reduction of nitroarenes, J. Colloid Interface Sci., 2016, 466, 360–
368. 
100 K. Elangovan, D. Elumalai, S. Anupriya, R. Shenbhagaraman, P. K. Kaleena and K. Murugesan, Phyto mediated 
biogenic synthesis of silver nanoparticles using leaf extract of Andrographis echioides and its bio-efficacy on 
anticancer and antibacterial activities, J. Photochem. Photobiol. B Biol., 2015, 151, 118–124. 
101 P. K. Jain, X. Huang, I. H. El-Sayed and M. A. El-Sayed, Noble Metals on the Nanoscale: Optical and Photothermal 
Properties and Some Applications in Imaging, Sensing, Biology, and Medicine, Acc. Chem. Res., 2008, 41, 1578–
1586. 
102 Y. H. Su, S.-L. Tu, S.-W. Tseng, Y.-C. Chang, S.-H. Chang and W.-M. Zhang, Influence of surface plasmon resonance 
on the emission intermittency of photoluminescence from gold nano-sea-urchins, Nanoscale, 2010, 2, 2639. 
103 Y. S. Jeong, J.-B. Park, H.-G. Jung, J. Kim, X. Luo, J. Lu, L. Curtiss, K. Amine, Y.-K. Sun, B. Scrosati and Y. J. Lee, Study 
on the Catalytic Activity of Noble Metal Nanoparticles on Reduced Graphene Oxide for Oxygen Evolution 
Reactions in Lithium–Air Batteries, Nano Lett., 2015, 15, 4261–4268. 
104 M.-A. Neouze and U. Schubert, Surface Modification and Functionalization of Metal and Metal Oxide 
Nanoparticles by Organic Ligands, Monatshefte für Chemie - Chem. Mon., 2008, 139, 183–195. 
105 F. Mirkhalaf, J. Paprotny and D. J. Schiffrin, Synthesis of Metal Nanoparticles Stabilized by Metal−Carbon Bonds, J. 
Am. Chem. Soc., 2006, 128, 7400–7401. 
106 K. Kawai, T. Narushima, K. Kaneko, H. Kawakami, M. Matsumoto, A. Hyono, H. Nishihara and T. Yonezawa, 
Synthesis and antibacterial properties of water‐dispersible silver nanoparticles stabilized by metal–carbon σ‐
bonds, Appl. Surf. Sci., 2012, 262, 76–80. 
107 V. K. R. Kumar and K. R. Gopidas, Synthesis and characterization of gold-nanoparticle-cored dendrimers stabilized 
by metal-carbon bonds, Chem. - An Asian J., 2010, 5, 887–896. 
108 J. J. Gooding, F. Mearns, W. Yang and J. Liu, Self-Assembled Monolayers into the 21st Century: Recent Advances 
and Applications, Electroanalysis, 2003, 15, 81–96. 
109 L. Laurentius, S. R. Stoyanov, S. Gusarov, A. Kovalenko, R. Du, G. P. Lopinski and M. T. McDermott, Diazonium-
derived aryl films on gold nanoparticles: Evidence for a carbon-gold covalent bond, ACS Nano, 2011, 5, 4219–4227. 
110 W. Chen, N. B. Zuckerman, X. Kang, D. Ghosh, J. P. Konopelski and S. Chen, Alkyne-Protected Ruthenium 
Nanoparticles, J. Phys. Chem. C, 2010, 114, 18146–18152. 
111 X. Kang, Y. Song and S. Chen, Nitrene-functionalized ruthenium nanoparticles, J. Mater. Chem., 2012, 22, 19250. 
112 P. Hu, Y. Song, L. Chen and S. Chen, Electrocatalytic activity of alkyne-functionalized AgAu alloy nanoparticles for 
oxygen reduction in alkaline media, Nanoscale, 2015, 7, 9627–9636. 
113 R. A. Sperling and W. J. Parak, Surface modification, functionalization and bioconjugation of colloidal Inorganic 
nanoparticles, Philos. Trans. R. Soc. A Math. Phys. Eng. Sci., 2010, 368, 1333–1383. 
114 T. R. Ray, B. Lettiere, J. de Rutte and S. Pennathur, Quantitative Characterization of the Colloidal Stability of 
Metallic Nanoparticles Using UV–vis Absorbance Spectroscopy, Langmuir, 2015, 31, 3577–3586. 
115 E. Roduner, Size matters: Why nanomaterials are different, Chem. Soc. Rev., 2006, 35, 583–592. 
116 N. C. Bigall and A. Eychmüller, Synthesis of noble metal nanoparticles and their non-ordered superstructures, 
Philos. Trans. R. Soc. A Math. Phys. Eng. Sci., 2010, 368, 1385–1404. 
117 J. He, T. Kunitake and A. Nakao, Facile In Situ Synthesis of Noble Metal Nanoparticles in Porous Cellulose Fibers, 
Chem. Mater., 2003, 15, 4401–4406. 
118 J. Gargiulo, S. Cerrota, E. Cortés, I. L. Violi and F. D. Stefani, Connecting Metallic Nanoparticles by Optical Printing, 
Nano Lett., 2016, 16, 1224–1229. 
119 A. Kirillova, C. Schliebe, G. Stoychev, A. Jakob, H. Lang and A. Synytska, Hybrid Hairy Janus Particles Decorated with 
Metallic Nanoparticles for Catalytic Applications, ACS Appl. Mater. Interfaces, 2015, 7, 21218–21225. 
120 N. Chakroune, G. Viau, S. Ammar, L. Poul, D. Veautier, M. M. Chehimi, C. Mangeney, F. Villain and F. Fiévet, 
Acetate- and Thiol-Capped Monodisperse Ruthenium Nanoparticles: XPS, XAS, and HRTEM Studies, Langmuir, 
2005, 21, 6788–6796. 
121 V. L. Nguyen, M. Ohtaki, T. Matsubara, M. T. Cao and M. Nogami, New Experimental Evidences of Pt–Pd Bimetallic 
Nanoparticles with Core–Shell Configuration and Highly Fine-Ordered Nanostructures by High-Resolution Electron 
Transmission Microscopy, J. Phys. Chem. C, 2012, 116, 12265–12274. 
122 J. C. Azcárate, M. H. Fonticelli and E. Zelaya, Radiation Damage Mechanisms of Monolayer-Protected 
Nanoparticles via TEM Analysis, J. Phys. Chem. C, 2017, 121, 26108–26116. 
123 K. A. Perrine and A. V. Teplyakov, Metallic Nanostructure Formation Limited by the Surface Hydrogen on Silicon, 
Langmuir, 2010, 26, 12648–12658. 
124 G. A. Wurtz, J. Hranisavljevic and G. P. Wiederrecht, Electromagnetic Scattering Pathways for Metallic 
Nanoparticles: A Near-Field Optical Study, Nano Lett., 2003, 3, 1511–1516. 
125 M. Glidden and M. Muschol, Characterizing Gold Nanorods in Solution Using Depolarized Dynamic Light 
Scattering, J. Phys. Chem. C, 2012, 116, 8128–8137. 
126 T. Zheng, S. Bott and Q. Huo, Techniques for Accurate Sizing of Gold Nanoparticles Using Dynamic Light Scattering 
with Particular Application to Chemical and Biological Sensing Based on Aggregate Formation, ACS Appl. Mater. 
Interfaces, 2016, 8, 21585–21594. 
127 J. D. Padmos and P. Zhang, Surface structure of organosulfur stabilized silver nanoparticles studied with X-ray 
absorption spectroscopy, J. Phys. Chem. C, 2012, 116, 23094–23101. 
128 G. Corthey, L. J. Giovanetti, J. M. Ramallo-López, E. Zelaya, A. A. Rubert, G. A. Benitez, F. G. Requejo, M. H. 
Fonticelli and R. C. Salvarezza, Synthesis and Characterization of Gold@Gold(I)−Thiomalate Core@Shell 
Nanoparticles, ACS Nano, 2010, 4, 3413–3421. 
129 H. Sharma and R. Singhal, Synthesis of Ag metallic nanoparticles by 120 keV Ag − ion implanta on in TiO 2 matrix, 
Radiat. Eff. Defects Solids, 2017, 172, 896–902. 
130 C. P. Shaw, D. A. Middleton, M. Volk and R. Lévy, Amyloid-Derived Peptide Forms Self-Assembled Monolayers on 
Gold Nanoparticle with a Curvature‐Dependent β‐Sheet Structure, ACS Nano, 2012, 6, 1416–1426. 
131 J. K. Navin, M. E. Grass, G. A. Somorjai and A. L. Marsh, Characterization of Colloidal Platinum Nanoparticles by 
MALDI-TOF Mass Spectrometry, Anal. Chem., 2009, 81, 6295–6299. 
132 F. Laborda, J. Jiménez-Lamana, E. Bolea and J. R. Castillo, Selective identification, characterization and 
determination of dissolved silver(i) and silver nanoparticles based on single particle detection by inductively 
coupled plasma mass spectrometry, J. Anal. At. Spectrom., 2011, 26, 1362. 
133 J. Lee, J. Yang, S. G. Kwon and T. Hyeon, Nonclassical nucleation and growth of inorganic nanoparticles, Nat. Rev. 
Mater., 2016, 1, 16034. 
134 D. Parial, H. K. Patra, A. K. Dasgupta and R. Pal, Screening of different algae for green synthesis of gold 
nanoparticles, Eur. J. Phycol., 2012, 47, 22–29. 
135 D. Parial, H. K. Patra, P. Roychoudhury, A. K. Dasgupta and R. Pal, Gold nanorod production by cyanobacteria—a 
green chemistry approach, J. Appl. Phycol., 2012, 24, 55–60. 
136 M. Azharuddin, S. Sahana, H. Datta and A. K. Dasgupta, Corneal Penetration of Gold Nanoparticles—Therapeutic 
Implications, J. Nanosci. Nanotechnol., 2014, 14, 5669–5675. 
137 H. K. Patra and A. P. F. Turner, The potential legacy of cancer nanotechnology: cellular selection, Trends 
Biotechnol., 2014, 32, 21–31. 
138 H. M. E. Azzazy and M. M. H. Mansour, In vitro diagnostic prospects of nanoparticles, Clin. Chim. Acta, 2009, 403, 
1–8. 
139 S. Kumar, N. Harrison, R. Richards-Kortum and K. Sokolov, Plasmonic nanosensors for imaging intracellular 
biomarkers in live cells, Nano Lett., 2007, 7, 1338–1343. 
140 B. D. Chithrani and W. C. W. Chan, Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated 
Gold Nanoparticles of Different Sizes and Shapes, Nano Lett., 2007, 7, 1542–1550. 
141 W. Jiang, B. Y. S. Kim, J. T. Rutka and W. C. W. Chan, Nanoparticle-mediated cellular response is size-dependent, 
Nat. Nanotechnol., 2008, 3, 145–150. 
142 J. Pelka, H. Gehrke, M. Esselen, M. Türk, M. Crone, S. Bräse, T. Muller, H. Blank, W. Send, V. Zibat, P. Brenner, R. 
Schneider, D. Gerthsen and D. Marko, Cellular Uptake of Platinum Nanoparticles in Human Colon Carcinoma Cells 
and Their Impact on Cellular Redox Systems and DNA Integrity, Chem. Res. Toxicol., 2009, 22, 649–659. 
143 J. A. Khan, R. A. Kudgus, A. Szabolcs, S. Dutta, E. Wang, S. Cao, G. L. Curran, V. Shah, S. Curley, D. Mukhopadhyay, J. 
D. Robertson, R. Bhattacharya and P. Mukherjee, Designing Nanoconjugates to Effectively Target Pancreatic 
Cancer Cells In Vitro and In Vivo, PLoS One, 2011, 6, e20347. 
144 C. M. Goodman, C. D. McCusker, T. Yilmaz and V. M. Rotello, Toxicity of Gold Nanoparticles Functionalized with 
Cationic and Anionic Side Chains, Bioconjug. Chem., 2004, 15, 897–900. 
145 A. Verma and F. Stellacci, Effect of Surface Properties on Nanoparticleâ&#128;&#147;Cell Interactions, Small, 
2010, 6, 12–21. 
146 A. Verma, O. Uzun, Y. Hu, Y. Hu, H.-S. Han, N. Watson, S. Chen, D. J. Irvine and F. Stellacci, Surface-structure-
regulated cell-membrane penetration by monolayer-protected nanoparticles, Nat. Mater., 2008, 7, 588–595. 
147 S. S. Agasti, A. Chompoosor, C.-C. You, P. Ghosh, C. K. Kim and V. M. Rotello, Photoregulated Release of Caged 
Anticancer Drugs from Gold Nanoparticles, J. Am. Chem. Soc., 2009, 131, 5728–5729. 
148 C. K. Kim, P. Ghosh, C. Pagliuca, Z.-J. Zhu, S. Menichetti and V. M. Rotello, Entrapment of Hydrophobic Drugs in 
Nanoparticle Monolayers with Efficient Release into Cancer Cells, J. Am. Chem. Soc., 2009, 131, 1360–1361. 
149 N. Ferrara and R. S. Kerbel, Angiogenesis as a therapeutic target, Nature, 2005, 438, 967–974. 
150 N. Ferrara, R. D. Mass, C. Campa and R. Kim, Targeting VEGF-A to Treat Cancer and Age-Related Macular 
Degeneration, Annu. Rev. Med., 2007, 58, 491–504. 
151 D. Bisacchi, R. Benelli, C. Vanzetto, N. Ferrari, F. Tosetti and A. Albini, Anti-angiogenesis and angioprevention: 
Mechanisms, problems and perspectives, Cancer Detect. Prev., 2003, 27, 229–238. 
152 A. Grothey and E. Galanis, Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules, Nat. 
Rev. Clin. Oncol., 2009, 6, 507–518. 
153 T. A. Yap, C. P. Carden and S. B. Kaye, Beyond chemotherapy: targeted therapies in ovarian cancer, Nat. Rev. 
Cancer, 2009, 9, 167–181. 
154 M. Ferrari, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 2005, 5, 161–171. 
155 P. Mukherjee, R. Bhattacharya, P. Wang, L. Wang, S. Basu, J. A. Nagy, A. Atala, D. Mukhopadhyay and S. Soker, 
Antiangiogenic Properties of Gold Nanoparticles, Clin. Cancer Res., 2005, 11, 3530–3534. 
156 R. Bhattacharya, P. Mukherjee, Z. Xiong, A. Atala, S. Soker and D. Mukhopadhyay, Gold Nanoparticles Inhibit 
VEGF165-Induced Proliferation of HUVEC Cells, Nano Lett., 2004, 4, 2479–2481. 
157 R. R. Arvizo, S. Rana, O. R. Miranda, R. Bhattacharya, V. M. Rotello and P. Mukherjee, Mechanism of anti-
angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge, Nanomedicine 
Nanotechnology, Biol. Med., 2011, 7, 580–587. 
158 S. Gurunathan, K.-J. Lee, K. Kalishwaralal, S. Sheikpranbabu, R. Vaidyanathan and S. H. Eom, Antiangiogenic 
properties of silver nanoparticles, Biomaterials, 2009, 30, 6341–6350. 
159 P. Mukherjee, R. Bhattacharya, N. Bone, Y. K. Lee, C. Patra, S. Wang, L. Lu, C. Secreto, P. C. Banerjee, M. J. 
Yaszemski, N. E. Kay and D. Mukhopadhyay, Potential therapeutic application of gold nanoparticles in B-chronic 
lymphocytic leukemia (BCLL): enhancing apoptosis, J. Nanobiotechnology, 2007, 5, 4. 
160 R. Bhattacharya, C. R. Patra, R. Verma, S. Kumar, P. R. Greipp and P. Mukherjee, Gold Nanoparticles Inhibit the 
Proliferation of Multiple Myeloma Cells, Adv. Mater., 2007, 19, 711–716. 
161 Y. He, Z. Du, S. Ma, Y. Liu, D. Li, H. Huang, S. Jiang, S. Cheng, W. Wu, K. Zhang and X. Zheng, Effects of green-
synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo, Int. J. 
Nanomedicine, 2016, 11, 1879–1887. 
162 J. A. Jacob and A. Shanmugam, Silver nanoparticles provoke apoptosis of Dalton’s ascites lymphoma in vivo by 
mitochondria dependent and independent pathways, Colloids Surfaces B Biointerfaces, 2015, 136, 1011–1016. 
163 R. L. Manthe, S. P. Foy, N. Krishnamurthy, B. Sharma and V. Labhasetwar, Tumor Ablation and Nanotechnology, 
Mol. Pharm., 2010, 7, 1880–1898. 
164 F. S. De Rosa and M. V. L. B. Bentley, Photodynamic therapy of skin cancers: Sensitizers, clinical studies and future 
directives, Pharm. Res., 2000, 17, 1447–1455. 
165 S. Lal, S. E. Clare and N. J. Halas, Nanoshell-Enabled Photothermal Cancer Therapy: Impending Clinical Impact, Acc. 
Chem. Res., 2008, 41, 1842–1851. 
166 R. Weissleder, A clearer vision for in vivo imaging, Nat. Biotechnol., 2001, 19, 316–317. 
167 M. Johannsen, U. Gneveckow, L. Eckelt, A. Feussner, N. WaldÖFner, R. Scholz, S. Deger, P. Wust, S. A. Loening and 
A. Jordan, Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial 
technique, Int. J. Hyperth., 2005, 21, 637–647. 
168 J. J. Fairbairn, M. W. Khan, K. J. Ward, B. W. Loveridge, D. W. Fairbairn and K. L. O’Neill, Induction of apoptotic cell 
DNA fragmentation in human cells after treatment with hyperthermia, Cancer Lett., 1995, 89, 183–188. 
169 C. M. Pitsillides, E. K. Joe, X. Wei, R. R. Anderson and C. P. Lin, Selective Cell Targeting with Light-Absorbing 
Microparticles and Nanoparticles, Biophys. J., 2003, 84, 4023–4032. 
170 X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Determination of the Minimum Temperature Required for 
Selective Photothermal Destruction of Cancer Cells with the Use of Immunotargeted Gold Nanoparticles, 
Photochem. Photobiol., 2006, 82, 412. 
171 V. Raji, J. Kumar, C. S. Rejiya, M. Vibin, V. N. Shenoi and A. Abraham, Selective photothermal efficiency of citrate 
capped gold nanoparticles for destruction of cancer cells, Exp. Cell Res., 2011, 317, 2052–2058. 
172 D. Bartczak, O. L. Muskens, S. Nitti, T. Sanchez-Elsner, T. M. Millar and A. G. Kanaras, Interactions of Human 
Endothelial Cells with Gold Nanoparticles of Different Morphologies, Small, 2012, 8, 122–130. 
173 G. von Maltzahn, J.-H. Park, A. Agrawal, N. K. Bandaru, S. K. Das, M. J. Sailor and S. N. Bhatia, Computationally 
Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas, Cancer Res., 2009, 69, 
3892–3900. 
174 M. A. Sirotkina, V. V. Elagin, M. V. Shirmanova, M. L. Bugrova, L. B. Snopova, V. A. Kamensky, V. A. Nadtochenko, 
N. N. Denisov and E. V. Zagaynova, OCT-guided laser hyperthermia with passively tumor-targeted gold 
nanoparticles, J. Biophotonics, 2010, 3, 718–727. 
175 J. Cardinal, J. R. Klune, E. Chory, G. Jeyabalan, J. S. Kanzius, M. Nalesnik and D. A. Geller, Noninvasive 
radiofrequency ablation of cancer targeted by gold nanoparticles, Surgery, 2008, 144, 125–132. 
176 S. H. Cho, Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: 
a preliminary Monte Carlo study, Phys. Med. Biol., 2005, 50, N163–N173. 
177 J. F. Hainfeld, F. A. Dilmanian, Z. Zhong, D. N. Slatkin, J. A. Kalef-Ezra and H. M. Smilowitz, Gold nanoparticles 
enhance the radiation therapy of a murine squamous cell carcinoma, Phys. Med. Biol., 2010, 55, 3045–3059. 
178 T. Kong, J. Zeng, X. Wang, X. Yang, J. Yang, S. McQuarrie, A. McEwan, W. Roa, J. Chen and J. Z. Xing, Enhancement 
of Radiation Cytotoxicity in Breast-Cancer Cells by Localized Attachment of Gold Nanoparticles, Small, 2008, 4, 
1537–1543. 
179 L. E. Taggart, G. R. Dickson, S. J. Mcmahon, W. B. Hyland, M. F. Muir, C. Trainor, A. R. Hounsell, J. M. O. Sullivan, G. 
Schettino, F. J. Currell, D. G. Hirst and K. M. Prise, Cell type-dependent uptake, localization, and Cytotoxicity of 1 . 
9 Nm Gold Nanoparticles, Int. J. Nanomedicine, 2012, 7, 2673–2685. 
180 R. R. Arvizo, O. R. Miranda, M. A. Thompson, C. M. Pabelick, R. Bhattacharya, J. D. Robertson, V. M. Rotello, Y. S. 
Prakash and P. Mukherjee, Effect of Nanoparticle Surface Charge at the Plasma Membrane and Beyond, Nano 
Lett., 2010, 10, 2543–2548. 
181 E. C. Cho, Q. Zhang and Y. Xia, The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles, 
Nat. Nanotechnol., 2011, 6, 385–391. 
182 C. Minelli, S. B. Lowe and M. M. Stevens, Engineering nanocomposite materials for cancer therapy, Small, 2010, 6, 
2336–2357. 
183 C. H. J. Choi, C. A. Alabi, P. Webster and M. E. Davis, Mechanism of active targeting in solid tumors with 
transferrin-containing gold nanoparticles, Proc. Natl. Acad. Sci., 2009, 107, 1235–1240. 
184 P. F. Jiao, H. Y. Zhou, L. X. Chen and B. Yan, Cancer-targeting multifunctionalized gold nanoparticles in imaging and 
therapy., Curr. Med. Chem., 2011, 18, 2086–102. 
185 X. Li, H. Zhou, L. Yang, G. Du, A. S. Pai-Panandiker, X. Huang and B. Yan, Enhancement of cell recognition in vitro by 
dual-ligand cancer targeting gold nanoparticles, Biomaterials, 2011, 32, 2540–2545. 
186 D. P. O’Neal, L. R. Hirsch, N. J. Halas, J. D. Payne and J. L. West, Photo-thermal tumor ablation in mice using near 
infrared-absorbing nanoparticles, Cancer Lett., 2004, 209, 171–176. 
187 K. Jans, G. Borghs, S. Muyldermans, G. Maes, L. Lagae, B. Van de Broek, H.-L. Gijs, A. D’Hollander and N. Devoogdt, 
Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy, ACS 
Nano, 2011, 5, 4319–4328. 
188 C. Loo, A. Lowery, N. Halas, J. West and R. Drezek, Immunotargeted Nanoshells for Integrated Cancer Imaging and 
Therapy, Nano Lett., 2005, 5, 709–711. 
189 W.-K. Rhim, J.-S. Kim and J.-M. Nam, Lipid-Gold-Nanoparticle Hybrid-Based Gene Delivery, Small, 2008, 4, 1651–
1655. 
190 F. Chen, Z. Zhong, C. Hu, R. Zhuo and Q. Peng, Low Molecular Weight Polyethylenimine Conjugated Gold 
Nanoparticles as Efficient Gene Vectors, Bioconjug. Chem., 2010, 21, 836–843. 
191 A. M. Chen, O. Taratula, D. Wei, H. Yen, T. Thomas, T. J. Thomas, T. Minko and H. He, Labile Catalytic Packaging of 
DNA / siRNA : Control of Gold Nanoparticles “ out ” of, 2010, 4, 3679–3688. 
192 Y. Cheng, A. C. Samia, J. Li, M. E. Kenney, A. Resnick and C. Burda, Delivery and efficacy of a cancer drug as a 
function of the bond to the gold nanoparticle surface, Langmuir, 2010, 26, 2248–2255. 
193 S. D. Brown, P. Nativo, J. A. Smith, D. Stirling, P. R. Edwards, B. Venugopal, D. J. Flint, J. A. Plumb, D. Graham and N. 
J. Wheate, Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin, J. 
Am. Chem. Soc., 2010, 132, 4678–4684. 
194 H. K. Patra, S. Banerjee, U. Chaudhuri, P. Lahiri and A. K. Dasgupta, Cell selective response to gold nanoparticles, 
Nanomedicine Nanotechnology, Biol. Med., 2007, 3, 111–119. 
195 N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K. R. Lytton-Jean, M. S. Han and C. A. Mirkin, Oligonucleotide-Modified 
Gold Nanoparticles for Intracellular Gene Regulation (Supporting Online Material), Science (80-. )., 2006, 312, 
1027. 
196 D. A. Giljohann, D. S. Seferos, A. E. Prigodich, P. C. Patel and C. A. Mirkin, Gene regulation with polyvalent siRNA-
nanoparticle conjugates. (Supplementary Information), J. Am. Chem. Soc., 2009, 131, 2072–3. 
197 P. S. Ghosh, C. Kim, G. Han, N. S. Forbes and V. M. Rotello, Efficient Gene Delivery Vectors by Tuning the Surface 
Charge Density of, J. Am. Chem. Soc., 2008, 2, 2213–2218. 
198 C. K. Kim, P. Ghosh and V. M. Rotello, Multimodal drug delivery using gold nanoparticles, Nanoscale, 2009, 1, 61–
67. 
199 M. E. Kenney, J. P. Basilion, C. Burda, A.-M. Broome, Y. Cheng and J. D. Meyers, Deep Penetration of a PDT Drug 
into Tumors by Noncovalent Drug-Gold Nanoparticle Conjugates, J. Am. Chem. Soc., 2011, 133, 2583–2591. 
200 B. Kim, N. S. Forbes, V. M. Rotello, G. Han, R. Hong and J. M. Fernández, Glutathione-Mediated Delivery and 
Release Using Monolayer Protected Nanoparticle Carriers, J. Am. Chem. Soc., 2006, 128, 1078–1079. 
201 H. Ishida, J. Nakanishi, T. Shimizu, K. Yamaguchi, Y. Horiike, H. Nakayama and Y. Kikuchi, Light-Regulated Activation 
of Cellular Signaling by Gold Nanoparticles That Capture and Release Amines, J. Am. Chem. Soc., 2009, 131, 3822–
3823. 
202 J. H. Bahng, P. Podsiadlo, N. A. Kotov, N. W. S. Kam, V. A. Sinani and J. Lee, Gold Nanoparticles Enhance the Anti-
Leukemia Action of a 6-Mercaptopurine Chemotherapeutic Agent, Langmuir, 2007, 24, 568–574. 
203 B. Kim, G. Han, B. J. Toley, C. K. Kim, V. M. Rotello and N. S. Forbes, Tuning payload delivery in tumour cylindroids 
using gold nanoparticles, Nat. Nanotechnol., 2010, 5, 465–472. 
204 A. C. Anselmo and S. Mitragotri, A Review of Clinical Translation of Inorganic Nanoparticles, AAPS J., 2015, 17, 
1041–1054. 
205 D. Paithankar, B. H. Hwang, G. Munavalli, A. Kauvar, J. Lloyd, R. Blomgren, L. Faupel, T. Meyer and S. Mitragotri, 
Ultrasonic delivery of silica-gold nanoshells for photothermolysis of sebaceous glands in humans: Nanotechnology 
from the bench to clinic, J. Control. Release, 2015, 206, 30–36. 
206 Y. Ge, N. Gu, W. Ma, Y. Zhang, X. Zhou, Y. Zhao, H. Zhou, Z. Huang, D. Guo, J. Wu, X. Zhang and L. Zhu, Anti-
leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver 
ions, Biomaterials, 2013, 34, 7884–7894. 
207 J. A. Coulter, W. B. Hyland, J. Nicol and F. J. Currell, Radiosensitising nanoparticles as novel cancer therapeutics - 
Pipe dream or realistic prospect?, Clin. Oncol., 2013, 25, 593–603. 
208 W. He, Y. T. Zhou, W. G. Wamer, M. D. Boudreau and J. J. Yin, Mechanisms of the pH dependent generation of 
hydroxyl radicals and oxygen induced by Ag nanoparticles, Biomaterials, 2012, 33, 7547–7555. 
209 M. Jeyaraj, G. Sathishkumar, G. Sivanandhan, D. MubarakAli, M. Rajesh, R. Arun, G. Kapildev, M. Manickavasagam, 
N. Thajuddin, K. Premkumar and A. Ganapathi, Biogenic silver nanoparticles for cancer treatment: An 
experimental report, Colloids Surfaces B Biointerfaces, 2013, 106, 86–92. 
210 S. Gurunathan, J. W. Han, A. A. Dayem, V. Eppakayala, J. H. Park, S. G. Cho, K. J. Lee and J. H. Kim, Green synthesis 
of anisotropic silver nanoparticles and its potential cytotoxicity in human breast cancer cells (MCF-7), J. Ind. Eng. 
Chem., 2013, 19, 1600–1605. 
211 J.-H. Kim, V. Eppakayala, M. Jeyaraj, J. W. Han and S. Gurunathan, Cytotoxicity of Biologically Synthesized Silver 
Nanoparticles in MDA-MB-231 Human Breast Cancer Cells, Biomed Res. Int., 2013, 2013, 1–10. 
212 J. Liu, Y. Zhao, Q. Guo, Z. Wang, H. Wang, Y. Yang and Y. Huang, TAT-modified nanosilver for combating multidrug-
resistant cancer, Biomaterials, 2012, 33, 6155–6161. 
213 K. R. Barnes and S. J. Lippard, Cisplatin and related anticancer drugs: recent advances and insights., Met. Ions Biol. 
Syst., 2004, 42, 143–177. 
214 H. Gehrke, J. Pelka, C. G. Hartinger, H. Blank, F. Bleimund, R. Schneider, D. Gerthsen, S. Bräse, M. Crone, M. Türk 
and D. Marko, Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic 
concentrations, Arch. Toxicol., 2011, 85, 799–812. 
215 E. Porcel, S. Liehn, H. Remita, N. Usami, K. Kobayashi, Y. Furusawa, C. Le Sech and S. Lacombe, Platinum 
nanoparticles: A promising material for future cancer therapy?, Nanotechnology, 2010, 21, 085103. 
216 C. Le Sech, K. Kobayashi, K. Takakura, H. Frohlich and N. Usami, Enhancement of X-Ray-Induced Breaks in DNA 
Bound to Molecules Containing Platinum: A Possible Application to Hadrontherapy, Radiat. Res., 2006, 157, 32–37. 
217 P. V. Asharani, N. Xinyi, M. P. Hande and S. Valiyaveettil, DNA damage and p53-mediated growth arrest in human 
cells treated with platinum nanoparticles, Nanomedicine, 2010, 5, 51–64. 
218 K. Eid, A. Eldesouky, A. Fahmy, A. Shahat and R. AbdElaal, Calcium Phosphate Scaffold Loaded with Platinum 
Nanoparticles for Bone Allograft, Am. J. Biomed. Sci., 2013, 242–249. 
219 J. Nellore, C. Pauline and K. Amarnath, Bacopa monnieri Phytochemicals Mediated Synthesis of Platinum 
Nanoparticles and Its Neurorescue Effect on 1-Methyl Parkinsonism in Zebrafish, J. Neurodegener. Dis., 2013, 
2013, 1–8. 
220 W. K. Kim, J. C. Kim, H. J. Park, O. J. Sul, M. H. Lee, J. S. Kim and H. S. Choi, Platinum nanoparticles reduce 
ovariectomy-induced bone loss by decreasing osteoclastogenesis, Exp. Mol. Med., 2012, 44, 432–439. 
221 L. Zhang, L. Laug, W. Münchgesang, E. Pippel, U. Gösele, M. Brandsch and M. Knez, Reducing stress on cells with 
apoferritin-encapsulated platinum nanoparticles, Nano Lett., 2010, 10, 219–223. 
222 T. Shimizu, Y. Miyamoto, T. Kondo, A. Honda, Y. Yoshihisa, H. Shimizu, Q.-L. Zhao, R. Abe, K. Matsui and T. Makino, 
Protective effects of platinum nanoparticles against UV-light-induced epidermal inflammation, Exp. Dermatol., 
2010, 19, 1000–1006. 
223 R. R. Arvizo, S. Bhattacharyya, R. A. Kudgus, K. Giri, R. Bhattacharya and P. Mukherjee, Intrinsic therapeutic 
applications of noble metal nanoparticles: Past, present and future, Chem. Soc. Rev., 2012, 41, 2943–2970. 
224 Q. Wang, X. Cui, J. Chen, X. Zheng, C. Liu, T. Xue, H. Wang, Z. Jin, L. Qiao and W. Zheng, Well-dispersed palladium 
nanoparticles on graphene oxide as a non-enzymatic glucose sensor, RSC Adv., 2012, 2, 6245–6249. 
225 S. Mubeen, T. Zhang, B. Yoo, M. A. Deshusses and N. V. Myung, Palladium nanoparticles decorated single-walled 
carbon nanotube hydrogen sensor, J. Phys. Chem. C, 2007, 111, 6321–6327. 
226 B. L. French, L. M. Davis, E. S. Munzinger, J. W. J. Slavin, P. C. Christy, D. W. Thompson and R. E. Southward, 
Palladium-polyimide nanocomposite membranes: Synthesis and characterization of reflective and electrically 
conductive surface-metallized films, Chem. Mater., 2005, 17, 2091–2100. 
227 E. S. Snow, B. V Shanabrook, D. Park, R. Leon, D. Leonard, J. L. Merz, P. M. Petroff, E. Betzig, T. D. Harris, L. N. 
Pfeiffer, C. P. Lutz, D. M. Eigler, G. Goldoni, F. Rossi, E. Molinari, G. Martino, R. Girlanda, A. Knorr, P. Thomas, S. W. 
Koch, O. Hollricher, O. Marti, R. D. Grober, D. Gammon, D. S. Katzer, T. Gmitter, J. P. Harbison, R. Bhat, P. Wolanin, 
A. Gafni, D. G. Steel, M. Jiang, D. G. Steel, R. Zimmermann, F. Spectroscopy and M. Sargent, Hydrogen Sensors and 
Switches from Electrodeposited Palladium Mesowire Arrays, 2001, 293, 2227–2231. 
228 L. M. Davis, J. M. Compton, D. E. Kranbuehl, D. W. Thompson and R. E. Southward, Reflective and electrically 
conductive palladium surface-metallized polyimide nanocomposite membranes, J. Appl. Polym. Sci., 2006, 102, 
2708–2716. 
229 Z. Chang, H. Fan, K. Zhao, M. Chen, P. He and Y. Fang, Electrochemical DNA biosensors based on palladium 
nanoparticles combined with carbon nanotubes, Electroanalysis, 2008, 20, 131–136. 
230 P. T. Finger, A. Berson and A. Szechter, Palladium-103 plaque radiotherapy for choroidal melanoma, 
Ophthalmology, 2003, 106, 606–613. 
231 B. Woodward, Platin. Met. Rev., 2012, 56, 213–217. 
232 J. T. Weiss, J. C. Dawson, K. G. Macleod, W. Rybski, C. Fraser, C. Torres-Sánchez, E. E. Patton, M. Bradley, N. O. 
Carragher and A. Unciti-Broceta, Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a 
bioorthogonally activated prodrug approach, Nat. Commun., 2014, 5, 3277. 
233 C. Fraser, M. Bradley, J. T. Weiss, J. C. Dawson, E. E. Patton, W. Rybski, A. Unciti-Broceta, C. Torres-Sánchez and N. 
O. Carragher, Development and Bioorthogonal Activation of Palladium-Labile Prodrugs of Gemcitabine, J. Med. 
Chem., 2014, 57, 5395–5404. 
234 X. Huang, S. Tang, X. Mu, Y. Dai, G. Chen, Z. Zhou, F. Ruan, Z. Yang and N. Zheng, Freestanding palladium 
nanosheets with plasmonic and catalytic properties, Nat. Nanotechnol., 2011, 6, 28–32. 
235 X. Huang, S. Tang, J. Yang, Y. Tan and N. Zheng, Etching growth under surface confinement: An effective strategy 
to prepare mesocrystalline Pd nanocorolla, J. Am. Chem. Soc., 2011, 133, 15946–15949. 
236 S. Tang, X. Huang and N. Zheng, Silica coating improves the efficacy of Pd nanosheets for photothermal therapy of 
cancer cells using near infrared laser, Chem. Commun., 2011, 47, 3948–3950. 
237 S. Tang, M. Chen and N. Zheng, Sub-10-nm Pd nanosheets with renal clearance for efficient near-infrared 
photothermal cancer therapy, Small, 2014, 10, 3139–3144. 
238 S. Tang, X. Fang, W. Fang, N. Zheng, P. Liu and J. Gong, Pd Nanosheet-Covered Hollow Mesoporous Silica 
Nanoparticles as a Platform for the Chemo-Photothermal Treatment of Cancer Cells, Small, 2012, 8, 3816–3822. 
239 A. M. Watson, X. Zhang, R. Alcaraz De La Osa, J. M. Sanz, F. González, F. Moreno, G. Finkelstein, J. Liu and H. O. 
Everitt, Rhodium nanoparticles for ultraviolet plasmonics, Nano Lett., 2015, 15, 1095–1100. 
240 H. Gu, P. L. Ho, E. Tong, L. Wang and B. Xu, Presenting vancomycin on nanoparticles to enhance antimicrobial 
activities, Nano Lett., 2003, 3, 1261–1263. 
241 A. Rai, A. Prabhune and C. C. Perry, Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial 
activity and their application in antimicrobial coatings, J. Mater. Chem., 2010, 20, 6789–6798. 
242 C. C. Berry, J. M. de la Fuente, M. Mullin, S. Wai Ling Chu and A. S. G. Curtis, Notice of Violation of IEEE Publication 
Principles Nuclear Localization of HIV-1 Tat Functionalized Gold Nanoparticles, IEEE Trans. Nanobioscience, 2007, 
6, 262–269. 
243 M.-C. Bowman, T. E. Ballard, C. J. Ackerson, D. L. Feldheim, D. M. Margolis and C. Melander, Inhibition of HIV 
Fusion with Multivalent Gold Nanoparticles, J. Am. Chem. Soc., 2008, 130, 6896–6897. 
244 J. M. B. Res, R. Kesarkar, G. Oza, S. Pandey, R. Dahake, S. Mukherjee, A. Chowdhary, M. Sharon, J. Phata and W. 
Ambernath, Gold nanoparticles : effective as both entry inhibitors and virus neutralizing agents against HIV, J. 
Microbiol. Biotech. Res., 2012, 2, 276–283. 
245 B. Arnáiz, O. Martínez-Ávila, J. M. Falcon-Perez and S. Penadés, Cellular uptake of gold nanoparticles bearing HIV 
gp120 oligomannosides, Bioconjug. Chem., 2012, 23, 814–825. 
246 M. Gajendiran, S. M. J. Yousuf, V. Elangovan and S. Balasubramanian, Gold nanoparticle conjugated PLGA-PEG-SA-
PEG-PLGA multiblock copolymer nanoparticles: Synthesis, characterization, in vivo release of rifampicin, J. Mater. 
Chem. B, 2014, 2, 418–427. 
247 X. Zhou, X. Zhang, X. Yu, X. Zha, Q. Fu, B. Liu, X. Wang, Y. Chen, Y. Chen, Y. Shan, Y. Jin, Y. Wu, J. Liu, W. Kong and J. 
Shen, The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer 
DNA vaccine, Biomaterials, 2008, 29, 111–117. 
248 Y. S. Chen, Y. C. Hung, W. H. Lin and G. S. Huang, Assessment of gold nanoparticles as a size-dependent vaccine 
carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide, 
Nanotechnology, 2010, 21, 195101. 
249 I.-H. Lee, S.-H. Im, S. Kim, H.-K. Kwon, S. Jon, T.-S. Lee, M. K. Yu, S. An, J.-H. Lee and D. Kim, Imageable Antigen-
Presenting Gold Nanoparticle Vaccines for Effective Cancer Immunotherapy In Vivo, Angew. Chemie Int. Ed., 2012, 
51, 8800–8805. 
250 R. Cao-Milán and L. M. Liz-Marzán, Gold nanoparticle conjugates: recent advances toward clinical applications, 
Expert Opin. Drug Deliv., 2014, 11, 741–752. 
251 J. P. M. Almeida, A. Y. Lin, E. R. Figueroa, A. E. Foster and R. A. Drezek, In vivo Gold Nanoparticle Delivery of 
Peptide Vaccine Induces Anti-Tumor Immune Response in Prophylactic and Therapeutic Tumor Models, Small, 
2015, 11, 1453–1459. 
252 N. Leys, R. Van Houdt, S. Silver, J. Mahillon and K. Mijnendonckx, Antimicrobial silver: uses, toxicity and potential 
for resistance, BioMetals, 2013, 26, 609–621. 
253 M. Rai, K. Kon, A. Ingle, N. Duran, S. Galdiero and M. Galdiero, Broad-spectrum bioactivities of silver nanoparticles: 
The emerging trends and future prospects, Appl. Microbiol. Biotechnol., 2014, 98, 1951–1961. 
254 M. E. Samberg, P. E. Orndorff and N. A. Monteiro-Riviere, Antibacterial efficacy of silver nanoparticles of different 
sizes, surface conditions and synthesis methods, Nanotoxicology, 2011, 5, 244–253. 
255 M. E. Samberg, S. J. Oldenburg and N. A. Monteiro-Riviere, Evaluation of silver nanoparticle toxicity in skin in vivo 
and keratinocytes in vitro, Environ. Health Perspect., 2010, 118, 407–413. 
256 M. E. Samberg, E. G. Loboa, S. J. Oldenburg and N. A. Monteiro-Riviere, Silver nanoparticles do not influence stem 
cell differentiation but cause minimal toxicity, Nanomedicine, 2012, 7, 1197–1209. 
257 L. Loomba and T. Scarabelli, Metallic nanoparticles and their medicinal potential. Part I: Gold and silver colloids, 
Ther. Deliv., 2013, 4, 859–873. 
258 P. V. Asharani, Y. Lian Wu, Z. Gong and S. Valiyaveettil, Toxicity of silver nanoparticles in zebrafish models, 
Nanotechnology, 2008, 19, 255102. 
259 P. V Asharani, G. Low, K. Mun, M. P. Hande and S. Valiyaveettil, Cytotoxicity and Genotoxicity of Silver, Acsn, 2009, 
3, 279–290. 
260 S. Arora, J. Jain, J. M. Rajwade and K. M. Paknikar, Cellular responses induced by silver nanoparticles: In vitro 
studies, Toxicol. Lett., 2008, 179, 93–100. 
261 I. Sondi and B. Salopek-Sondi, Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for 
Gram-negative bacteria, J. Colloid Interface Sci., 2004, 275, 177–182. 
262 M. Banerjee, S. Mallick, A. Paul, A. Chattopadhyay and S. S. Ghosh, Heightened reactive oxygen species generation 
in the antimicrobial activity of a three component iodinated chitosan?silver nanoparticle composite, Langmuir, 
2010, 26, 5901–5908. 
263 S. Pal, Y. K. Tak and J. M. Song, Does the antibacterial activity of silver nanoparticles depend on the shape of the 
nanoparticle? A study of the gram-negative bacterium Escherichia coli, J. Biol. Chem., 2015, 290, 1712–1720. 
264 S. Wang, M. J. Yaszemski, L. Lu, C. Secreto, D. Mukhopadhyay, C. Patra, P. Mukherjee, N. Bone, R. Bhattacharya, N. 
E. Kay, P. C. Banerjee, Y. K. Lee, N. Bone, Y. K. Lee, C. Patra, S. Wang, L. Lu, C. Secreto, P. C. Banerjee, M. J. 
Yaszemski, N. E. Kay, D. Mukhopadhyay, L. Lu, C. Secreto, D. Mukhopadhyay, C. Patra, P. Mukherjee, N. Bone, R. 
Bhattacharya, N. E. Kay, P. C. Banerjee, Y. K. Lee, N. Bone, Y. K. Lee, C. Patra, S. Wang, L. Lu, C. Secreto, P. C. 
Banerjee, M. J. Yaszemski, N. E. Kay, D. Mukhopadhyay, L. Lu, C. Secreto, D. Mukhopadhyay, C. Patra, P. 
Mukherjee, N. Bone, R. Bhattacharya, N. E. Kay, P. C. Banerjee, Y. K. Lee, N. Bone, Y. K. Lee, C. Patra, S. Wang, L. Lu, 
C. Secreto, P. C. Banerjee, M. J. Yaszemski, N. E. Kay, D. Mukhopadhyay, L. Lu, C. Secreto, D. Mukhopadhyay, C. 
Patra, P. Mukherjee, N. Bone, R. Bhattacharya, N. E. Kay, P. C. Banerjee, Y. K. Lee, N. Bone, Y. K. Lee, C. Patra, S. 
Wang, L. Lu, C. Secreto, P. C. Banerjee, M. J. Yaszemski, N. E. Kay and D. Mukhopadhyay, Potential therapeutic 
application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis, J. 
Nanobiotechnology, 2007, 5, 4. 
265 C.-Y. Tsai, A.-L. Shiau, S.-Y. Chen, Y.-H. Chen, P.-C. Cheng, M.-Y. Chang, D.-H. Chen, C.-H. Chou, C.-R. Wang and C.-L. 
Wu, Amelioration of collagen-induced arthritis in rats by nanogold, Arthritis Rheum., 2007, 56, 544–554. 
266 X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Determination of the Minimum Temperature Required for 
Selective Photothermal Destruction of Cancer Cells with the Use of Immunotargeted Gold Nanoparticles, 
Photochem. Photobiol., 2006, 82, 412. 
267 L. S. Devi and S. R. Joshi, Antimicrobial and synergistic effects of silver nanoparticles synthesized using: Soil fungi of 
high altitudes of Eastern Himalaya, Mycobiology, 2012, 40, 27–34. 
268 K. Shameli, M. Bin Ahmad, S. D. Jazayeri, P. Shabanzadeh, P. Sangpour, H. Jahangirian and Y. Gharayebi, 
Investigation of antibacterial properties silver nanoparticles prepared via green method, Chem. Cent. J., 2012, 6, 
469. 
269 M. K. Rai, S. D. Deshmukh, A. P. Ingle and A. K. Gade, Silver nanoparticles: The powerful nanoweapon against 
multidrug-resistant bacteria, J. Appl. Microbiol., 2012, 112, 841–852. 
270 M. Gajbhiye, J. Kesharwani, A. Ingle, A. Gade and M. Rai, Fungus-mediated synthesis of silver nanoparticles and 
their activity against pathogenic fungi in combination with fluconazole, Nanomedicine Nanotechnology, Biol. Med., 
2009, 5, 382–386. 
271 Y. Xu, C. Gao, X. Li, Y. He, L. Zhou, G. Pang and S. Sun, In Vitro Antifungal Activity of Silver Nanoparticles Against 
Ocular Pathogenic Filamentous Fungi, J. Ocul. Pharmacol. Ther., 2013, 29, 270–274. 
272 Y. W. Choi, S. M. Hussain, J. L. Speshock, J. V. Rogers and C. V. Parkinson, A Preliminary Assessment of Silver 
Nanoparticle Inhibition of Monkeypox Virus Plaque Formation, Nanoscale Res. Lett., 2008, 3, 129–133. 
273 H. H. Lara, L. Ixtepan-Turrent, E. N. Garza-Treviño and C. Rodriguez-Padilla, PVP-coated silver nanoparticles block 
the transmission of cell-free and cell-associated HIV-1 in human cervical culture, J. Nanobiotechnology, 2010, 8, 1–
11. 
274 J. L. Elechiguerra, J. L. Burt, J. R. Morones, A. Camacho-, X. Gao, H. H. Lara and M. J. Yacaman, Antibacterial Effects 
of Silver and Gold Nanoparticles on the Growth of Bacteria, 2009, 42, 2087. 
275 H. H. Lara, N. V. Ayala-Nuñez, L. Ixtepan-Turrent and C. Rodriguez-Padilla, Mode of antiviral action of silver 
nanoparticles against HIV-1, J. Nanobiotechnology, 2010, 8, 1–10. 
276 H. H. Lara, L. Ixtepan-Turrent, E. N. Garza Treviño and D. K. Singh, Use of silver nanoparticles increased inhibition 
of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins, J. 
Nanobiotechnology, 2011, 9, 1–9. 
277 R. W.-Y. Sun, R. Chen, N. P.-Y. Chung, C.-M. Ho, C.-L. S. Lin and C.-M. Che, Silver nanoparticles fabricated in Hepes 
buffer exhibit cytoprotective activities toward HIV-1 infected cells, Chem. Commun., 2005, 5059. 
278 D. Xiang, Q. Chen, L. Pang and C. Zheng, Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro, 
J. Virol. Methods, 2011, 178, 137–142. 
279 S. Galdiero, M. Rai, A. Gade, A. Falanga, N. Incoronato, L. Russo, M. Galdiero, S. Gaikwad and A. Ingle, Antiviral 
activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 
3, Int. J. Nanomedicine, 2013, 8, 4303. 
280 D. Baram-Pinto, S. Shukla, N. Perkas, A. Gedanken and R. Sarid, Inhibition of Herpes Simplex Virus Type 1 Infection 
by Silver Nanoparticles Capped with Mercaptoethane Sulfonate, Bioconjug. Chem., 2009, 20, 1497–1502. 
281 N. Chen, Y. Zheng, J. Yin, X. Li and C. Zheng, Inhibitory effects of silver nanoparticles against adenovirus type 3 in 
vitro, J. Virol. Methods, 2013, 193, 470–477. 
282 J. L. Speshock, R. C. Murdock, L. K. Braydich-Stolle, A. M. Schrand and S. M. Hussain, Interaction of silver 
nanoparticles with Tacaribe virus, J. Nanobiotechnology, 2010, 8, 1–9. 
283 L. S. Abebe, Y. H. Su, R. L. Guerrant, N. S. Swami and J. A. Smith, Point-of-Use Removal of Cryptosporidium parvum 
from Water: Independent Effects of Disinfection by Silver Nanoparticles and Silver Ions and by Physical Filtration in 
Ceramic Porous Media, Environ. Sci. Technol., 2015, 49, 12958–12967. 
284 N. Durán, B. Rossi-Bergmann, P. D. Marcato, W. Pacienza-Lima and R. de Conti, Therapeutic Potential of Biogenic 
Silver Nanoparticles in Murine Cutaneous Leishmaniasis, J. Nano Res., 2012, 20, 89–97. 
285 A. Allahverdiyev, E. Ş. Abamor, BAGIROVA, C. B. USTUNDAG, KAYA, KAYA and RAFAILOVICH, Antileishmanial effect 
of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light, Int. J. Nanomedicine, 2011, 
6, 2705. 
286 C. Panneerselvam, S. Ponarulselvam and K. Murugan, Potential Anti-plasmodial Activity of Synthesized Silver 
Nanoparticle using Andrographis paniculata Nees (Acanthaceae), Arch. Appl. Sci. Res., 2011, 3, 208–217. 
287 S. Ponarulselvam, C. Panneerselvam, K. Murugan, N. Aarthi, K. Kalimuthu and S. Thangamani, Synthesis of silver 
nanoparticles using leaves of Catharanthus roseus Linn. G. Don and their antiplasmodial activities, Asian Pac. J. 
Trop. Biomed., 2012, 2, 574–580. 
288 J. Tian, K. K. Y. Wong, C.-M. Ho, C.-N. Lok, W.-Y. Yu, C.-M. Che, J.-F. Chiu and P. K. H. Tam, Topical Delivery of Silver 
Nanoparticles Promotes Wound Healing, ChemMedChem, 2007, 2, 129–136. 
289 X. Liu, P. Lee, C. Ho, V. C. H. Lui, Y. Chen, C. Che, P. K. H. Tam and K. K. Y. Wong, Silver Nanoparticles Mediate 
Differential Responses in Keratinocytes and Fibroblasts during Skin Wound Healing, ChemMedChem, 2010, 5, 468–
475. 
290 F. F. Larese, F. D’Agostin, M. Crosera, G. Adami, N. Renzi, M. Bovenzi and G. Maina, Human skin penetration of 
silver nanoparticles through intact and damaged skin, Toxicology, 2009, 255, 33–37. 
291 J. Gopal, N. Hasan, M. Manikandan and H. F. Wu, Bacterial toxicity/compatibility of platinum nanospheres, 
nanocuboids and nanoflowers, Sci. Rep., 2013, 3, 1–8. 
292 K. Gopinath, V. Karthika, S. Gowri, V. Senthilkumar, S. Kumaresan and A. Arumugam, Antibacterial activity of 
ruthenium nanoparticles synthesized using Gloriosa superba L. leaf extract, J. Nanostructure Chem., 2014, 4, 4–9. 
293 Ali, Jamal, Ahmed, Hameed, U. Kiran and S. Z. Naqvi, Combined efficacy of biologically synthesized silver 
nanoparticles and different antibiotics against multidrug-resistant bacteria, Int. J. Nanomedicine, 2013, 3187. 
294 J. R. Morones, J. L. Elechiguerra, A. Camacho, K. Holt, J. B. Kouri, J. T. Ramírez and M. J. Yacaman, The bactericidal 
effect of silver nanoparticles, Nanotechnology, 2005, 16, 2346–2353. 
295 P. Kanmani and S. T. Lim, Synthesis and structural characterization of silver nanoparticles using bacterial 
exopolysaccharide and its antimicrobial activity against food and multidrug resistant pathogens, Process Biochem., 
2013, 48, 1099–1106. 
296 S. Hsu, Liu, S. Dai and Fu, Antibacterial properties of silver nanoparticles in three different sizes and their 
nanocomposites with a new waterborne polyurethane, Int. J. Nanomedicine, 2010, 5, 1017–1028. 
297 N. G. Kandile, H. T. Zaky, M. I. Mohamed and H. M. Mohamed, Silver nanoparticles effect on antimicrobial and 
antifungal activity of new heterocycles, Bull. Korean Chem. Soc., 2010, 31, 3530–3538. 
298 S.-K. Moon, B. K. Suh, K.-J. Kim, W. S. Sung, D. G. Lee, J. G. Kim and J.-S. Choi, Antifungal activity and mode of 
action of silver nano-particles on Candida albicans, BioMetals, 2008, 22, 235–242. 
299 S. Galdiero, A. Falanga, M. Vitiello, M. Cantisani, V. Marra and M. Galdiero, Silver nanoparticles as potential 
antiviral agents, Molecules, 2011, 16, 8894–8918. 
300 B. De Gusseme, L. Sintubin, L. Baert, E. Thibo, T. Hennebel, G. Vermeulen, M. Uyttendaele, W. Verstraete and N. 
Boon, Biogenic silver for disinfection of water contaminated with viruses, Appl. Environ. Microbiol., 2010, 76, 
1082–1087. 
301 X. X. Yang, C. M. Li and C. Z. Huang, Curcumin modified silver nanoparticles for highly efficient inhibition of 
respiratory syncytial virus infection, Nanoscale, 2016, 8, 3040–3048. 
302 K. Kusada, H. Kobayashi, T. Yamamoto, S. Matsumura, N. Sumi, K. Sato, K. Nagaoka, Y. Kubota and H. Kitagawa, 
Discovery of face-centered-cubic ruthenium nanoparticles: Facile size-controlled synthesis using the chemical 
reduction method, J. Am. Chem. Soc., 2013, 135, 5493–5496. 
303 Y. Zhang, J. Yu, H. Niu and H. Liu, Synthesis of PVP-stabilized ruthenium colloids with low boiling point alcohols, J. 
Colloid Interface Sci., 2007, 313, 503–510. 
304 F. Y. Lee, A. I. Cooper, F. Su, X. S. Zhao, L. Lv and T. Liu, Thermally Reduced Ruthenium Nanoparticles as a Highly 
Active Heterogeneous Catalyst for Hydrogenation of Monoaromatics, J. Am. Chem. Soc., 2007, 129, 14213–14223. 
305 H. Liu, C. Song, L. Zhang, J. Zhang, H. Wang and D. P. Wilkinson, A review of anode catalysis in the direct methanol 
fuel cell, J. Power Sources, 2006, 155, 95–110. 
306 J. Kang, S. Zhang, Q. Zhang and Y. Wang, Ruthenium nanoparticles supported on carbon nanotubes as efficient 
catalysts for selective conversion of synthesis gas to diesel fuel, Angew. Chemie - Int. Ed., 2009, 48, 2565–2568. 
307 S. Gupta, C. Giordano, M. Gradzielski and S. K. Mehta, Microwave-assisted synthesis of small Ru nanoparticles and 
their role in degradation of congo red, J. Colloid Interface Sci., 2013, 411, 173–181. 
308 N. Perkas, D. Pham Minh, P. Gallezot, A. Gedanken and M. Besson, Platinum and ruthenium catalysts on 
mesoporous titanium and zirconium oxides for the catalytic wet air oxidation of model compounds, Appl. Catal. B 
Environ., 2005, 59, 121–130. 
309 B. C. Kress, Subwavelength Optics, F. Guid. to Digit. Micro-Optics, 2015, 424, 824–830. 
310 R. Elghanian, J. J. Storhoff, R. C. Mucic, R. L. Letsinger and C. A. Mirkin, Selective colorimetric detection of 
polynucleotides based on the distance-dependent optical properties of gold nanoparticles, Science (80-. )., 1997, 
277, 1078–1081. 
311 C. A. Mirkin, R. L. Letsinger, R. C. Mucic and J. J. Storhoff, A DNA-based method for rationally assembling 
nanoparticles into macroscopic materials, Nature, 1996, 382, 607–609. 
312 J. M. Nam, S. I. Stoeva and C. A. Mirkin, Bio-Bar-Code-Based DNA Detection with PCR-like Sensitivity, J. Am. Chem. 
Soc., 2004, 126, 5932–5933. 
313 Y. F. Huang, Y. W. Lin, Z. H. Lin and H. T. Chang, Aptamer-modified gold nanoparticles for targeting breast cancer 
cells through light scattering, J. Nanoparticle Res., 2009, 11, 775–783. 
314 L. A. Gearheart, H. J. Ploehn and C. J. Murphy, Oligonucleotide adsorption to gold nanoparticles: A surface-
enhanced Raman spectroscopy study of intrinsically bent DNA, J. Phys. Chem. B, 2001, 105, 12609–12615. 
315 F. A. Aldaye and H. F. Sleiman, Sequential self-assembly of a DNA hexagon as a template for the organization of 
gold nanoparticles, Angew. Chemie - Int. Ed., 2006, 45, 2204–2209. 
316 S. M. Shawky, D. Bald and H. M. E. Azzazy, Direct detection of unamplified hepatitis C virus RNA using unmodified 
gold nanoparticles, Clin. Biochem., 2010, 43, 1163–1168. 
317 H. Lee, T. Kang, K. A. Yoon, S. Y. Lee, S. W. Joo and K. Lee, Colorimetric detection of mutations in epidermal growth 
factor receptor using gold nanoparticle aggregation, Biosens. Bioelectron., 2010, 25, 1669–1674. 
318 H. Lee, S. W. Joo, S. Y. Lee, C. H. Lee, K. A. Yoon and K. Lee, Colorimetric genotyping of single nucleotide 
polymorphism based on selective aggregation of unmodified gold nanoparticles, Biosens. Bioelectron., 2010, 26, 
730–735. 
319 J. H. Kim and B. H. Chung, Naked eye detection of mutagenic DNA photodimers using gold nanoparticles, Biosens. 
Bioelectron., 2011, 26, 2805–2809. 
320 F. Wei, R. Lam, S. Cheng, S. Lu, D. Ho and N. Li, Rapid detection of melamine in whole milk mediated by 
unmodified gold nanoparticles, Appl. Phys. Lett., 2010, 96, 133702. 
321 G. L. Wang, Y. M. Dong, X. Y. Zhu, W. J. Zhang, C. Wang and H. J. Jiao, Ultrasensitive and selective colorimetric 
detection of thiourea using silver nanoprobes, Analyst, 2011, 136, 5256–5260. 
322 C. C. Wang, S. M. Wu, H. W. Li and H. T. Chang, Biomedical Applications of DNA-Conjugated Gold Nanoparticles, 
ChemBioChem, 2016, 1052–1062. 
323 V. Beni, K. Hayes, T. M. Lerga and C. K. O’Sullivan, Development of a gold nano-particle-based fluorescent 
molecular beacon for detection of cystic fibrosis associated mutation, Biosens. Bioelectron., 2010, 26, 307–313. 
324 A. Nakatsuma, M. Kaneda, H. Kodama, M. Morikawa, S. Watabe, K. Nakaishi, M. Yamashita, T. Yoshimura, T. 
Miura, M. Ninomiya and E. Ito, Detection of HIV-1 p24 at attomole level by ultrasensitive ELISA with Thio-NAD 
cycling, PLoS One, 2015, 10, 1–9. 
325 S. Tang and I. Hewlett, Nanoparticle‐Based Immunoassays for Sensitive and Early Detection of HIV‐1 Capsid (p24) 
Antigen, J. Infect. Dis., 2010, 201, S59–S64. 
326 D. Xi, X. Luo, Q. Ning, Q. Lu, K. Yao and Z. Liu, The detection of HBV DNA with gold nanoparticle gene probes, J. 
Nanjing Med. Univ., 2007, 21, 207–212. 
327 P. V. Baptista, M. Koziol-Montewka, J. Paluch-Oles, G. Doria and R. Franco, Gold-nanoparticle-probe-based assay 
for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples [5], Clin. Chem., 2006, 52, 
1433–1434. 
328 P. C. Soo, Y. T. Horng, K. C. Chang, J. Y. Wang, P. R. Hsueh, C. Y. Chuang, C. C. Lu and H. C. Lai, A simple gold 
nanoparticle probes assay for identification of Mycobacterium tuberculosis and Mycobacterium tuberculosis 
complex from clinical specimens, Mol. Cell. Probes, 2009, 23, 240–246. 
329 P. Costa, A. Amaro, A. Botelho, J. Inácio and P. V. Baptista, Gold nanoprobe assay for the identification of 
mycobacteria of the Mycobacterium tuberculosis complex, Clin. Microbiol. Infect., 2010, 16, 1464–1469. 
330 A. J. Haes, L. Chang, W. L. Klein and R. P. Van Duyne, Detection of a biomarker for Alzheimer’s disease from 
synthetic and clinical samples using a nanoscale optical biosensor, J. Am. Chem. Soc., 2005, 127, 2264–2271. 
331 C. Liu, D. Jiang, G. Xiang, L. Liu, F. Liu and X. Pu, An electrochemical DNA biosensor for the detection of 
Mycobacterium tuberculosis, based on signal amplification of graphene and a gold nanoparticle-polyaniline 
nanocomposite, Analyst, 2014, 139, 5460–5465. 
332 E. A. Vitol, E. Brailoiu, Z. Orynbayeva, N. J. Dun, G. Friedman and Y. Gogotsi, Surface-enhanced raman 
spectroscopy as a tool for detecting Ca2+ mobilizing second messengers in cell extracts, Anal. Chem., 2010, 82, 
6770–6774. 
333 E. Podstawka and Y. Ozaki, Surface-enhanced Raman difference between Bombesin and its modified analogues on 
the colloidal and electrochemically roughen silver surfaces, Biopolymers, 2008, 89, 807–819. 
334 S. R. Scattering, X. X. Han, G. G. Huang, B. Zhao and Y. Ozaki, Label-Free Highly Sensitive Detection of Proteins in 
Aqueous Solutions Using Absorbance Wavelength / nm Raman shift / cm, 2009, 81, 1–3. 
335 W. Q. Xu, B. Zhao, X. X. Han, Y. Kitahama, Y. Ozaki, J. Guo and Y. Tanaka, Simplified Protocol for Detection of 
Protein−Ligand Interac ons via Surface-Enhanced Resonance Raman Scattering and Surface-Enhanced 
Fluorescence, Anal. Chem., 2008, 80, 6567–6572. 
336 J. M. Yuen, N. C. Shah, J. T. Walsh, M. R. Glucksberg and R. P. Van Duyne, Transcutaneous Glucose Sensing by 
Surface-Enhanced Spatially Offset Raman Spectroscopy in a Rat Model, Anal. Chem., 2010, 82, 8382–8385. 
337 K. E. Shafer-Peltier, C. L. Haynes, M. R. Glucksberg and R. P. Van Duyne, Toward a glucose biosensor based on 
surface-enhanced Raman scattering, J. Am. Chem. Soc., 2003, 125, 588–593. 
338 L. Fabris, M. Dante, G. Braun, S. J. Lee, N. O. Reich, M. Moskovits, T.-Q. Nguyen and G. C. Bazan, A Heterogeneous 
PNA-Based SERS Method for DNA Detection, J. Am. Chem. Soc., 2007, 129, 6086–6087. 
339 K. Ryu, A. J. Haes, H. Y. Park, S. Nah, J. Kim, H. Chung, M. Y. Yoon and S. H. Han, Use of peptide for selective and 
sensitive detection of an Anthrax biomarker via peptide recognition and surface-enhanced Raman scattering, J. 
Raman Spectrosc., 2010, 41, 121–124. 
340 M. Culha, D. Stokes, L. R. Allain and T. Vo-Dinh, Surface-Enhanced Raman Scattering Substrate Based on a Self-
Assembled Monolayer for Use in Gene Diagnostics, Anal. Chem., 2003, 75, 6196–6201. 
341 T. Vo-Dinh, L. R. Allain and D. L. Stokes, Cancer gene detection using surface-enhanced Raman scattering (SERS), J. 
Raman Spectrosc., 2002, 33, 511–516. 
342 T. Vo-Dinh, K. Houck and D. L. Stokes, Surface-Enhanced Raman Gene Probes, Anal. Chem., 1994, 66, 3379–3383. 
343 T. Vo-Dinh, F. Yan and M. B. Wabuyele, Surface-enhanced Raman scattering for medical diagnostics and biological 
imaging, J. Raman Spectrosc., 2005, 36, 640–647. 
344 S. S. Xu, X. Ji, W. Xu, X. Li, L. Wang, Y. Bai, B. Zhao and Y. Ozaki, Immunoassay using probe-labelling immunogold 
nanoparticles with silver staining enhancement via surface-enhanced Raman scattering, Analyst, 2004, 129, 63. 
345 H.-N. Wang and T. Vo-Dinh, Multiplex detection of breast cancer biomarkers using plasmonic molecular sentinel 
nanoprobes, Nanotechnology, 2009, 20, 065101. 
346 L.-N. Zhang, H.-H. Deng, F.-L. Lin, X.-W. Xu, S.-H. Weng, A.-L. Liu, X.-H. Lin, X.-H. Xia and W. Chen, In Situ Growth of 
Porous Platinum Nanoparticles on Graphene Oxide for Colorimetric Detection of Cancer Cells, Anal. Chem., 2014, 
86, 2711–2718. 
347 M. Il Kim, M. S. Kim, M.-A. Woo, Y. Ye, K. S. Kang, J. Lee and H. G. Park, Highly efficient colorimetric detection of 
target cancer cells utilizing superior catalytic activity of graphene oxide–magnetic-platinum nanohybrids, 
Nanoscale, 2014, 6, 1529–1536. 
348 Y. Wang, J. Ping, Z. Ye, J. Wu and Y. Ying, Impedimetric immunosensor based on gold nanoparticles modified 
graphene paper for label-free detection of Escherichia coli O157:H7, Biosens. Bioelectron., 2013, 49, 492–498. 
349 R. Li, K. Wu, C. Liu, Y. Huang, Y. Wang, H. Fang, H. Zhang and C. Li, 4-Amino-1-(3-mercapto-propyl)-pyridine 
Hexafluorophosphate Ionic Liquid Functionalized Gold Nanoparticles for IgG Immunosensing Enhancement, Anal. 
Chem., 2014, 86, 5300–5307. 
350 H.-P. Peng, Y. Hu, A.-L. Liu, W. Chen, X.-H. Lin and X.-B. Yu, Label-free electrochemical immunosensor based on 
multi-functional gold nanoparticles–polydopamine–thionine–graphene oxide nanocomposites film for 
determination of alpha-fetoprotein, J. Electroanal. Chem., 2014, 712, 89–95. 
351 H. Wang, H. Li, Y. Zhang, Q. Wei, H. Ma, D. Wu, Y. Li, Y. Zhang and B. Du, Label-free immunosensor based on Pd 
nanoplates for amperometric immunoassay of alpha-fetoprotein, Biosens. Bioelectron., 2014, 53, 305–309. 
352 V. Kumar, S. Srivastava, S. Umrao, R. Kumar, G. Nath, G. Sumana, P. S. Saxena and A. Srivastava, Nanostructured 
palladium-reduced graphene oxide platform for high sensitive, label free detection of a cancer biomarker, RSC 
Adv., 2014, 4, 2267–2273. 
353 J. Peng, L.-N. Feng, Z.-J. Ren, L.-P. Jiang and J.-J. Zhu, Synthesis of Silver Nanoparticle-Hollow Titanium Phosphate 
Sphere Hybrid as a Label for Ultrasensitive Electrochemical Detection of Human Interleukin-6, Small, 2011, 7, 
2921–2928. 
354 X. Jiang, K. Chen, J. Wang, K. Shao, T. Fu, F. Shao, D. Lu, J. Liang, M. F. Foda and H. Han, Solid-state voltammetry-
based electrochemical immunosensor for Escherichia coli using graphene oxide–Ag nanoparticle composites as 
labels, Analyst, 2013, 138, 3388. 
355 J. Yang, W. Wen, X. Zhang and S. Wang, Electrochemical immunosensor for the prostate specific antigen detection 
based on carbon nanotube and gold nanoparticle amplification strategy, Microchim. Acta, 2015, 182, 1855–1861. 
356 J. Wilcoxon, Optical absorption properties of dispersed gold and silver alloy nanoparticles, J. Phys. Chem. B, 2009, 
113, 2647–2656. 
357 P. K. Jain, K. S. Lee, I. H. El-Sayed and M. A. El-Sayed, Calculated absorption and scattering properties of gold 
nanoparticles of different size, shape, and composition: Applications in biological imaging and biomedicine, J. 
Phys. Chem. B, 2006, 110, 7238–7248. 
358 S. Kawata, WITH SURFACE Edited by. 
359 K. S. Lee and M. A. El-Sayed, Gold and silver nanoparticles in sensing and imaging: Sensitivity of plasmon response 
to size, shape, and metal composition, J. Phys. Chem. B, 2006, 110, 19220–19225. 
360 M.-C. Daniel and D. Astruc, Gold Nanoparticles:  Assembly, Supramolecular Chemistry, Quantum-Size-Related 
Properties, and Applications toward Biology, Catalysis, and Nanotechnology, Chem. Rev., 2004, 104, 293–346. 
361 T. A. Klar, T. Franzl, J. Feldmann, A. Nichtl, G. Raschke, K. Kürzinger, S. Kowarik and C. Sönnichsen, Biomolecular 
Recognition Based on Single Gold Nanoparticle Light Scattering, Nano Lett., 2003, 3, 935–938. 
362 P. K. Jain, S. Eustis and M. A. El-Sayed, Plasmon coupling in nanorod assemblies: Optical absorption, discrete dipole 
approximation simulation, and exciton-coupling model, J. Phys. Chem. B, 2006, 110, 18243–18253. 
363 B. Dubertret, M. Calame and A. J. Libchaber, Single-mismatch detection using gold-quenched fluorescent 
oligonucleotid, Nat. Biotechnol., 2001, 19, 365–370. 
364 O. R. Miranda, B. Creran and V. M. Rotello, Array-based sensing with nanoparticles: ‘Chemical noses’ for sensing 
biomolecules and cell surfaces, Curr. Opin. Chem. Biol., 2010, 14, 728–736. 
365 S. Rana, H. Akpinar, R. R. Arvizo, M. De, U. H. F. Bunz, V. M. Rotello and O. R. Miranda, Sensing of proteins in 
human serum using conjugates of nanoparticles and green fluorescent protein, Nat. Chem., 2009, 1, 461–465. 
366 U. H. F. Bunz and V. M. Rotello, Gold nanoparticle-fluorophore complexes: Sensitive and discerning ‘noses’ for 
biosystems sensing, Angew. Chemie - Int. Ed., 2010, 49, 3268–3279. 
367 A. Bajaj, V. M. Rotello, I.-B. Kim, U. H. F. Bunz, O. R. Miranda, D. J. Jerry and R. L. Phillips, Detection and 
differentiation of normal, cancerous, and metastatic cells using nanoparticle-polymer sensor arrays, Proc. Natl. 
Acad. Sci., 2009, 106, 10912–10916. 
368 Y. Kim, R. C. Johnson and J. T. Hupp, Gold Nanoparticle-Based Sensing of “Spectroscopically Silent” Heavy Metal 
Ions, Nano Lett., 2002, 1, 165–167. 
369 G. S. Wilson and Y. Hu, Enzyme-based biosensors for in vivo measurements, Chem. Rev., 2000, 100, 2693–2704. 
370 S. Zhang, N. Wang, H. Yu, Y. Niu and C. Sun, Covalent attachment of glucose oxidase to an Au electrode modified 
with gold nanoparticles for use as glucose biosensor, Bioelectrochemistry, 2005, 67, 15–22. 
371 B. K. Jena and C. R. Raj, Enzyme-free amperometric sensing of glucose by using gold nanoparticles, Chem. - A Eur. 
J., 2006, 12, 2702–2708. 
372 B. Y. Wu, S. H. Hou, F. Yin, J. Li, Z. X. Zhao, J. D. Huang and Q. Chen, Amperometric glucose biosensor based on 
layer-by-layer assembly of multilayer films composed of chitosan, gold nanoparticles and glucose oxidase modified 
Pt electrode, Biosens. Bioelectron., 2007, 22, 838–844. 
373 I. Pastoriza-Santos, C. Kinnear, J. Pérez-Juste, P. Mulvaney and L. M. Liz-Marzán, Plasmonic polymer 
nanocomposites, Nat. Rev. Mater., 2018, 3, 375–391. 
374 R. Tanaka, T. Yuhi, N. Nagatani, T. Endo, K. Kerman, Y. Takamura and E. Tamiya, A novel enhancement assay for 
immunochromatographic test strips using gold nanoparticles, Anal. Bioanal. Chem., 2006, 385, 1414–1420. 
375 B. Y. Hsieh, Y. F. Chang, M. Y. Ng, W. C. Liu, C. H. Lin, H. T. Wu and C. Chou, Localized surface plasmon coupled 
fluorescence fiber-optic biosensor with gold nanoparticles, Anal. Chem., 2007, 79, 3487–3493. 
376 L. R. Hirsch, J. B. Jackson, A. Lee, N. J. Halas and J. L. West, A whole blood immunoassay using gold nanoshells, 
Anal. Chem., 2003, 75, 2377–2381. 
377 K. Sokolov, M. Follen, J. Aaron, I. Pavlova, A. Malpica, R. Lotan and R. Richards-Kortum, Real-Time Vital Optical 
Imaging of Precancer Using Anti-Epidermal Growth Factor Receptor Antibodies Conjugated to Gold Nanoparticles 
Advances in Brief Real-Time Vital Optical Imaging of Precancer Using Anti-Epidermal Growth Factor Receptor 
Antibodies Conj, Cancer Res., 2003, 63, 1999–2004. 
378 E. Boisselier and D. Astruc, Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and 
toxicity, Chem. Soc. Rev., 2009, 38, 1759–1782. 
379 L. G. Carrascosa, M. Moreno, M. Álvarez and L. M. Lechuga, Nanomechanical biosensors: A new sensing tool, TrAC 
- Trends Anal. Chem., 2006, 25, 196–206. 
380 M. Hakim, U. Tisch, G. Peng, N. Shehada, A. Kuten, H. Haick, R. Abdah-Bortnyak, Y. Y. Broza, O. Adams and S. Billan, 
Diagnosing lung cancer in exhaled breath using gold nanoparticles, Nat. Nanotechnol., 2009, 4, 669–673. 
381 W. Gao, X. Cao, Y. Wang, L. Zhou and J. Tang, Visual DNA microarrays for simultaneous detection of human 
immunodeficiency virus type-1 and Treponema pallidum coupled with multiplex asymmetric polymerase chain 
reaction, Diagn. Microbiol. Infect. Dis., 2009, 65, 372–378. 
382 T. Vo-Dinh, H. N. Wang and J. Scaffidi, Plasmonic nanoprobes for SERS biosensing and bioimaging, J. Biophotonics, 
2010, 3, 89–102. 
383 K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, Ö. Kurtuluş, S. H. Lee, N. C. Lindquist, S. H. Oh and C. L. Haynes, 
Recent progress in SERS biosensing, Phys. Chem. Chem. Phys., 2011, 13, 11551–11567. 
384 Semrock, Surface-Enhanced Raman Scattering (SERS). 
385 A. M. Michaels, Jiang and L. Brus, Ag Nanocrystal Junctions as the Site for Surface-Enhanced Raman Scattering of 
Single Rhodamine 6G Molecules, J. Phys. Chem. B, 2002, 104, 11965–11971. 
386 J. D. Driskell, K. M. Kwarta, R. J. Lipert, M. D. Porter, J. D. Neill and J. F. Ridpath, Low-Level Detection of Viral 
Pathogens by a Surface-Enhanced Raman Scattering Based Immunoassay, Anal. Chem., 2005, 77, 6147–6154. 
387 M. B. Wabuyele and T. Vo-Dinh, Detection of Human Immunodeficiency Virus Type 1 DNA Sequence Using 
Plasmonics Nanoprobes, Anal. Chem., 2005, 77, 7810–7815. 
388 H. Su, R. Yuan, Y. Chai, L. Mao and Y. Zhuo, Ferrocenemonocarboxylic–HRP@Pt nanoparticles labeled RCA for 
multiple amplification of electro-immunosensing, Biosens. Bioelectron., 2011, 26, 4601–4604. 
389 J. Zhou, M. Xu, D. Tang, Z. Gao, J. Tang and G. Chen, Nanogold-based bio-bar codes for label-free immunosensing 
of proteins coupling with an in situ DNA-based hybridization chain reaction, Chem. Commun., 2012, 48, 12207. 
390 Q. Guo, X. Li, C. Shen, S. Zhang, H. Qi, T. Li and M. Yang, Electrochemical immunoassay for the protein biomarker 
mucin 1 and for MCF-7 cancer cells based on signal enhancement by silver nanoclusters, Microchim. Acta, 2015, 
182, 1483–1489. 
391 Y. Zhao, Z. He and Z. Yan, Copper@carbon coaxial nanowires synthesized by hydrothermal carbonization process 
from electroplating wastewater and their use as an enzyme-free glucose sensor, Analyst, 2013, 138, 559–568. 
392 L.-M. Lu, L. Zhang, F.-L. Qu, H.-X. Lu, X.-B. Zhang, Z.-S. Wu, S.-Y. Huan, Q.-A. Wang, G.-L. Shen and R.-Q. Yu, A nano-
Ni based ultrasensitive nonenzymatic electrochemical sensor for glucose: Enhancing sensitivity through a 
nanowire array strategy, Biosens. Bioelectron., 2009, 25, 218–223. 
393 J. Wang, S. V. Boriskina, H. Wang and B. M. Reinhard, Illuminating Epidermal Growth Factor Receptor Densities on 
Filopodia through Plasmon Coupling, ACS Nano, 2011, 5, 6619–6628. 
394 J. Wang, Electrochemical biosensing based on noble metal nanoparticles, Microchim. Acta, 2012, 177, 245–270. 
395 A. Mohanty, N. Garg and R. Jin, A Universal Approach to the Synthesis of Noble Metal Nanodendrites and Their 
Catalytic Properties, Angew. Chemie, 2010, 122, 5082–5086. 
396 K. Saha, S. S. Agasti, C. Kim, X. Li and V. M. Rotello, Gold Nanoparticles in Chemical and Biological Sensing, Chem. 
Rev., 2012, 112, 2739–2779. 
397 R. Elshafey, A. C. Tavares, M. Siaj and M. Zourob, Electrochemical impedance immunosensor based on gold 
nanoparticles–protein G for the detection of cancer marker epidermal growth factor receptor in human plasma 
and brain tissue, Biosens. Bioelectron., 2013, 50, 143–149. 
398 Q. Gao, J. Han and Z. Ma, Polyamidoamine dendrimers-capped carbon dots/Au nanocrystal nanocomposites and 
its application for electrochemical immunosensor, Biosens. Bioelectron., 2013, 49, 323–328. 
399 Y. Ding, D. Li, B. Li, K. Zhao, W. Du, J. Zheng and M. Yang, A water-dispersible, ferrocene-tagged peptide nanowire 
for amplified electrochemical immunosensing, Biosens. Bioelectron., 2013, 48, 281–286. 
400 J. Lin, H. Zhang and S. Niu, Simultaneous determination of carcinoembryonic antigen and α‐fetoprotein using an 
ITO immunoelectrode modified with gold nanoparticles and mesoporous silica, Microchim. Acta, 2015, 182, 719–
726. 
401 J. Tang and D. Tang, Non-enzymatic electrochemical immunoassay using noble metal nanoparticles: a review, 
Microchim. Acta, 2015, 182, 2077–2089. 
402 J. Zhou, L. Du, L. Zou, Y. Zou, N. Hu and P. Wang, An ultrasensitive electrochemical immunosensor for 
carcinoembryonic antigen detection based on staphylococcal protein A—Au nanoparticle modified gold electrode, 
Sensors Actuators B Chem., 2014, 197, 220–227. 
403 L. Zhu, L. Xu, N. Jia, B. Huang, L. Tan, S. Yang and S. Yao, Electrochemical immunoassay for carcinoembryonic 
antigen using gold nanoparticle–graphene composite modified glassy carbon electrode, Talanta, 2013, 116, 809–
815. 
404 N. Yan, When nanotechnology meets catalysis, Nanotechnol. Rev., 2013, 2, 485–486. 
405 P. Bhawana and M. H. Fulekar, Nanotechnology: Remediation Technologies to clean up the Environmental 
pollutants, Res. J. Chem. Sci., 2012, 2, 90–96. 
406 M. I. Setyawati, W. Fang, S. L. Chia and D. T. Leong, Nanotoxicology of common metal oxide based nanomaterials: 
their ROS-y and non-ROS-y consequences, Asia-Pacific J. Chem. Eng., 2013, 8, 205–217. 
407 L. Zeng, E. W. Miller, A. Pralle, E. Y. Isacoff and C. J. Chang, A Selective Turn-On Fluorescent Sensor for Imaging 
Copper in Living Cells, J. Am. Chem. Soc., 2006, 128, 10–11. 
408 S. Yoon, E. W. Miller, Q. He, P. H. Do and C. J. Chang, A Bright and Specific Fluorescent Sensor for Mercury in 
Water, Cells, and Tissue, Angew. Chemie, 2007, 119, 6778–6781. 
409 L. Basabe-Desmonts, D. N. Reinhoudt and M. Crego-Calama, Design of fluorescent materials for chemical sensing, 
Chem. Soc. Rev., 2007, 36, 993. 
410 P.-C. Chen, P. Roy, L.-Y. Chen, R. Ravindranath and H.-T. Chang, Gold and Silver Nanomaterial-Based Optical 
Sensing Systems, Part. Part. Syst. Charact., 2014, 31, 917–942. 
411 Z. Luo, K. Zheng and J. Xie, Engineering ultrasmall water-soluble gold and silver nanoclusters for biomedical 
applications, Chem. Commun., 2014, 50, 5143–5155. 
412 X. Yuan, Z. Luo, Y. Yu, Q. Yao and J. Xie, Luminescent Noble Metal Nanoclusters as an Emerging Optical Probe for 
Sensor Development, Chem. - An Asian J., 2013, 8, 858–871. 
413 P. C. Ray, Size and Shape Dependent Second Order Nonlinear Optical Properties of Nanomaterials and Their 
Application in Biological and Chemical Sensing, Chem. Rev., 2010, 110, 5332–5365. 
414 R. Wilson, The use of gold nanoparticles in diagnostics and detection, Chem. Soc. Rev., 2008, 37, 2028. 
415 X. Liu, M. Atwater, J. Wang and Q. Huo, Extinction coefficient of gold nanoparticles with different sizes and 
different capping ligands, Colloids Surfaces B Biointerfaces, 2007, 58, 3–7. 
416 F. Chai, C. Wang, T. Wang, L. Li and Z. Su, Colorimetric Detection of Pb 2+ Using Glutathione Functionalized Gold 
Nanoparticles, ACS Appl. Mater. Interfaces, 2010, 2, 1466–1470. 
417 J. M. Slocik, J. S. Zabinski, D. M. Phillips and R. R. Naik, Colorimetric Response of Peptide-Functionalized Gold 
Nanoparticles to Metal Ions, Small, 2008, 4, 548–551. 
418 D. Liu, W. Qu, W. Chen, W. Zhang, Z. Wang and X. Jiang, Highly Sensitive, Colorimetric Detection of Mercury(II) in 
Aqueous Media by Quaternary Ammonium Group-Capped Gold Nanoparticles at Room Temperature, Anal. Chem., 
2010, 82, 9606–9610. 
419 K. P. Lisha, Anshup and T. Pradeep, Towards a practical solution for removing inorganic mercury from drinking 
water using gold nanoparticles, Gold Bull., 2009, 42, 144–152. 
420 Y.-H. Lin and W.-L. Tseng, Ultrasensitive Sensing of Hg 2+ and CH 3 Hg + Based on the Fluorescence Quenching of 
Lysozyme Type VI-Stabilized Gold Nanoclusters, Anal. Chem., 2010, 82, 9194–9200. 
421 H. Kawasaki, K. Hamaguchi, I. Osaka and R. Arakawa, ph-Dependent Synthesis of Pepsin-Mediated Gold 
Nanoclusters with Blue Green and Red Fluorescent Emission, Adv. Funct. Mater., 2011, 21, 3508–3515. 
422 G. Guan, S.-Y. Zhang, Y. Cai, S. Liu, M. S. Bharathi, M. Low, Y. Yu, J. Xie, Y. Zheng, Y.-W. Zhang and M.-Y. Han, 
Convenient purification of gold clusters by co-precipitation for improved sensing of hydrogen peroxide, mercury 
ions and pesticides, Chem. Commun., 2014, 50, 5703. 
423 H. K. Sung, S. Y. Oh, C. Park and Y. Kim, Colorimetric Detection of Co 2+ Ion Using Silver Nanoparticles with 
Spherical, Plate, and Rod Shapes, Langmuir, 2013, 29, 8978–8982. 
424 J. Yguerabide and E. E. Yguerabide, Light-Scattering Submicroscopic Particles as Highly Fluorescent Analogs and 
Their Use as Tracer Labels in Clinical and Biological Applications, Anal. Biochem., 1998, 262, 137–156. 
425 Y. Wang, F. Yang and X. Yang, Colorimetric Detection of Mercury(II) Ion Using Unmodified Silver Nanoparticles and 
Mercury-Specific Oligonucleotides, ACS Appl. Mater. Interfaces, 2010, 2, 339–342. 
426 X. Yuan, T. J. Yeow, Q. Zhang, J. Y. Lee and J. Xie, Highly luminescent Ag+ nanoclusters for Hg2+ ion detection, 
Nanoscale, 2012, 4, 1968. 
427 L. Shang and S. Dong, Silver nanocluster-based fluorescent sensors for sensitive detection of Cu(ii), J. Mater. 
Chem., 2008, 18, 4636. 
428 G.-W. Wu, S.-B. He, H.-P. Peng, H.-H. Deng, A.-L. Liu, X.-H. Lin, X.-H. Xia and W. Chen, Citrate-Capped Platinum 
Nanoparticle as a Smart Probe for Ultrasensitive Mercury Sensing, Anal. Chem., 2014, 86, 10955–10960. 
429 Y.-L. Hung, T.-M. Hsiung, Y.-Y. Chen, Y.-F. Huang and C.-C. Huang, Colorimetric Detection of Heavy Metal Ions 
Using Label-Free Gold Nanoparticles and Alkanethiols, J. Phys. Chem. C, 2010, 114, 16329–16334. 
430 G. Sener, L. Uzun and A. Denizli, Lysine-Promoted Colorimetric Response of Gold Nanoparticles: A Simple Assay for 
Ultrasensitive Mercury(II) Detection, Anal. Chem., 2014, 86, 514–520. 
431 J. Zheng, P. R. Nicovich and R. M. Dickson, Highly Fluorescent Noble-Metal Quantum Dots, Annu. Rev. Phys. Chem., 
2007, 58, 409–431. 
432 S. Choi, R. M. Dickson and J. Yu, Developing luminescent silver nanodots for biological applications, Chem. Soc. 
Rev., 2012, 41, 1867–1891. 
433 L. Zhang and E. Wang, Metal nanoclusters: New fluorescent probes for sensors and bioimaging, Nano Today, 2014, 
9, 132–157. 
434 Y. Yue, T.-Y. Liu, H.-W. Li, Z. Liu and Y. Wu, Microwave-assisted synthesis of BSA-protected small gold nanoclusters 
and their fluorescence-enhanced sensing of silver(i) ions, Nanoscale, 2012, 4, 2251. 
435 J. Xie, Y. Zheng and J. Y. Ying, Highly selective and ultrasensitive detection ofHg2+ based on fluorescence 
quenching of Au nanoclusters by Hg2+–Au+ interactions, Chem. Commun., 2010, 46, 961–963. 
436 A. Sreekumaran Nair, R. T. Tom and T. Pradeep, Detection and extraction of endosulfan by metal nanoparticles, J. 
Environ. Monit., 2003, 5, 363–365. 
437 A. Agarwal, S. W. Huang, M. O’Donnell, K. C. Day, M. Day, N. Kotov and S. Ashkenazi, Targeted gold nanorod 
contrast agent for prostate cancer detection by photoacoustic imaging, J. Appl. Phys., 2007, 102, 064701. 
438 D. Pan, M. Pramanik, A. Senpan, S. Ghosh, S. A. Wickline, L. V. Wang and G. M. Lanza, Near infrared photoacoustic 
detection of sentinel lymph nodes with gold nanobeacons, Biomaterials, 2010, 31, 4088–4093. 
439 L. Bickford, J. Sun, K. Fu, N. Lewinski, V. Nammalvar, J. Chang and R. Drezek, Enhanced multi-spectral imaging of 
live breast cancer cells using immunotargeted gold nanoshells and two-photon excitation microscopy, 
Nanotechnology, 2008, 19, 315102. 
440 X. He, J. Gao, S. S. Gambhir and Z. Cheng, Near-infrared fluorescent nanoprobes for cancer molecular imaging: 
status and challenges, Trends Mol. Med., 2010, 16, 574–583. 
441 E. İ. Altınoğlu and J. H. Adair, Near infrared imaging with nanoparticles, Wiley Interdiscip. Rev. Nanomedicine 
Nanobiotechnology, 2010, 2, 461–477. 
442 D. Kim, S. Park, J. H. Lee, Y. Y. Jeong and S. Jon, Antibiofouling Polymer-Coated Gold Nanoparticles as a Contrast 
Agent for in Vivo X-ray Computed Tomography Imaging, J. Am. Chem. Soc., 2007, 129, 7661–7665. 
443 X. Qian, X.-H. Peng, D. O. Ansari, Q. Yin-Goen, G. Z. Chen, D. M. Shin, L. Yang, A. N. Young, M. D. Wang and S. Nie, 
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags, Nat. 
Biotechnol., 2008, 26, 83–90. 
444 A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek and J. L. West, Near-Infrared Resonant Nanoshells for 
Combined Optical Imaging and Photothermal Cancer Therapy, Nano Lett., 2007, 7, 1929–1934. 
445 Y. Wang, X. Xie, X. Wang, G. Ku, K. L. Gill, D. P. O’Neal, G. Stoica and L. V. Wang, Photoacoustic Tomography of a 
Nanoshell Contrast Agent in the in Vivo Rat Brain, Nano Lett., 2004, 4, 1689–1692. 
446 K. Ataka and J. Heberle, Biochemical applications of surface-enhanced infrared absorption spectroscopy, Anal. 
Bioanal. Chem., 2007, 388, 47–54. 
447 X. He, K. Wang and Z. Cheng, In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes, 
Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology, 2010, 2, 349–366. 
448 B. D. Chithrani, Nanoparticles for Improved Therapeutics and Imaging in Cancer Therapy, Recent Pat. 
Nanotechnol., 2010, 4, 171–180. 
449 E. C. Cho, C. Glaus, J. Chen, M. J. Welch and Y. Xia, Inorganic nanoparticle-based contrast agents for molecular 
imaging, Trends Mol. Med., 2010, 16, 561–573. 
450 J. C. Y. Kah, M. Olivo, T. H. Chow, K. S. Song, K. Z. Y. Koh, S. Mhaisalkar and C. J. R. Sheppard, Control of optical 
contrast using gold nanoshells for optical coherence tomography imaging of mouse xenograft tumor model in 
vivo, J. Biomed. Opt., 2009, 14, 054015. 
451 J. Kneipp, H. Kneipp, B. Wittig and K. Kneipp, Novel optical nanosensors for probing and imaging live cells, 
Nanomedicine Nanotechnology, Biol. Med., 2010, 6, 214–226. 
452 A. L. Oldenburg, M. N. Hansen, T. S. Ralston, A. Wei and S. A. Boppart, Imaging gold nanorods in excised human 
breast carcinoma by spectroscopic optical coherence tomography, J. Mater. Chem., 2009, 19, 6407. 
453 P. Vartholomeos, M. Fruchard, A. Ferreira and C. Mavroidis, MRI-Guided Nanorobotic Systems for Therapeutic and 
Diagnostic Applications, Annu. Rev. Biomed. Eng., 2011, 13, 157–184. 
454 X. Yang, E. W. Stein, S. Ashkenazi and L. V. Wang, Nanoparticles for photoacoustic imaging, Wiley Interdiscip. Rev. 
Nanomedicine Nanobiotechnology, 2009, 1, 360–368. 
455 E. V Zagaynova, M. V Shirmanova, M. Y. Kirillin, B. N. Khlebtsov, A. G. Orlova, I. V Balalaeva, M. A. Sirotkina, M. L. 
Bugrova, P. D. Agrba and V. A. Kamensky, Contrasting properties of gold nanoparticles for optical coherence 
tomography: phantom, in vivo studies and Monte Carlo simulation, Phys. Med. Biol., 2008, 53, 4995–5009. 
456 J. Zhang, Y. Fu, Y. Mei, F. Jiang and J. R. Lakowicz, Fluorescent Metal Nanoshell Probe to Detect Single miRNA in 
Lung Cancer Cell, Anal. Chem., 2010, 82, 4464–4471. 
457 S. Lee, S. Kim, J. Choo, S. Y. Shin, Y. H. Lee, H. Y. Choi, S. Ha, K. Kang and C. H. Oh, Biological Imaging of HEK293 
Cells Expressing PLCγ1 Using Surface‐Enhanced Raman Microscopy, Anal. Chem., 2007, 79, 916–922. 
458 J. Kneipp, H. Kneipp, M. McLaughlin, D. Brown and K. Kneipp, In Vivo Molecular Probing of Cellular Compartments 
with Gold Nanoparticles and Nanoaggregates, Nano Lett., 2006, 6, 2225–2231. 
459 A. Matschulat, D. Drescher and J. Kneipp, Surface-Enhanced Raman Scattering Hybrid Nanoprobe Multiplexing and 
Imaging in Biological Systems, ACS Nano, 2010, 4, 3259–3269. 
460 P. J. Vikesland, Nanosensors for water quality monitoring, Nat. Nanotechnol., 2018, 13, 651–660. 
461 I. Gupta, N. Duran and M. Rai, in Nano-Antimicrobials, Springer Berlin Heidelberg, Berlin, Heidelberg, 2012, pp. 
525–548. 
462 S. Shinde, N. Grampurohit, D. Gaikwad, S. Jadhav, M. Gadhave and P. Shelke, Toxicity induced by nanoparticles, 
Asian Pacific J. Trop. Dis., 2012, 2, 331–334. 
463 M. Yu and J. Zheng, Clearance Pathways and Tumor Targeting of Imaging Nanoparticles, ACS Nano, 2015, 9, 6655–
6674. 
464 S. Park, A. Aalipour, O. Vermesh, J. H. Yu and S. S. Gambhir, Towards clinically translatable in vivo nanodiagnostics, 
Nat. Rev. Mater., 2017, 2, 17014. 
465 M. Longmire, P. L. Choyke and H. Kobayashi, Clearance properties of nano-sized particles and molecules as 
imaging agents: considerations and caveats, Nanomedicine, 2008, 3, 703–717. 
466 J. Liu, M. Yu, C. Zhou, S. Yang, X. Ning and J. Zheng, Passive Tumor Targeting of Renal-Clearable Luminescent Gold 
Nanoparticles: Long Tumor Retention and Fast Normal Tissue Clearance, J. Am. Chem. Soc., 2013, 135, 4978–4981. 
467 X.-D. Zhang, Z. Luo, J. Chen, S. Song, X. Yuan, X. Shen, H. Wang, Y. Sun, K. Gao, L. Zhang, S. Fan, D. T. Leong, M. Guo 
and J. Xie, Ultrasmall Glutathione-Protected Gold Nanoclusters as Next Generation Radiotherapy Sensitizers with 
High Tumor Uptake and High Renal Clearance, Sci. Rep., 2015, 5, 8669. 
468 E. B. Ehlerding, F. Chen and W. Cai, Biodegradable and Renal Clearable Inorganic Nanoparticles, Adv. Sci., 2016, 3, 
1500223. 
469 D. Cassano, S. Pocoví-Martínez and V. Voliani, Ultrasmall-in-Nano Approach: Enabling the Translation of Metal 
Nanomaterials to Clinics, Bioconjug. Chem., 2018, 29, 4–16. 
470 D. Cassano, M. Santi, F. D’Autilia, A. K. Mapanao, S. Luin and V. Voliani, Photothermal effect by NIR-responsive 
excretable ultrasmall-in-nano architectures, Mater. Horizons, 2019, 6, 531–537. 
471 R. Coradeghini, S. Gioria, C. P. García, P. Nativo, F. Franchini, D. Gilliland, J. Ponti and F. Rossi, Size-dependent 
toxicity and cell interaction mechanisms of gold nanoparticles on mouse fibroblasts, Toxicol. Lett., 2013, 217, 205–
216. 
472 Y. Pan, S. Neuss, A. Leifert, M. Fischler, F. Wen, U. Simon, G. Schmid, W. Brandau and W. Jahnen-Dechent, Size-
Dependent Cytotoxicity of Gold Nanoparticles, Small, 2007, 3, 1941–1949. 
473 C. L. Villiers, H. Freitas, R. Couderc, M.-B. Villiers and P. N. Marche, Analysis of the toxicity of gold nano particles on 
the immune system: effect on dendritic cell functions, J. Nanoparticle Res., 2010, 12, 55–60. 
474 Y. Pan, A. Leifert, D. Ruau, S. Neuss, J. Bornemann, G. Schmid, W. Brandau, U. Simon and W. Jahnen-Dechent, Gold 
Nanoparticles of Diameter 1.4 nm Trigger Necrosis by Oxidative Stress and Mitochondrial Damage, Small, 2009, 5, 
2067–2076. 
475 C.-T. Ng, S. T. Dheen, W.-C. G. Yip, C.-N. Ong, B.-H. Bay and L.-Y. Lanry Yung, The induction of epigenetic regulation 
of PROS1 gene in lung fibroblasts by gold nanoparticles and implications for potential lung injury, Biomaterials, 
2011, 32, 7609–7615. 
476 J. J. Li, D. Hartono, C.-N. Ong, B.-H. Bay and L.-Y. L. Yung, Autophagy and oxidative stress associated with gold 
nanoparticles, Biomaterials, 2010, 31, 5996–6003. 
477 Q. Zhang, V. M. Hitchins, A. M. Schrand, S. M. Hussain and P. L. Goering, Uptake of gold nanoparticles in murine 
macrophage cells without cytotoxicity or production of pro-inflammatory mediators, Nanotoxicology, 2011, 5, 
284–295. 
478 N. M. Schaeublin, L. K. Braydich-Stolle, A. M. Schrand, J. M. Miller, J. Hutchison, J. J. Schlager and S. M. Hussain, 
Surface charge of gold nanoparticles mediates mechanism of toxicity, Nanoscale, 2011, 3, 410. 
479 A. Chompoosor, K. Saha, P. S. Ghosh, D. J. Macarthy, O. R. Miranda, Z.-J. Zhu, K. F. Arcaro and V. M. Rotello, The 
Role of Surface Functionality on Acute Cytotoxicity, ROS Generation and DNA Damage by Cationic Gold 
Nanoparticles, Small, 2010, 6, 2246–2249. 
480 H. K. Patra and A. K. Dasgupta, Cancer cell response to nanoparticles: Criticality and optimality, Nanomedicine 
Nanotechnology, Biol. Med., 2012, 8, 842–852. 
481 W. H. De Jong, W. I. Hagens, P. Krystek, M. C. Burger, A. J. A. M. Sips and R. E. Geertsma, Particle size-dependent 
organ distribution of gold nanoparticles after intravenous administration, Biomaterials, 2008, 29, 1912–1919. 
482 M. A. K. Abdelhalim and B. M. Jarrar, The appearance of renal cells cytoplasmic degeneration and nuclear 
destruction might be an indication of GNPs toxicity, Lipids Health Dis., 2011, 10, 147. 
483 X.-D. Zhang, Wu, Shen, Liu, Sun, Zhang and Fan, Size-dependent in vivo toxicity of PEG-coated gold nanoparticles, 
Int. J. Nanomedicine, 2011, 2071. 
484 K.-T. Kim, T. Zaikova, J. E. Hutchison and R. L. Tanguay, Gold Nanoparticles Disrupt Zebrafish Eye Development and 
Pigmentation, Toxicol. Sci., 2013, 133, 275–288. 
485 Zhang, Toxicologic effects of gold nanoparticles in vivo by different administration routes, Int. J. Nanomedicine, 
2010, 5, 771. 
486 K. K. Panda, V. M. M. Achary, R. Krishnaveni, B. K. Padhi, S. N. Sarangi, S. N. Sahu and B. B. Panda, In vitro 
biosynthesis and genotoxicity bioassay of silver nanoparticles using plants, Toxicol. Vitr., 2011, 25, 1097–1105. 
487 E.-J. Park, E. Bae, J. Yi, Y. Kim, K. Choi, S. H. Lee, J. Yoon, B. C. Lee and K. Park, Repeated-dose toxicity and 
inflammatory responses in mice by oral administration of silver nanoparticles, Environ. Toxicol. Pharmacol., 2010, 
30, 162–168. 
488 Y. S. Kim, J. S. Kim, H. S. Cho, D. S. Rha, J. M. Kim, J. D. Park, B. S. Choi, R. Lim, H. K. Chang, Y. H. Chung, I. H. Kwon, 
J. Jeong, B. S. Han and I. J. Yu, Twenty-Eight-Day Oral Toxicity, Genotoxicity, and Gender-Related Tissue 
Distribution of Silver Nanoparticles in Sprague-Dawley Rats, Inhal. Toxicol., 2008, 20, 575–583. 
489 K. M. Newton, H. L. Puppala, C. L. Kitchens, V. L. Colvin and S. J. Klaine, Silver nanoparticle toxicity to Daphnia 
magna is a function of dissolved silver concentration, Environ. Toxicol. Chem., 2013, 32, 2356–2364. 
490 H. Peng, X. Zhang, Y. Wei, W. Liu, S. Li, G. Yu, X. Fu, T. Cao and X. Deng, Cytotoxicity of Silver Nanoparticles in 
Human Embryonic Stem Cell-Derived Fibroblasts and an L-929 Cell Line, J. Nanomater., 2012, 2012, 1–9. 
491 R. Foldbjerg, D. A. Dang and H. Autrup, Cytotoxicity and genotoxicity of silver nanoparticles in the human lung 
cancer cell line, A549, Arch. Toxicol., 2011, 85, 743–750. 
492 S. Kim, J. E. Choi, J. Choi, K.-H. Chung, K. Park, J. Yi and D.-Y. Ryu, Oxidative stress-dependent toxicity of silver 
nanoparticles in human hepatoma cells, Toxicol. Vitr., 2009, 23, 1076–1084. 
493 E. Oberdörster, Manufactured Nanomaterials (Fullerenes, C 60 ) Induce Oxidative Stress in the Brain of Juvenile 
Largemouth Bass, Environ. Health Perspect., 2004, 112, 1058–1062. 
494 X. Sun, Z. Wang, S. Zhai, Y. Cheng, J. Liu and B. Liu, In vitro cytotoxicity of silver nanoparticles in primary rat hepatic 
stellate cells, Mol. Med. Rep., 2013, 8, 1365–1372. 
495 E.-J. Park, J. Yi, Y. Kim, K. Choi and K. Park, Silver nanoparticles induce cytotoxicity by a Trojan-horse type 
mechanism, Toxicol. Vitr., 2010, 24, 872–878. 
496 S. M. Hussain, K. L. Hess, J. M. Gearhart, K. T. Geiss and J. J. Schlager, In vitro toxicity of nanoparticles in BRL 3A rat 
liver cells, Toxicol. Vitr., 2005, 19, 975–983. 
497 M. J. Piao, K. A. Kang, I. K. Lee, H. S. Kim, S. Kim, J. Y. Choi, J. Choi and J. W. Hyun, Silver nanoparticles induce 
oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of 
mitochondria-involved apoptosis, Toxicol. Lett., 2011, 201, 92–100. 
498 J. S. Teodoro, A. M. Simões, F. V. Duarte, A. P. Rolo, R. C. Murdoch, S. M. Hussain and C. M. Palmeira, Assessment 
of the toxicity of silver nanoparticles in vitro: A mitochondrial perspective, Toxicol. Vitr., 2011, 25, 664–670. 
499 R. Zhang, M. J. Piao, K. C. Kim, A. D. Kim, J.-Y. Choi, J. Choi and J. W. Hyun, Endoplasmic reticulum stress signaling is 
involved in silver nanoparticles-induced apoptosis, Int. J. Biochem. Cell Biol., 2012, 44, 224–232. 
500 H. Rosas-Hernández, S. Jiménez-Badillo, P. P. Martínez-Cuevas, E. Gracia-Espino, H. Terrones, M. Terrones, S. M. 
Hussain, S. F. Ali and C. González, Effects of 45-nm silver nanoparticles on coronary endothelial cells and isolated 
rat aortic rings, Toxicol. Lett., 2009, 191, 305–313. 
501 A. Chrastina and J. E. Schnitzer, Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging, Int. J. 
Nanomedicine, 2010, 5, 653. 
502 J. H. Sung, J. H. Ji, J. U. Yoon, D. S. Kim, M. Y. Song, J. Jeong, B. S. Han, J. H. Han, Y. H. Chung, J. Kim, T. S. Kim, H. K. 
Chang, E. J. Lee, J. H. Lee and I. J. Yu, Lung Function Changes in Sprague-Dawley Rats After Prolonged Inhalation 
Exposure to Silver Nanoparticles, Inhal. Toxicol., 2008, 20, 567–574. 
503 D. P. K. Lankveld, A. G. Oomen, P. Krystek, A. Neigh, A. Troost – de Jong, C. W. Noorlander, J. C. H. Van Eijkeren, R. 
E. Geertsma and W. H. De Jong, The kinetics of the tissue distribution of silver nanoparticles of different sizes, 
Biomaterials, 2010, 31, 8350–8361. 
504 M. Korani, M. Rezayat and K. Gilani, Acute and subchronic dermal toxicity of nanosilver in guinea pig, Int. J. 
Nanomedicine, 2011, 6, 855–862. 
505 P. V. Asharani, Y. Lianwu, Z. Gong and S. Valiyaveettil, Comparison of the toxicity of silver, gold and platinum 
nanoparticles in developing zebrafish embryos, Nanotoxicology, 2011, 5, 43–54. 
506 Y. Yamagishi, A. Watari, Y. Hayata, X. Li, M. Kondoh, Y. Tsutsumi and K. Yagi, Hepatotoxicity of sub-nanosized 
platinum particles in mice., Pharmazie, 2013, 68, 178–82. 
507 Y. Yamagishi, A. Watari, Y. Hayata, X. Li, M. Kondoh, Y. Yoshioka, Y. Tsutsumi and K. Yagi, Acute and chronic 
nephrotoxicity of platinum nanoparticles in mice, Nanoscale Res. Lett., 2013, 8, 395. 
508 J. Jura, P. Konieczny, G. Goralczyk, Anna, L. Skalniak, J. Koziel, L. Filon, Francesca, M. Crosera, A. Cierniak, Zuba-
Surma, J. Borowczyk, E. Laczna, J. Drukala, E. Pyza, D. Semik, O. Woznicka, A. Klein and R. Szmyd, Effects triggered 
by platinum nanoparticles on primary keratinocytes, Int. J. Nanomedicine, 2013, 8, 3963–3975. 
509 Y. Cheng, L. Yin, S. Lin, M. Wiesner, E. Bernhardt and J. Liu, Toxicity Reduction of Polymer-Stabilized Silver 
Nanoparticles by Sunlight, J. Phys. Chem. C, 2011, 115, 4425–4432. 
510 J. Lan Hou, G. Shuo and L. Grozova, Reduction Of Silver Nanoparticle Toxicity By Sulfide, Adv. Mater. Lett., 2013, 4, 
131–133. 
511 S. Dominguez-Medina, J. Blankenburg, J. Olson, C. F. Landes and S. Link, Adsorption of a Protein Monolayer via 
Hydrophobic Interactions Prevents Nanoparticle Aggregation under Harsh Environmental Conditions, ACS Sustain. 
Chem. Eng., 2013, 1, 833–842. 
512 J. E. Newton, J. A. Preece and B. G. Pollet, Control of nanoparticle aggregation in PEMFCs using surfactants, Int. J. 
Low-Carbon Technol., 2012, 7, 38–43. 
513 A. K. Gupta and M. Gupta, Synthesis and surface engineering of iron oxide nanoparticles for biomedical 
applications, Biomaterials, 2005, 26, 3995–4021. 
514 Z. S. Pillai and P. V. Kamat, What Factors Control the Size and Shape of Silver Nanoparticles in the Citrate Ion 
Reduction Method?, J. Phys. Chem. B, 2004, 108, 945–951. 
515 H. Hattori, M. Ishihara, T. Ono, Y. Miyahira, S. Nakamura, T. Matsui and V. Q. Nguyen, Interaction of Silver 
Nanoparticles and Chitin Powder with Different Sizes and Surface Structures: The Correlation with Antimicrobial 
Activities, J. Nanomater., 2013, 2013, 1–9. 
516 T. K. Sau, A. Pal, N. R. Jana, Z. L. Wang and T. Pal, Size controlled synthesis of gold nanoparticles using 
photochemically prepared seed particles, J. Nanoparticle Res., 2001, 3, 257–261. 
517 C. J. Ackerson, P. D. Jadzinsky and R. D. Kornberg, Thiolate Ligands for Synthesis of Water-Soluble Gold Clusters, J. 
Am. Chem. Soc., 2005, 127, 6550–6551. 
518 S. Roux, B. Garcia, J.-L. Bridot, M. Salomé, C. Marquette, L. Lemelle, P. Gillet, L. Blum, P. Perriat and O. Tillement, 
Synthesis, Characterization of Dihydrolipoic Acid Capped Gold Nanoparticles, and Functionalization by the 
Electroluminescent Luminol, Langmuir, 2005, 21, 2526–2536. 
519 J. D. E. T. Wilton-Ely, The surface functionalisation of gold nanoparticles with metal complexes, Dalt. Trans., 2008, 
0, 25–29. 
